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Dansk resumé 
Denne afhandling omhandler oprensning og karakterisering af jern enzymet tryptophanhydroxylase (TPH). 
TPH eksisterer i to isoformer, TPH1 og TPH2. Hver isoform består af 3 strukturelt forskellige domæner: det 
regulatoriske, det katalytiske og det tetrameriserende domæne. TPH katalyserer omdannelsen af 
tryptophan til 5-hydroxytryptophan, hvilket er det hastighedsbestemmende trin i biosyntesen af serotonin. 
Serotonin er en vigtig neurotransmitter, som er involveret i en række psykiske sygdommme såsom 
depression og tvangstanker. Målet med dette projekt var at udvikle oprensningsmetoder for fuldlængde 
TPH1 og TPH2 samt at karakterisere de oprensede TPH varianter. 
Der blev udviklet en succesfuld oprensningsmetode for fuldlængde human TPH1 (hTPH1), som resulterede i 
rent, aktivt og stabilt protein. Metoden inkluderede affinitetsoprensning med maltose bindende protein 
(MBP) tag og høje salt koncentrationer i alle buffere. Det er første gang en succesfuld oprensningsmetode 
for hTPH1 præsenteres, som også opnår stabilt protein efter kløvning fra affinitetstagget. Ydermere blev 
der udviklet succesfulde oprensningsprocedurer for en række andre TPH varianter. En oprensningsmetode 
for det regulatoriske og katalytiske domæne af TPH1 (rchTPH1) med MBP tag blev udviklet, og afslørede at 
det regulatoriske domæne forårsager dimerisering. En ny oprensningsmetode for det katalytiske domæne 
at human TPH1 (chTPH1) med gluthathione S-transferase (GST) tag blev også udviklet. To humane TPH2 
varianter indeholdende det regulatoriske domæne blev forsøgt oprenset efter den samme generelle 
metode som hTPH1, men udbytterne var lave og produkterne ustabile og kunne ikke opkoncentreres. Den 
høje salt koncentration stabiliserer altså ikke det regulatoriske domæne af TPH2. Stabiliteten af 4 TPH 
varianter blev undersøgt vha. differential skanningsfluorimetri (DSF) and resultaterne giver information om 
effekten af pH, salt type og ionstyrke. 
Resultaterne fra krystallisationsarbejdet var desværre meget begrænsede. Krystallisationsproceduren for 
the katalytiske domæne af gallus gallus TPH1 (cgTPH1) blev optimeret til hurtigere krystal dannelse ved 
tilsætning af tryptophan og inkubation ved stuetemperatur. Krystaller uden imidazole i 
krystallisationsbetingelserne blev lavet. De løste strukturer var dog af dårlig kvalitet og bidrager ikke med 
ny viden om TPH. En strategisk fremgangsmåde til krystallisation af TPH varianter blev udviklet, og 
screeningen producerede lovende betingelser for rchTPH1 og flere krystaller for chTPH1. 
Fire mutanter af det katalytiske domæne af human TPH2 (chTPH2) blev fremstillet, og det kan konkluderes 
ar Glu363, som er jern ligand, er essentiel for aktivitet, mens Tyr358 påvirker aktiviteten, uden at være 
essentiel. Cirkulærdikroisme (CD) og magnetisk cirkulærdikroisme (MCD) resultater viste at jern i det aktive 
site skifter konformation fra 6 til 5 koordineret kun når både substrat og cofaktor binder. Der blev 
observeret forskelle mellem prøver lavet i glycerol og sucrose. Tilsætning af glycerol til chTPH2 med bundet 
Fe(III) resulterede i en gul farve som indikerer interaktion mellem de to. DSF målinger demonstrerede at 
chTPH2 er signifikant mere stabil i Fe(II) formen end i Fe(III) formen. Ydermere stabiliserer tilsætningen af 
substrat og cofaktor kun chTPH2 på Fe(II) formen. Isotermisk titreringskalorimetri målinger blev udført på 
chTPH2 og dissociationskonstanten for BH2 blev bestemt til 5 µM, men dissociationskonstanten for 
tryptophan var noget højere. Tryptophan og BH2 binder uafhængigt af hinanden. 
Generelt har arbejdet udført i dette projekt bidraget signifikant til forskningen i TPH, både ved at udvikle 
nye oprensningsprocedurer samt tilføje viden om mekanismen af TPH.  
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Abstract 
This thesis deals with the purification and characterization of the iron-containing enzyme tryptophan 
hydroxylase (TPH). TPH exists in two isoforms, called TPH1 and TPH2. Each isoform consists of three 
structural distinct domains: the regulatory, the catalytic and the tetramerization domain. TPH catalyzes the 
hydroxylation of tryptophan to 5-hydroxytryptophan, which is the rate-limiting step in the biosynthesis of 
serotonin. Serotonin is an important neurotransmitter, which is involved in a range of psychiatric disorders 
including depression and obsessive-compulsive disorder. The goal of this project was to develop 
purification methods for full-length TPH1 and TPH2 as well as to characterize purified TPH variants. 
A successful purification method for full-length human TPH1 (hTPH1) was developed, which resulted in 
pure, active and stable protein. The method includes affinity-purification using maltose binding protein 
(MBP) tag and high salt concentration in all buffers. It is the first time a successful purification method for 
hTPH1 has been presented, which also yields stable protein after cleavage from the affinity tag. 
Furthermore, successful purification procedures were developed for a number of other TPH variants. A 
purification method for the regulatory and catalytic domains of human TPH1 (rchTPH1) using MBP affinity 
tag was developed, and revealed that the regulatory domain causes dimerization. Also, a new purification 
method for the catalytic domain of human TPH1 (chTPH1) using gluthathione S-tranferase (GST) tag was 
developed. Two human TPH2 variants containing the regulatory domain were attempted purified using the 
same general method as for hTPH1, but the yields were very low and the products were unstable and could 
not be concentrated. The high salt concentration does thus not seem to stabilize the regulatory domain of 
TPH2. The thermal stability of 4 TPH variants was studied by differential scanning fluorimetry (DSF), and the 
results gave information on the effect of pH, salt type and ionic strength. 
The results from crystallization were unfortunately rather limited. The crystallization procedure for the 
catalytic domain of gallus gallus TPH1 (cgTPH1) was optimized to faster crystal growth by addition of 
tryptophan and incubation at room temperature. Crystals without imidazole in the crystallization 
conditions could be obtained. The solved structures were however of poor quality and did not contribute 
with any new information on TPH. A strategic approach to crystallization of TPH variants was developed, 
and the pipeline screening produced leads for rchTPH1 and several crystals for chTPH1. 
Four mutants of the catalytic domain of human TPH2 (chTPH2) were made, and it can be concluded that 
Glu363, which is an iron ligand, is essential for activity, while Tyr358 affects the activity, but is not 
absolutely required. Circular dichroism and magnetic circular dichroism results on chTPH2 clearly 
demonstrated that the active site iron changes conformation from 6 to 5 coordinated only when both 
substrate and cofactor binds. A difference between samples made in glycerol and sucrose was observed. 
Addition of glycerol to chTPH2 in the Fe(III) form gave a yellow color indicative of interaction. DSF 
measurements demonstrated that chTPH2 is significantly more stable in the Fe(II) form compared to the 
Fe(III) form. Furthermore, the addition of substrates and cofactor only stabilizes chTPH2 when Fe(II) is 
present. Isothermal titration calorimetry measurements on chTPH2 determined the dissociation constant of 
BH2 to 5 µM, while the dissociation constant for tryptophan is somewhat higher. Tryptophan and BH2 bind 
independently of each other. 
Overall, the work performed in this project has made significant contributions to the research on TPH, both 
by providing new purification procedures as well as advancements in the knowledge on the mechanism of 
TPH. 
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Figure 2: Overview of the biosynthesis of the neurotransmitter serotonin and the hormone melatonin from the amino acid 
tryptophan. Tryptophan hydroxylase catalyzes the reaction from tryptophan to 5
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variants of the different domains were made. Purification methods for truncated variants containing the 
catalytic domains of gallus gallus (chicken) TPH1, human TPH1 and human TPH2 have been developed(9, 
10). Also, a variant containing the catalytic and tetramerization domains of human TPH2 has been 
purified(9, 11). These variants have all been kinetically characterized and some have also been structurally 
characterized(9–13). Recently, a purification method for the regulatory domain of human TPH1 was 
developed using affinity tags(10). 
This project had two main goals: I) To develop purification methods for full-length human TPH1 and TPH2, 
and II) to characterize purified variants of TPH to achieve a better understanding of the structure-functional 
relationship. Large efforts were put into crystallization of TPH variants to solve the three-dimensional 
structures; however the results from this work were unfortunately very limited. 
1.1 Outline of thesis 
This thesis has been divided into three main chapters, concerning purification, crystallization and 
mechanistic studies, respectively. First, an introduction to the current relevant knowledge on TPH is given 
as an overview of the literature on the topic in chapter 2. In chapter 3, the background for and the 
strategies followed in this project are briefly presented. Chapter 4 concerns the development of suitable 
purification procedures for both TPH1 and TPH2 variants. The end-products from the purifications are in 
many cases characterized by mass spectrometry and the stability is studied by differential scanning 
fluorimetry. The attempts to structurally characterize the purified TPH variants by crystallization are 
described in chapter 5. Several different characterization methods were used in the mechanistic studies 
presented in chapter 6. The results from these are presented and discussed. Finally, in chapter 7 the overall 
conclusions from the work done in this project are given. 
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2 Tryptophan  hydroxylase 
In this chapter, a brief introduction to the relevant knowledge on tryptophan hydroxylase will be given. The 
information given here only represents an overview, and more specific and thorough discussions on 
relevant literature will be given in the following chapters according to topic. 
2.1 The aromatic amino acid hydroxylases 
Tryptophan hydroxylase (EC 1.14.16.4) is a non-heme iron-containing enzyme, which catalyzes the reaction 
between L-tryptophan (trp), O2, and 5,6,7,8-tetrahydrobiopterin (BH4) to give 5-hydroxytryptophan (5-OH-
trp) and 4a-hydroxy-tetrahydrobiopterin (4a-OH-BH4) (14).  
BH4 acts as electron donor in the reduction of O2 and hydroxylation of trp.  In vivo 4a-OH-BH4 is 
regenerated by the enzymes pterin-4a-carbinolamin dehydratase  and dihydrobiopteridine reductase 
producing H2O at the expense of nicotinamide adenine dinucleotide (NADH)(15). Thus, TPH is defined as a 
mono-oxygenase and BH4 as a cofactor, even though BH4 actually acts as a co-substrate in the TPH-
catalyzed reaction. For the rest of this thesis, BH4 will be referred to as a cofactor, and trp and O2 as 
substrates. 
 
Figure 3: The reactions catalyzed by the aromatic amino acid hydroxylases, where the amino acid side chain is hydroxylated 
utilizing tetrahydrobiopterin as electron donor and O2 as the oxygen source. PAH: Phenylalanine hydroxylase. TH: Tyrosine 
hydroxylase. TPH: Tryptophan hydroxylase. Adapted with permission from (14). Copyright 2003 American Chemical Society. 
Together with phenylalanine hydroxylase (PAH) and tyrosine hydroxylase (TH), TPH constitutes the enzyme 
family of aromatic amino acid hydroxylases (AAAHs)(16, 17). The AAAHs all require Fe(II) and BH4 for 
hydroxylation of their respective amino acids (see Figure 3), and show substantial similarities in their 
PAH 
TH 
TPH 
O2 
Tetrahydrobiopterin (BH4) 
2.2 The two isoforms of tryptophan hydroxylase 
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structure and catalytic mechanism(16). The mammalian AAAHs form homotetramers, and each monomer 
consists of three distinct structural and functional domains: The N-terminal regulatory domain, the catalytic 
domain including the iron active site and substrate binding pockets, and the small C-terminal 
tetramerization domain(14). 
PAH is found in the liver(18), where it catalyzes the rate-limiting step in catabolism of phenylalanine by 
converting phenylalanine to tyrosine (19). Deficiency in PAH lead to phenylketonuria (PKU), a disease 
where excess phenylalanine is converted to phenylpyruvate(17). Phenylpyrovate is toxic and can lead to 
mental retardation, but usually this can be avoided through a low phenylalanine-diet(20). In Denmark, all 
newborns are tested for PKU 48-72 hours after birth, to ensure early treatment. Only 1 in 11000 newborns 
is diagnosed with PKU in Denmark(21). 
TH is found in the central nervous system (CNS) and adrenal gland, where it catalyzes the formation of 3,4-
dihydroxyphenylalanine (DOPA) from tyrosine(22). This is the first and rate-limiting step in the biosynthesis 
of cathecolamine neurotransmitters such as dopamine, norepinephrine (noradrenaline), and epinephrine 
(adrenaline)(20). Deficiencies in TH have been related to the genetic disease L-DOPA responsive 
dystonia(23) and Parkinson’s disease(24, 25). 
The sequential and structural homology of the catalytic domains of the AAAHs and the similarity in the 
reactions they catalyze, suggests that they share a common catalytic mechanism(14, 26). Thus, knowledge 
on PAH and TH can be used for understanding the mechanism of TPH. The latter has been characterized to 
much less extent compared to PAH and TH due to the inherent instability of the protein, and hence the 
difficulty to purify it(5). The three AAAHs regulatory domains differ significantly in sequence and length, 
and different regulatory properties are observed(14).  
2.2 The two isoforms of tryptophan hydroxylase 
TPH exists in two isoforms(6), called TPH isoform 1 (TPH1) and TPH isoform 2 (TPH2). The two TPH isoforms 
are highly homologous with a sequence identity of 71 %(7), but are expressed in different tissues of the 
body. TPH1 appears to be mainly expressed in non-neuronal serotonergic cells, e.g. skin, pineal gland, and 
enterochromaffin cells in the intestines (1, 7, 27–30). TPH2 is expressed in neuronal serotonergic cells, e.g. 
serotonergic neurons of the brain and gut (6, 28, 29, 31, 32). TPH2 is thus responsible for synthesis of 
serotonin in the CNS, while TPH1 controls serotonin synthesis in the peripheral system. 
The main differences between TPH1 and TPH2 are found in the regulatory domain, where the N-terminal is 
extended with 46 residues in TPH2(7), as shown in Figure 4. The extra amino acids in TPH2 are believed to 
reduce the expression level compared to TPH1(33), and to inhibit enzyme activity(34). 
 
Figure 4: The division of the three domains in human TPH1 and human TPH2. The regulatory domains are shown in blue, the 
catalytic domains in green, and the tetramerization domains in red. 
The peripheral and central serotonergic systems, which are regulated by TPH1 and TPH2, respectively, are 
coupled to different physiological functions and thus different disorders(7). TPH1 is involved in 
 
 
 
 
gastrointestinal disorders associated with exce
for treatment of chronic diarrhea(35
target for gastro-intestinal disorders related to serotonin dysregulation. Dysfunction of the central 
serotonergic system is associated with several neuropsychiatric disorders, such as obsessive
disorder (OCD), anxiety disorders, attention deficit hyperactivity disorder (ADHD), bipolar affective 
disorder, anorexia, schizophrenia and depression
the biosynthesis of serotonin in the CNS, a possible correlation between genetic variation in TPH2 and the 
occurrence of the above mentioned disorders have been extensively studied. Such correlations have indeed 
been found for depression(40), suicidal behavior
However, most of the association studies have failed to be confirmed in samples from others, and thus the 
exact role of TPH2 in neuropsychiatric disorders remain unclear
a potential drug target for serotonin related psyc
2.3 Structure 
Only a limited number of TPH structures are available in the literature
structural information comes from the related enzymes TH and PAH. The domains are presented
by one. 
2.3.1 Regulatory domain 
The N-terminal regulatory domain is the most diverse domain among the AAAHs. No structure of the 
regulatory domain of TPH has been solved, but the structure of the regulatory and catalytic domain of PAH 
has been determined(49). In this structure, t
electron density. The N-terminal residues 19
active site, as seen in Figure 5. Movement of this part of the regulatory domain is believed to be involved in 
regulation of PAH(49).  
                       
Figure 5: Structure of the regulatory (light blue) and catalytic (green) domain
Residues 19-33 are not shown in the figure
33 are included and shown as spheres. They clearly restrict the access to the active site.
2 Tryptophan  hydroxylase 
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(5, 45). Despite this, TPH2 is still considered 
hiatric disorders(45, 46). 
(12, 47, 
he first 18 amino acids are lacking
-33 extend across the catalytic domain restricting acc
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The regulation of TPH1 and TPH2 is not well understood
regulated by phosphorylation by protein kinase A and calmodulin
interactions with 14-3-3 protein(53, 
57). 
2.3.2 Catalytic domain 
5 structures of the catalytic domain of TPH1 are available from the PDB database. 4 of these are of the 
catalytic domain of human TPH1, one binding the cofactor analogue and inhibitor 
(BH2)(47), and the 3 others binding designed inhibitors
gallus TPH1 binding the substrate tryptophan 
group(12). The structures of the catalytic domain of TPH are very similar to those of PAH and TH as 
expected from the high sequence identity
with iron at the floor of this cavity 13 Å below the surface
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Figure 6: Structure of the catalytic domain of human TPH1
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mutation of this Phe in TPH1 to Trp and the corresponding Trp in PAH to Phe, which significantly changed 
the substrate specificity (59–61). Also Tyr236 (gallus gallus TPH1 numbering), which is not conserved in 
PAH and TH, has been identified as important for substrate binding(62). 
 
Figure 7: Schematic view of the tryptophan substrate interactions with gallus gallus TPH1 (PDB ID: 3E2T). Tryptophan is shown in 
red, hydrogen bonds as dashed lines, and the filled gray circles represent water molecules. Semi circled residues have 
hydrophobic interactions with the tryptophan substrate. For residues which are not conserved in PAH and TH, the corresponding 
residue is shown. The C-atom that is hydroxylated is marked with *. Adapted with permission from (12). Copyright 2008 
American Chemical Society. 
2.3.2.2 Cofactor binding site 
The cofactor binding site can be investigated in the structure of human TPH1 with the cofactor analogue 
BH2 bound(47). The cofactor binds in the same orientation and position as in PAH. The pterin π-stacks on 
Phe241 and Tyr325 (human TPH1 numbering) and forms hydrogen bonds to Gly234 and Leu236. The O4 
atom in the pterin is hydrogen bonded to two of the three water molecules coordinated to iron. Glu273 
also forms two water-mediated hydrogen bonds to the pterin. The distance between the C-atom that is 
hydroxylated in pterin and iron is 5.7 Å. 
2.3.3 Tetramerization domain 
There is no structure of the tetramerization domain of TPH available in the literature. However, structures 
of the tetrameric forms of both TH(63) and PAH(64) have been solved. The small tetramerization domain at 
the C-terminal of the AAAHs is responsible for oligomerization through hydrophobic interactions in a coiled-
coil motif, as shown in Figure 8. 
* 
 
 
 
Figure 8: Structure of the catalytic and tetramerization domains of TH (PDB ID
monomers is seen in the center of the structure. Each monomer is a different color, and iron is shown 
2.4 Mechanism 
It is assumed that the AAAHs share a common
divided into three parts: The pre-reaction events including the effect of substrate and cofactor binding on 
the active site iron coordination, the oxygen activation step, which yields the hydroxylating intermediate, 
and the hydroxylation of the aromatic amino acid.
2.4.1 Substrate and cofactor binding
The effect of amino acid substrate and cofactor binding ha
structures(65, 66) and spectroscopic techniques
catalytically relevant +2 oxidation state
coordinated (6C) through 2 histidines, 1 glutamate and 3 water molecules (see 
either amino acid substrate or cofactor, no large structural changes are seen in overall structure or iron 
coordination. However, when both amino acid substrate and cofactor bind
complex, the enzyme structure closes in what appears to be a sub
pocket of the substrate closes, leaving only a small entrance for oxygen to enter the active site. 
Furthermore, the iron coordination changes from 6C to 5 coordinated (5C)
glutamate and the loss of 2 water ligands
initiate the reaction. 
By comparing PAH structures with cofactor (
(PDB ID: 1MMK), the effect of substrate binding on the active site and overal
as seen in Figure 9. The overall conformation changes from open to closed, along with a cha
active site iron coordination from 6C to 5C.
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Figure 9: Comparison of the open (left) and closed (right) structures of PAH before and after substrate
Surface representation of PAH with Fe(II) (red sphere) and BH
analogue) and BH4 are aligned into the structure from the 1MMK structure by PyMOL and shown in 
active site iron coordination. Right: Surface representation of PAH with Fe(II) (red sphere), BH
sticks) (PDB ID 1MMK). BH4 is aligned into the structure from the 1J8U structure by PyMOL and shown in 
the active site
Comparison of the two structures furthermore
movement of the backbone when substrate binds
away from the active site; HOH1251 which was coordinated to iron and Glu286, and HOH1142 which was 
coordinated to Glu286 and BH4 before substrate binding
positions for a tighter binding. 
HOH1253 also coordinated to iron is not directly pushed away by the BH
BH4 and HOH1253 is 2.1 Å). Instead it might be removed with Tyr325 that swing
water with it. The remaining iron-coordinated water 1250 is the water closest to the position of the one 
iron-coordinated water in the ternary structure.
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 iron coordination. The figure was made using PyMOL(50).
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Figure 10: The movement of BH4 upon substrate analogue binding
in green and the structure with both BH4 and substrate analogue bound (PDB ID: 
orange sphere, and water as small spheres. Left: Interactions between Glu286 and water 1142 and 1251. Both waters are pushed 
away by the movement of BH4. Right: Tyr325 swings out upon substrate binding and might take water 1253 with it, s
can coordinate bidentate to Fe(II).
The catalytic mechanism and order of substrate binding have
state kinetics(8, 9, 48, 71–73). It is concluded that the mechanism is sequential i.e. all three substrates must 
be bound in the active site before the reaction can occur. However, there is no consensus in the literature 
on the order of substrate binding or whether or not it is partially or fully ordered. 
2.4.2 Oxygen activation and hydroxylation
The enzymatic reaction mechanism can be separated into 
the hydroxylating intermediate through activation of dioxygen and the second is the hydroxylation of the 
aromatic amino acid. The overall react
literature(14),  but specific reactions are still being discussed due to the lack of convincing experimental 
evidence.  
Figure 11: The proposed enzymatic reaction mechanism for TPH
Theoretical investigations show that a ferryl oxy species (Fe
hydroxylating intermediate(74–78)
intermediate, presumably Fe(IV)=O, was found for TH
hydroxylation(81) and is an intermediate in several mononuclear iron enzymes with facial triad 
1251 
2.4 Mechanism 
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coordination(75, 82). The Fe(IV)=O intermediate is formed from heterolytic cleavage of a Fe(II) peroxypterin 
bridge. However, disagreements exist on whether oxygen reacts with iron or pterin before formation of the 
peroxy bridge(74, 83, 84). 
After formation of the hydroxylating intermediate, the first step in the hydroxylation of the amino acid is 
believed to be the electrophilic attack of Fe(IV)=O on the aromatic C-atom as shown in Figure 11. The 
product is an arenium cation intermediate. This step has been supported by experimental evidence(26, 85–
87). The formation of the arenium cation is followed by a NIH-shift, which has been experimentally 
observed for all AAAHs(85, 88–90). The hydroxylation reaction mechanism proposed is furthermore 
supported by theoretical calculations(77, 91, 92). 
The hydroxylation of tryptophan is the rate-limiting step in the enzymatic turnover by TPH(26, 86, 91). On 
the contrary, the oxygen activation step is believed to be the rate-limiting step of TH and PAH(71, 83, 91, 
93).  
Even though several steps in the reaction mechanism have been studied, there are still many unknown 
factors which need to be investigated in order to present a clear picture of the mechanism. 
2.5 Nomenclature 
In this thesis, the different TPH variants have been given abbreviations, which follow the general rules 
described here. If the variant is fused to an affinity tag, the abbreviation for the affinity tag is written first 
followed by “-“. Affinity tags featured in this project includes gluthathione S-transferase (GST) and maltose 
binding protein (MBP). The first letter (or first two letters) refers to the domains. The regulatory domain is 
assigned “r”, the catalytic domain “c”, and the tetramerization domain “t”. For the full-length enzymes no 
letter is included. The next letter in italic refers to the species that the protein sequence originates from. 
“h” refers to homo sapiens (human) and “g” to gallus gallus (chicken). The protein name is abbreviated in 
capital letters, such as “TPH1”. Examples of the most commonly used abbreviations are given in Table 1. 
Table 1: Overview of the abbreviations used in this thesis for TPH variants. 
Abbreviation Affinity-
tag 
Domains Species Protein 
cgTPH1 - Catalytic domain Chicken  TPH1 
GST-chTPH1 GST Catalytic domain Human TPH1 
MBP-hTPH1 MBP Full-length Human TPH1 
MBP-rchTPH1 MBP Regulatory and catalytic domains Human TPH1 
chTPH2 - Catalytic domain Human TPH2 
cthTPH2 - Catalytic and tetramerization domains Human TPH2 
hTPH2 - Full-length Human TPH2 
MBP-hTPH2  MBP Full-length Human TPH2 
MBP-rchTPH2 MBP Regulatory and catalytic domains Human TPH2 
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3 Project background and 
strategy 
The Metalloprotein Chemistry & Engineering group at DTU Chemistry started working with TPH in 2003. 
Since then, a vast amount of experimental data has been accumulated. All these data along with the 
contributions from other groups studying TPH gives the knowledge platform upon which this project is 
build. In this chapter, a short review of the project background for the three main topics (purification, 
crystallization and mechanistic studies) will be given, and the strategies followed in this project will be 
presented. 
From the very beginning, purification of full-length TPH proved difficult. The soluble amount of protein 
after expression in Escherichia coli (E. coli) was very low, and the protein easily precipitated and would not 
bind to the columns tested(9). Thus, a new strategy was developed were each of the three domains were 
studied, first individually and later in different combinations, to achieve knowledge on which parameters 
were important for stability. The purification of the catalytic domain was rather simple, as this variant was 
expressed in large amounts and was very soluble. The method of purification included a capture step using 
anion-exchange chromatography and a polishing step using size-exclusion chromatography(13). The yields 
were high and the product rather stable. chTPH2 was found to be more stable than chTPH1, and could be 
concentrated to a much higher concentration (2.5 mM vs. 0.2 mM). The inclusion of the tetrameric domain 
did not complicate the purification process and cthTPH2 could be purified using the same method as for the 
catalytic domain(11). cthTPH1 could be expressed however in a relatively low yield, but was found 
soluble(94). A purification method for cthTPH1 has not been developed. Experiments with variants 
containing the regulatory domain gave either insoluble protein, or partly soluble protein that existed in 
large aggregates and did not bind to ion-exchange columns or eluted in several different peaks(9, 94). No 
suitable method for purification of any variant containing the regulatory domain was developed until 
recently, when a successful purification method for GST-rhTPH1 was found(10). The method includes a high 
concentration of salt in the buffers used, in order to stabilize the regulatory domain and prevent 
oligomerization and/or aggregation. This important result is the base for developing purification strategies 
for the full-length variants of TPH1 and TPH2. The strategy when developing new purification methods is 
that they should be as simple as possible, meaning the fewer steps the better. If the yield is low, any critical 
steps should be identified and improvements or replacement of the critical step should be tested. If the 
same purification method can be used for several different variants, this is preferred, as it limits the 
number of protocols and columns in use. Furthermore, the product from the purification should be tested 
for purity (using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and mass 
spectrometry) and activity. The stability of the product can also be tested. 
As mentioned in the introduction, only very limited information on the structure of TPH is available. The 
only crystal structures available are of the catalytic domains of isoform 1. Crystal structures of both cgTPH1 
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and chTPH1 have been solved in the Metalloprotein Chemistry & Engineering group(10, 12). Several 
attempts have been made to crystallize chTPH2 and cthTPH2, but all were unsuccessful(9, 11). In my master 
thesis a low-resolution structure of cthTPH2 was determined using small angle X-ray scattering, and this 
showed a structure very similar to the crystal structure of tetrameric TH(11). The purification products of 
chTPH2 and cthTPH2 were also tested using different scattering techniques, and it was found that chTPH2 
was polydisperse, while cthTPH2 was monodisperse, also after freezing and thawing(11). Further 
explanations for the lack of crystallization results could be the high content of glycerol in the purification 
buffers (10 (w/v) %), which might have a negative effect on the crystallization process. Crystallization is 
indeed a hit-or-miss science, and great effort does far from always lead to great results. There is a vast 
amount of parameters which can be varied in crystallization, both for the purification product (purification 
method, buffer, concentration, freezing/thawing etc), and for the crystallization conditions (precipitant, 
temperature, additives, substrates, drop size, drop type (hanging, sitting etc)). Generally, if no hits are 
found when testing two different screens at two different temperatures and two different protein 
concentrations, then the protein sample should be checked for monodispersity, purity etc(95). The goal in 
this project regarding crystallization was to find crystal structures for any variants of TPH that have not 
been crystallized before, or of known structures in new combinations with substrates. The strategy 
involved getting pure protein samples for as many variants as possible, so screens could be set up. For 
crystallization, both random variation (sparse matrix screens) as well as variations of specific parameters 
(fine-tuning), were tested.  
Since the achievement of pure and stable products of TPH in the group is relatively new, the 
characterization results are also limited. However, chTPH1, chTPH2 and cgTPH1 have been kinetically 
characterized by determining the apparent Michaelis menten parameters, KM and Vmax, for all 3 
substrates(13, 96). chTPH1 and cgTPH1 were inhibited by tryptophan at high concentrations, while chTPH2 
did not show such substrate inhibition. Moreover, the KM value for the cofactor BH4 differed significantly 
between the isoforms, as KM,BH4 was 10-fold higher for chTPH1 than for chTPH2. These isoform specific 
differences are rather surprising, as the catalytic domains have a high sequence identity. Whether these 
differences in KM arise from difference in association constants or different reaction rates is unknown. So 
far, the reaction mechanism of TPH has not been studied in the Metalloprotein Chemistry & Engineering 
group. The strategy in this project regarding mechanistic studies was to gain as much information as 
possible on the structure-functional relationship and reaction mechanism of TPH using several different 
techniques available.  
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4 Purification 
In this chapter the purification methods developed for a wide range of TPH variants will be presented. The 
characterization of the final products will also be shown and discussed. For most variants, only the final 
purification procedure is presented, even though several purifications have been performed during 
development and optimization of the method. 
First, an introduction to previous work with purification of TPH is given along with a strategy for the work 
performed in this project. Then the experimental procedures are presented, followed by results and 
discussion. The stability of some of TPH variants was studied by differential scanning fluorimetry (DSF), and 
these results will also be presented. Finally, a comparison between the yields, solubility, and activities of 
the different variants will be made. 
4.1 Introduction and background 
A requirement for thorough characterization is a pure and stable protein sample. This is usually achieved by 
expression in recombinant systems followed by purification.  Alternatively, the protein can be purified from 
the original source. 
For many years work have been performed on purification of full-length variants of TPH from recombinant 
systems. Both PAH and TH have been purified, but the inherent instability of TPH and its tendency to 
aggregate makes it very hard to work with. The Metalloprotein Chemistry & Engineering group has 
succeeded in developing purification procedures for several truncated variants containing the catalytic and 
tetramerization domains, as described in the previous chapter. These include purification of chTPH1(13), 
chTPH2(13), cgTPH1(96), and cthTPH2(9). The products have been characterized kinetically(9, 13), and a 
crystal structure of cgTPH1 was also solved(12). Recently, a purification method for the regulatory domain 
(rhTPH1) was developed using GST as affinity tag and high salt concentrations in the buffer systems(10).  
From the literature it is known that other research groups have purified full-length human TPH fused to 
affinity tags(51, 97–101). Especially the group of Jan Haavik has in recent years developed promising 
purification procedures for both human TPH1 and TPH2(51, 98, 102). In all studies, TPH becomes unstable 
and precipitate or aggregate after cleavage from the affinity tags resulting in no or very low yields. For 
TPH2, the protein solution is not pure after cleavage(51). Only one successful purification for full-length 
human TPH1 has been reported, using a pterin-agarose column(103). Some discrepancies are however seen 
in the results from this purification method. One example is a 10-fold increase in activity upon purification, 
which is explained by the presence of unknown endogenous inhibitors of TPH in the crude extract(103). 
Furthermore, when the method with pterin-agarose columns was tested in our lab it did not succeed in 
binding TPH(104). Thus, the evidence of a pure and stable full-length TPH product remains elusive. 
The objective for the purification part of this project was to develop purification methods for full-length 
hTPH1 and hTPH2. The initially developed procedures for the catalytic domains of TPH consist of an anion-
exchange step followed by a size-exclusion step. However, as earlier studies have shown that the regulatory 
domain of hTPH1 requires high salt concentration for stabilization(10), new methods should be developed 
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that allows for this requirement. Thus, ion-exchange is excluded. Affinity purification was chosen as the 
preferred method due to high selectivity, fast purification and the possibility for high salt concentration. 
Affinity purification was combined with size-exclusion chromatography in order to allow for aggregates to 
be removed (vide infra, see section 4.3.2.2) and for effective removal of the eluent before the second 
affinity step.  
For monomer TPH variants gluthathione S-transferase (GST) can be used as affinity tag. However, due to 
the common dimerization of GST(105) it is not suitable as affinity tag for tetrameric variants of TPH. Thus, 
maltose binding protein (MBP) was chosen as the preferred affinity tag for all TPH variants except chTPH1 
which was fused to GST. For cleavage of affinity tag from target protein, human rhinovirus 3C protease 
(3CP) was chosen as this allows for quick and specific cleavage(106). 3CP recognizes the amino acid 
sequence Leu-Glu-Val-Leu-Phe-Gln↓Gly-Pro, cleaving between the Gln and Gly residues(107). Thus, two 
extra amino acids will be left on the target protein after cleavage. 3CP displays maximum activity at 4°C, 
hence the cleavage can be performed at low temperatures ensuring protein stability. Furthermore, the 
protease can be fused to affinity tags such as GST or MBP and removed from the solution by affinity 
purification in an easy procedure. 
 
Figure 12: Flow chart of the general purification method for affinity-tagged TPH variants. In the middle each purification step is 
shown, to the left the primary goal of the purification step is shown, and to the right any notes on the purification step are 
shown.
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The genes for affinity-tagged TPH variants were constructed encoding an affinity-tag at the N-terminal 
followed by a linker (MBP variants only), the protease recognition sequence, and TPH. For the affinity-
tagged 3CP no recognition sequence was included. For complete amino acid sequences, see appendix 9.1. 
A flow chart of the overall purification method for TPH variants using affinity tags can be seen in Figure 12. 
The method includes sonication followed by the first affinity and size-exclusion steps. Then the affinity-
tagged TPH variant is cleaved by 3CP overnight, and the product is purified by the second affinity and size-
exclusion steps. Finally the product is concentrated using ultrafiltration. 
4.2 Experimental procedures 
In this section the experimental procedures for expression and purification of different TPH variants and 
proteases will be presented. The methods are described for 3 tubes of cells (corresponding to 1.95 L 
culture) whenever possible, but can easily be downscaled to one tube by using smaller columns. 
The construction of genes was performed by other members of the group, and will not be described. The 
expression and purification methods for chTPH2 and cthTPH2 were developed by Nielsen(9) and myself(11) 
in earlier projects, and have only been slightly modified in this project. The purification method for hTPH2 
without affinity tag was developed in my master thesis (11), and was also only slightly modified in this 
project. The modifications include purification without glycerol in the buffers and without reducing 
conditions (addition of dithiothreitol (DTT) and argon flow). 
During my PhD I have supervised several bachelor-students, who have contributed to the experimental 
work. Barbara Gonzalez, Stine Jørgensen and Mads Friis worked on purification, stability and kinetic 
analysis of hTPH1, Maria Oettinger on purification and mass spectrometry of chTPH1, Katrine Bünger on 
mass spectrometry of chTPH2 and Gro Nyborg on purification of hTPH2 using MBP as affinity tag. 
All chemicals used are of analytical grade and the term “water” refers to 18.2 MΩ/cm water from a Milli-Q 
synthesis A10 Q-Gard system (Millipore). During purification, all solutions containing TPH were kept on ice 
or at 4 °C except during the chromatographic steps, which were performed at room temperature. High-
performance liquid chromatography (HPLC) was performed using columns and an ÄKTApurifier 100 from GE 
Healthcare. Protein concentration was measured by ultraviolet-visible spectroscopy (UV-Vis) using a 
Nanodrop 1000 spectrophotometer from Thermo Scientific. Theoretical extinction coefficients at 280 nm 
(ε280nm) were determined according to reference (108) using the ProtParam program from the Expasy 
webpage(109). 
4.2.1 Expression 
E. coli BL21(DE3) strains expressing the target-protein from a pET26 expression vector were taken from 
frozen glycerol stocks and streaked into single colonies on a Luria Bertani (LB) agar plate containing either 
30 µg/mL kanamycin sulfate (30kan) or 100 µg/mL ampenicillin (100amp), according to Table 2. The plate 
was incubated overnight at 37 °C. A single colony was inoculated in 50 mL media in a 250 ml shake flask. 
This pre-culture was incubated at 37 °C and 250 rpm for approx. 4 hours until an optical density at 600 nm 
(OD600) of 0.6-1.0 was reached. The cells were transferred to a 50 mL polypropylene tube and sedimented 
by centrifugation at 4 °C and 1800 x g for 10 min. The cells were resuspended in 50 mL fresh media. 6.5 mL 
cell resuspension was used to inoculate 650 mL media in a 2 L triple baffled shake flask. The culture was 
incubated at 30 °C and 250 rpm. For most target-proteins, the temperature was lowered to 20 °C after 
approx. 3½, but for some it was kept at 30 °C, see Table 2. When an OD600 of 0.4-0.6 was attained, the 
target-protein expression was induced by addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final 
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concentration of 0.1 mM. For some target-proteins a freshly made sterile solution of (NH4)2Fe(II)(SO4)2 was 
added to a final concentration of 0.2 mM. The cells were incubated overnight at 20 °C/30 °C and 250 rpm. 
The cells were harvested by centrifugation at 4 °C and 3000 x g for 15 min. The cells from 650 ml culture 
were resuspendend in 25 ml of the appropriate buffer (see Table 2), transferred to 50 ml polypropylene 
tubes and centrifuged again at 4 °C and 3000 x g for 15 min. The supernatant was discarded and the cells 
were stored at -80 °C until further use. 
The expression of hTPH2 using auto-inducing media is described in reference (11). 
Table 2: Expression details of strains used in this project. HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. 
Variant 
Internal 
ID 
number 
Media 
Expression 
temperature 
Addition 
of Fe(II) 
Harvesting buffer 
GST-3CP HC2510 LB/100amp 30 °C No 
1xPBS, pH 7.3 
 
MBP-3CP HC2647 LB/30kan 30 °C No 
20 mM Tris/H2SO4, 70 mM 
(NH4)2SO4, pH 8.0 
GST-chTPH1 HC2641 LB/100amp 20 °C Yes 
1xPBS/NaOH, 200 
mM (NH4)2SO4, pH 8.5 
MBP-hTPH1 HC2595 LB/30kan 20 °C Yes 
20 mM Tris/H2SO4, 300 
mM (NH4)2SO4, pH 8.0 
MBP-rchTPH1 HC2750 LB/30kan 20 °C Yes 
20 mM Tris/H2SO4, 300 
mM (NH4)2SO4, pH 8.0 
chTPH2 HC1168 LB/30Kan 20 °C No 
20 mM Bis Tris 
Propane/HCl, pH 7.2 
cthTPH2 HC2334 LB/30Kan 20 °C No 
20 mM Bis Tris 
Propane/HCl, pH 7.2 
MBP-hTPH2 HC2878 LB/30kan 20 °C Yes 
20 mM HEPES/NaOH, 300 
mM (NH4)2SO4, pH 7.0 
MBP-rchTPH2 HC2875 LB/30kan 20 °C Yes 
20 mM HEPES/NaOH, 300 
mM (NH4)2SO4, pH 7.0 
4.2.2 Purification of proteases and cleavage test 
A simple purification of the affinity-tagged proteases was performed as described below. The procedure 
involved only one step, as the purity of the product is not of great importance. 
4.2.2.1 Purification of GST-3CP 
Cells expressing GST-3CP (HC2510) from 3 x 650 ml culture were resuspended in 1xPBS, pH 7.3 to a total 
volume of approx. 3 x 40 mL. The cells were lysed on ice by sonication for 3 x 30 sec using a Satorius 
Labsonic P at 80 % amplitude. The cell extract was centrifuged in high-speed centrifuge tubes at 18000 x g 
and 4 °C for 25 min. The supernatant was collected and filtrated through a 0.45 μm GHP Acrodisc GF syringe 
filter. The filtrated sample was loaded (1 ml/min) onto a 20 mL GSTPrep FF 16/10 column, which was 
equilibrated with 1xPBS, pH 7.3. The protein was eluted with 50 mM Tris/H2SO4, 50 mM (NH4)2SO4, 10 mM 
reduced glutathione, pH 8.0. Reduced glutathione was added just before use, followed by pH readjustment 
with H2SO4. The eluted protein was collected and exchanged into a storage buffer containing 50 mM 
Tris/H2SO4, 50 mM (NH4)2SO4, 1 mM DTT, 10 mM ethylenediaminetetraacetic acid (EDTA), 20 % glycerol, pH 
8.0. DTT was added just before use. The buffer exchange was performed by concentrating the protein using 
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ultrafiltration on an Amicon stirred pressure cell with a PL-3 membrane and subsequently diluting it with 
storage buffer. This was repeated three times. The concentration of GST-3CP was determined using ε280nm = 
64290 M-1 cm-1. The protein was stored at -20 °C. 
4.2.2.1.1 Cleavage test 
A cleavage test was performed in order to investigate the optimal ratio between GST-chTPH1 and GST-3CP 
for complete cleavage. GST-chTPH1 was purified as described in section 4.2.3.1 and mixed in different 
molar ratios with GST-3CP purified as described in section 4.2.2.1. The solution was left overnight at 4 °C 
The molar ratios tested were 1:1, 1:2, 1:4, 1:7, 1:15, 1:29, and 1:59 (GST-3CP:GST-chTPH1). To allow for a 
direct comparison on SDS-PAGE, all samples had the same total volume, and the concentration of GST-
chTPH1 was also kept constant.  
4.2.2.2 Purification of MBP-3CP 
Cells expressing MBP-3CP (HC2647) from 3 x 650 ml culture were resuspended in 20 mM Tris/H2SO4, 70 
mM (NH4)2SO4, pH 8.0 to a total volume of approx. 3 x 40 mL. The cells were lysed on ice by sonication for 3 
x 30 sec. The cell extract was centrifuged in high-speed centrifuge tubes at 18000 x g and 4 °C for 25 min. 
The supernatant was collected and filtrated. The filtrated sample was loaded (2.5 ml/min) onto a 20 mL 
Dextrin Sepharose HP 16/10 MBP column, which was equilibrated with 20 mM Tris/H2SO4, 70 mM 
(NH4)2SO4, pH 8.0. The protein was eluted with 20 mM Tris/H2SO4, 70 mM (NH4)2SO4, 10 mM maltose, pH 
8.0. The eluted protein was collected and exchanged into a storage buffer containing 50 mM Tris/H2SO4, 50 
mM (NH4)2SO4, 1 mM DTT, 10 mM EDTA, 20 % glycerol, pH 8.0. DTT was added just before use. The buffer 
exchange was performed by concentrating the protein using ultrafiltration and subsequently diluting it with 
storage buffer. This was repeated three times. The concentration of MBP-3CP was determined using ε280nm 
= 87780 M-1 cm-1. The protein was stored at -20 °C. 
4.2.2.2.1 Cleavage test 
A cleavage test was performed in order to investigate the optimal ratio between MBP-hTPH1 and MBP-3CP 
for complete cleavage. MBP-hTPH1 was purified as described in section 4.2.3.2 and mixed in different 
molar ratios with MBP-3CP purified as described in section 4.2.2.2. The solution was left overnight at 4 °C. 
The molar ratios tested were 1:3, 1:6, 1:50, 1:100, and 1:200 (MBP-3CP:MBP-hTPH1). To allow for a direct 
comparison on SDS-PAGE, all samples had the same total volume, and the concentration of MBP-hTPH1 
was also kept constant. 
4.2.3 Purification of TPH1 
Development of the purification procedure started with purification of GST-chTPH1. The original 
purification procedure for chTPH1 containing an anion-exchange step followed by a gel-filtration step was 
found insufficient, as mass spectrometry revealed impurities in the final product(10). Thus, a new method 
involving affinity tag was developed for chTPH1. Later, the method was extended to hTPH1, where MBP 
was used as affinity tag. The experimental procedures for the final purification procedures will be described 
in this section.  
4.2.3.1 Purification of GST-tagged chTPH1 
GST-chTPH1 was purified according to the general procedure shown in Figure 12 including an affinity step 
followed by gel-filtration, cleavage, a second affinity step and a second gel-filtration. The first gel-filtration 
was included to remove reduced glutathione from the solution, which would otherwise disturb the second 
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affinity step. The last gel-filtration step was included as a polishing step to remove any left-over GST or GST-
3CP and to allow for buffer exchange and monodispersity check.  
Cells expressing GST-chTPH1 (HC2641) from 3 x 650 ml culture were resuspended in 1xPBS/NaOH, 200 mM 
(NH4)2SO4, pH 8.5 to a total volume of approx. 3 x 40 mL. The cells were lysed on ice by sonication for 3 x 30 
sec. The cell extract was centrifuged in high-speed centrifuge tubes at 18000 x g and 4 °C for 35 min. The 
supernatant was collected and filtrated. The filtrated sample was loaded (2.0 ml/min) onto a 20 mL 
GSTPrep FF 16/10 column, which was equilibrated with 1xPBS/NaOH, 200 mM (NH4)2SO4, pH 8.5. The 
protein was eluted with 100 mM Tris/NaOH, 200 mM (NH4)2SO4, 10 mM reduced glutathione, pH 8.5. 
Reduced glutathione was added just before use, followed by pH readjustment. The eluted protein was 
collected and concentrated by ultrafiltration to approx. 5 mL. The concentrated sample was filtrated and 
loaded  onto a HiLoad Superdex 200 26/60 prep grade column, which was equilibrated with 1xPBS/NaOH, 
200 mM (NH4)2SO4, pH 8.5. The fractions containing GST-chTPH1 were collected and the concentration was 
determined using ε280nm = 76210 M
-1 cm-1.The cleavage was performed by mixing GST-3CP with GST-chTPH1 
in a molar ratio of 1:7. The solution was left overnight at 4 °C. The cleaved sample was filtrated and loaded 
(1 ml/min) onto a 20 mL GSTPrep FF 16/10 column, which was equilibrated with 1xPBS/NaOH, 200 mM 
(NH4)2SO4, pH 8.5. chTPH1 was collected from the flow-through, and the concentration was determined 
using ε280nm = 33350 M
-1 cm-1. Fe(II) was added in 1.5 x molar excess from a freshly made 100 mM 
(NH4)2Fe(II)(SO4)2 solution, and the sample was incubated for 15 min. The sample was concentrated by 
ultrafiltration to approx. 5 mL. The concentrated sample was filtrated and loaded  onto a HiLoad Superdex 
75 26/60 prep grade column, which was equilibrated with 1xPBS/NaOH, 200 mM (NH4)2SO4, pH 8.5. The 
fractions containing chTPH1 were collected and concentrated using ultrafiltration. The final product was 
frozen in liquid nitrogen and stored at -80 °C. 
4.2.3.2 Purification of MBP-tagged hTPH1 
MBP-hTPH1 was purified according to the general procedure shown in Figure 12.  
Cells expressing MBP-hTPH1 (HC2595) from 3 x 650 ml culture were resuspended in 20 mM Tris/H2SO4, 300 
mM (NH4)2SO4, pH 8.0 to a total volume of approx. 3 x 40 mL. The cells were lysed on ice by sonication for 3 
x 30 sec. The cell extract was centrifuged in high-speed centrifuge tubes at 18000 x g and 4 °C for 35 min. 
The supernatant was collected and filtrated. The filtrated sample was loaded (2.5 ml/min) onto a 20 mL 
Dextrin Sepharose HP 16/10 MBP column, which was equilibrated with 20 mM Tris/H2SO4, 300 mM 
(NH4)2SO4, pH 8.0. The protein was eluted with 20 mM Tris/ H2SO4, 300 mM (NH4)2SO4, 10 mM maltose, pH 
8.0. The eluted protein was collected and concentrated by ultrafiltration to approx. 5 mL. The concentrated 
sample was filtrated and loaded  onto a HiLoad Superdex 200 26/60 prep grade column, which was 
equilibrated with 20 mM Tris/H2SO4, 300 mM (NH4)2SO4, pH 8.0. The fractions containing MBP-hTPH1 were 
collected and the concentration was determined using ε280nm = 99700 M
-1 cm-1.The cleavage was performed 
by mixing MBP-3CP with MBP-hTPH1 in a molar ratio of 1:7. The solution was left overnight at 4 °C. The 
cleaved sample was filtrated and loaded (1.5 ml/min) onto a 20 mL Dextrin Sepharose HP 16/10 MBP 
column, which was equilibrated with 20 mM Tris/H2SO4, 300 mM (NH4)2SO4, pH 8.0. hTPH1 was collected 
from the flow-through, and the concentration was determined using ε280nm = 33350 M
-1 cm-1. Fe(II) was 
added in 1.5 x molar excess from a freshly made 100 mM (NH4)2Fe(II)(SO4)2 solution, and the sample was 
incubated for 15 min. The sample was concentrated by ultrafiltration to approx. 5 mL. The concentrated 
sample was filtrated and loaded  onto a HiLoad Superdex 200 26/60 prep grade column, which was 
equilibrated with 20 mM Tris/H2SO4, 300 mM (NH4)2SO4, pH 8.0. The fractions containing hTPH1 were 
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collected and concentrated by ultrafiltration. The final product was frozen in liquid nitrogen and stored at -
80 °C. 
The purification was also performed with 50 mM (NH4)2SO4, 300 mM Na2SO4 and 900 mM (NH4)2SO4 instead 
of 300 mM (NH4)2SO4 in all buffers.  
The solubility of GST-hTPH1 was tested in 20 mM Tris/H2SO4, 300 mM (NH4)2SO4, pH 8.0 using the first part 
of the procedure for MBP-hTPH1 described above. 
4.2.3.3 Purification of MBP-tagged rchTPH1 
MBP-rchTPH1 was purified using the exact same procedures as for MBP-hTPH1 described in section 4.2.3.2. 
The concentration was determined using the same extinction coefficients as for MBP-hTPH1, as the 
tetramerization domain in MBP-hTPH1 does not contribute to the absorption at 280 nm due to the lack of 
tryptophan, tyrosine and cystine residues. 
4.2.4 Purification of TPH2 
The purification procedure for chTPH2, cthTPH2, and hTPH2 without affinity tag are quite different from 
the previous described methods. They consist only of an anion-exchange step and a gel-filtration step, and 
can be performed in one day. The experimental procedures for purification of both non affinity-tagged and 
affinity-tagged TPH2 variants will be described here. 
4.2.4.1 Purification of chTPH2 
Cells expressing chTPH2  (HC1168) from 3 x 650 ml culture were resuspended in 20 mM Bis Tris 
Propane/HCl, pH 7.2 to a total volume of approx. 3 x 40 mL. The cells were lysed on ice by sonication for 3 x 
30 sec. The cell extract was centrifuged in high-speed centrifuge tubes at 18000 x g and 4 °C for 25 min. The 
supernatant was collected and filtrated. The filtrated supernatant was diluted with ice cold water to a 
conductivity of ~2 mS/cm. The diluted supernatant was loaded (7ml/min) onto a Q Sepharose High 
Performance 26/10 column, which was equilibrated in 20 mM Bis Tris Propane/HCl, pH 7.2. For elution, a 
linear gradient of 0-4 % 20 mM Bis Tris Propane, 0.8 M (NH4)2SO4, pH 7.2 (0-32 mM (NH4)2SO4)  over one 
column volume (CV) was applied to the column, followed by a gradient from 4-12 % 20 mM Bis Tris 
Propane, 0.8 M (NH4)2SO4, pH 7.2  (32-96 mM (NH4)2SO4) over 5 CV. The fractions containing chTPH2 were 
collected and the concentration was determined using ε280nm = 39310 M
-1 cm-1. Fe(II) was added in 1.5 x 
molar excess from a freshly made 100 mM (NH4)2Fe(II)(SO4)2 solution, and the sample was incubated for 15 
min. The sample was concentrated by ultrafiltration to approx. 5 mL. The concentrated sample was filtrated 
and loaded  onto a HiLoad Superdex 75 26/60 prep grade column, which was equilibrated with 20 mM 
HEPES/NaOH, 100 mM (NH4)2SO4, pH 7.2. The fractions containing chTPH2 were collected and concentrated 
using ultrafiltration. The final product was frozen in liquid nitrogen and stored at -80 °C. 
The gel-filtration step was performed in several different buffers including 300 mM NH4OAc and 20 mM 
HEPES/NaOH, 200 mM NaCl, pH 7.2. The purification has also been performed with 5 (w/v)% glycerol in all 
buffers. 
4.2.4.2 Purification of cthTPH2 
cthTPH2 was purified using the same method as for chTPH2 described in section 4.2.4.1, with the following 
exceptions: I) A linear gradient of 5-25 % 20 mM Bis Tris Propane, 0.8 M (NH4)2SO4, pH 7.2 (0-200 mM 
(NH4)2SO4) over 10 CV was applied to the anion-exchange column. II) ε280 = 40800 M
-1 cm-1 for cthTPH2. III) 
A HiLoad Superdex 200 26/60 prep grade column was used in the gel-filtration step. 
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The gel-filtration step was performed in several different buffers including 0.3 M NH4OAc /NH3, pH 7.2 and 
10 mM HEPES/NaOH, 200 mM NaCl, pH 7.2 The purification has also been performed with 10 (w/v)% 
glycerol in all buffers for an extra stabilizing effect. 
4.2.4.3 Purification of hTPH2 
The purification procedure for hTPH2 was developed in reference (11), and generally follows the same 
procedure as for chTPH2 and cthTPH2. Only small modifications to the procedure have been performed in 
this project. 
hTPH2 was purified using the same methods as for chTPH2 described in section 4.2.4.1, with the following 
exceptions: I) A linear gradient of 0-35 % 20 mM Bis Tris Propane, 0.8 M (NH4)2SO4, pH 7.2 (0-280 mM 
(NH4)2SO4) over 10 CV was applied to the anion-exchange column. II) 2M (NH4)2SO4 solution was added to 
the protein sample to a final concentration of 100 mM after the anion-exchange step. III) ε280 = 53290 M
-1 
cm-1 for hTPH2. IV) A HiLoad Superdex 200 26/60 prep grade column was used in the gel-filtration step. 
4.2.4.4 Purification of MBP-tagged rchTPH2 
MBP-rchTPH2 was purified using the same procedures as for MBP-hTPH1 described in section 4.2.3.2, with 
the following exceptions: I) Only one tube of cells was used for the purification. II) The buffers used were 20 
mM HEPES/NaOH, 300 mM (NH4)2SO4, pH 7.0 and 20 mM HEPES/NaOH, 300 mM (NH4)2SO4, 10 mM 
maltose, pH 7.0. III) The MBP column used was a MBPTrap HP 5 mL column. IV) ε280 = 118150 M
-1 cm-1 for 
MBP-rchTPH2 and ε280 = 51800 M
-1 cm-1 for rchTPH2. 
4.2.4.5 Purification of MBP-tagged hTPH2 
MBP-hTPH2 was purified using the same procedures as for MBP-hTPH1 described in section 4.2.3.2, with 
the following exceptions: I) The buffers used were 20 mM HEPES/NaOH, 300 mM (NH4)2SO4, pH 7.0 and 20 
mM HEPES/NaOH, 300 mM (NH4)2SO4, 10 mM maltose, pH 7.0. II) ε280 = 119640 M
-1 cm-1 for MBP-hTPH2 
and ε280 = 53290 M
-1 cm-1 for hTPH2. 
4.2.5 Characterization methods 
The experimental procedures for the characterization methods used in this chapter are presented here. 
4.2.5.1 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out as described here. 
Tris-HCl gels from Bio-Rad were used and depending on the target protein 7.5 %, 12 % or 18 % gels were 
chosen for optimal separation. The gels were prepared as described in the standard protocol from Bio-
Rad(110). Compositions of buffers and solutions used can be seen in Table 3.  
Table 3: Composition of buffers and solutions used for SDS-PAGE. 
Buffer Composition 
Running buffer 3.0 g Tris base, 14.4 g glycine and 5 ml 20 % SDS diluted to 1 L with water 
Sample buffer 2.0 ml water, 2.0 ml 1.0 M Tris/HCl pH 6.8, 4.0 ml glycerol, 2.0 ml 10 % SDS, 4 
mg Coomassie Blue G-250 
Before use 28 μl β-mercaptoethanol was mixed with 190 μl of sample buffer 
Fixative solution 500 ml water, 400 ml 96% ethanol, 100 ml glacial acetic acid 
Staining solution 900 ml water, 100 ml glacial acetic acid, 0.25g Coomassie blue G-250 
De-staining solution 900 ml water, 100 ml glacial acetic acid 
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The marker contained 0.5 μl protein-standard (nr. 161-0304 from Bio-Rad) and 19.5 μl water. All samples 
were mixed with 5 μl sample buffer and heated at 80 °C for 10 min. The samples were loaded into the wells 
and the proteins were separated at 100 V for approx. 90 min with running buffer. After electrophoresis the 
gels were transferred to a fixing solution and soaked for 30 min. The gels were then stained for 1 hour in a 
staining solution, followed by overnight de-staining. 
4.2.5.2 Activity assay 
The activity measurements were performed on a Varian Cary Eclipse Fluorescence Spectrophotometer. The 
excitation wavelength was 300 nm and the emission was measured at 330 nm. Excitation and emission slits 
were 5 nm and the photomultiplicator tube voltage was 650 V. The measurements were done in 10.00 mm 
x 10.00 mm QS quartz cuvettes from Helma. The fluorescence spectrophotometer was equipped with a 
temperature-controlled-four-cuvette holder with stirring. All measurements were conducted at 15 °C. 
For standard activity measurement, the TPH sample was thawed on ice and centrifuged for 15 min at 17000 
x g in a Heraeus Pico centrifuge at 4 °C. The supernatant was collected, and the concentration was 
determined by at least 3 consecutive measurements using the NanoDrop spectrophotometer and the 
corresponding extinction coefficient at 280 nm. The sample was diluted to a concentration of 9.4 µM in the 
corresponding gel-filtration buffer and stored on ice. 
The assay volume was 2500 µl and contained the components shown in Table 4. Buffer, premix, TPH 
sample, and MilliQ water was added to the cuvette containing a small magnetic stirring bar. The cuvette 
was placed in the sample holder, stirring was started, and the temperature was allowed to equilibrate for 2 
min. The measurement was started, and after 30 s BH4 was added to initiate the reaction. 
Table 4: Concentration and volumes of stock solutions used in the activity assay. 
Stock solution Content Concentration in 
stock solution 
Volume added 
to assay 
Concentration 
in assay 
Buffer 
(room temperature) 
HEPES/NaOH, pH 7,0 
(NH4)2SO4 
125 mM 
500 mM 
1000 μL 50 mM 
200 mM 
Premix 
(freshly mixed) 
Catalase 
(-20 ˚C) 
1,25 g/L 50 μL 0,025 g/L 
(NH4)2Fe(II)(SO4)2∙6H2O 
(freshly prepared) 
1,27 mM 50 μL 25 μM 
DTT 
(freshly prepared) 
175 mM 100 μL 7 mM 
Tryptophan 
(-20 ˚C) 
3,0 mM 50 μL 60 μM 
TPH 
(-80 ˚C) 
TPH diluted in 
purification buffer 
9.4 μM 400 μL 1.5 μM 
MilliQ water   800 μL   
BH4 
(-20 ˚C) 
 15 mM 50 μL 300 μM 
The initial slope (int/min) was determined using the fluorescence spectrophotometer software. The 
software performs linear regression on an interval of the progression curve. The interval was selected 
manually and individually for each measurement, but stretched over minimum 0.04 min. The initial rate 
was converted to µM 5-OH-trp/min from standard curves produced in earlier projects(9). To calculate the 
specific activity, this value was divided by protein concentration. 
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When activity was measured during purification, the protein concentration was often low. In order to 
determine if any TPH was present in such low concentration samples, the temperature of the assay was 
occasionally increased. When determining specific activity, the measurements were always performed at 
15 °C. 
4.2.5.3 Stability studies by DSF 
Differential scanning fluorimetry (DSF) can be used to determine the melting or unfolding temperature of a 
protein under different conditions. Here, it is used to study the stabilizing effect of different buffer 
compositions. All DSF measurements were performed at the Cassiopeia crystallization facility at MaxLab in 
Lund under supervision of Facility Manager Dr. Maria Håkansson. The results shown in this thesis are all 
from home-made non-commercial screens. 
All screen solutions were prepared with concentrations 1.3 x the final concentration. They were transferred 
to a deep well block in volumes of 1.5 mL and frozen until use. At the crystallization facility, the deep well 
block was thawed and a Tecan pipetting robot was used to distribute the screen solutions to a white 
ABgene 96 well PCR plate (low profile, no skirts). 24 µL screen solution was added to each well. Protein 
solutions were made by diluting the concentrated protein to 300 µg/mL in 10 mM HEPES/NaOH, pH 7.0 
(chTPH2 and cthTPH2) or 20 mM Tris/H2SO4, 300 mM (NH4)2SO4, pH 8.0 (chTPH1 and hTPH1). This gives a 
protein concentration of 75 µg/mL in the final screen solution. SyPro orange was added in a volume ratio of 
1:333, meaning that 1.5 µL SyPro orange was added to 500 µL protein solution. 8 µL protein solution with 
SyPro orange was added to each well in the PCR plate already containing 24 µL screen solution, to a total 
volume of 32 µL. The PCR plate was covered with clear PCR seal film and centrifuged at 200 x g for 1 min. It 
was then placed in an AH diagnostics Stratagene Mx3005p realtime PCR instrument. The fluorescence of 
SyPro orange was measured in the temperature interval 25-95 °C with an increase of 1 °C/min using an 
excitation wavelength of 492 nm and an emission wavelength of 610 nm. The melting temperature of the 
protein was determined as the maximum of the first derivative of the fluorescence curve. 
The different screen conditions that were tested will not be presented here, but can be found in the results 
and discussion in section 4.3.2.3 and 4.3.3.3. 
4.2.5.4 Mass spectrometry 
All mass spectrometric measurements were performed on a LCT Premier mass spectrometer from Waters, 
Manchester, UK. The mass spectrometer is equipped with a Z-spray nano-flow ESI (electrospray ionization) 
source and an orthogonal acceleration time-of-flight (oa-TOF) mass analyzer(111).  
For mass spectrometric analysis, protein samples were thawed, and exchanged into the volatile mass 
spectrometry buffer using Micro Bio-Spin 6 Chromatography columns from Bio-Rad. The mass 
spectrometry buffers used contain NH4OAc in different concentrations (0.3-1.0 M) and some had pH 
adjusted. For denaturing conditions, 2-5 % formic acid was used. Some samples were filtrated using a 0.22 
µm Millex-GV syringe filter.  The protein concentration varied between 2-25 µM.  
The instrument was calibrated with a solution of cesium iodide containing 100 mg/mL in 50 % 2-propanol. 
Typical instrument settings were: Sample cone 25 V, capillary voltage 1100-1800 V, cone gas-flow 20 L/h, 
source temperature 30 °C and ion guide 5-150 V. The function MaxEnt1 in the software suite MassLynx 4.1 
was used to determine the mass of the detected ions. 
 4 Purification   
   
  
  
25 
 
4.2.5.5 Monodispersity test 
The monodispersity of purification products were tested after concentrating and freezing, following the 
general method described here. The protein sample was thawed, and either centrifuged (2000 x g, 3 
minutes) or filtrated. 250-500 µL sample was loaded on an analytical gel-filtration column corresponding to 
the gel-filtration column used in the last purification step (Superdex 75 10 300 GL or Superdex 200 10 300 
GL). The column was equilibrated in the same buffer used in the last gel-filtration step in the purification. If 
several peaks were observed in the first run, the main peak was collected and loaded on the column again, 
to see if the sample remains monodisperse or if an equilibrium between different oligomer species is 
present. 
4.3 Results and discussion 
In this section, the results from the purification part of this project will be presented and discussed. First, 
the results from the purification and cleavage test of proteases will be given. This is followed by a 
presentation of the purification results for TPH1 variants and then TPH2 variants. In the end of this section 
an overall discussion is provided comparing the many purification and characterization results from 
different variants giving an overview of the data obtained in this project. 
4.3.1 Purification of proteases and cleavage test 
Both proteases were purified using a simple one-step purification method with affinity chromatography. 
The proteases were then exchanged into a storage buffer. If the proteases are stored in elution buffer, 
cleavage is less effective and requires large amount of protease (data not shown). Furthermore, the 
protease looses activity upon freezing if kept in elution buffer, however exchange into storage buffer 
eliminates this activity loss. The storage buffer resembles that from previous publications on 3CP(112, 113), 
and includes DTT, EDTA and glycerol for stabilization. 
4.3.1.1 Purification of GST-3CP 
The procedure described in section 4.2.2.1 was followed and GST-3CP was collected from the elution peak 
of the affinity step. SDS-PAGE analysis shows that the solution contains GST-3CP, and some GST impurity 
(data not shown). Both can be removed from the target-protein solution after cleavage using affinity 
purification. The yields of GST-3CP were 5-8 mg/L culture, which is rather low compared to the yield of 
MBP-3CP (vide infra, see section 4.3.1.2). 
4.3.1.1.1 Cleavage test 
A cleavage test was performed in order to determine which ratio of protease to protein that is optimal and 
gives complete cleavage, as described in section 4.2.2.1.1. GST-chTPH1 purified as described in section 
4.2.3.1 was used as test protein. The cleavage test included different molar ratios of protease to protein, 
and the resulting SDS-PAGE can be seen in Figure 13. A complete cleavage is seen for all ratios from 1:1 to 
1:7. For the ratio 1:15 there is a weak band representing GST-chTPH1, indicating that cleavage was not 
complete. This band becomes even stronger for ratios 1:29 and 1:59. A ratio of protease to protein of 1:7 
was chosen as optimal, since the cleavage is complete and it allows for the smallest consumption of 
protease. The latter is also an important parameter, especially since the yield of the protease purification is 
rather low. 
  
Figure 13: SDS-PAGE analysis of the cleavage test for GST
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4.3.2 Purification of TPH1 
In this section, the results from the development of different purification methods for TPH1 will be 
presented. First, the purification of GST-tagged chTPH1 will be described, followed by purification of MBP-
tagged hTPH1 and rchTPH1. A section on stability studies of purified chTPH1 and hTPH1 using DSF is also 
included. 
4.3.2.1 Purification of GST-tagged chTPH1 
A method for purification of chTPH1 has been developed in earlier projects(13). This methods includes an 
anion-exchange step followed by a gel-filtration step, and can be performed in one day. However, a mass 
spectrometric analysis of the intact chTPH1 product from this purification method showed significant 
impurities(10). Thus, a new method for purification was developed using GST as affinity tag. 
The overall purification method consists of an affinity step followed by a gel-filtration step. Then the 
sample is cleaved overnight by GST-3CP and the product is again purified by an affinity step and a 
gelfiltration step. The first gel-filtration step is included to remove any gluthathione in the solution left over 
from the first affinity step, so it does not interfere with the second affinity step. The last gel-filtration step 
allows for buffer change and for checking monodispersity and size of the purified protein. 
The chromatogram from the first affinity step in the purification of GST-chTPH1 can be seen in Figure 15. 
 
Figure 15: Chromatogram from the affinity purification of GST-chTPH1 on a GST FF 16/10 column. FT1: First part of the flow-
through. FT2: Last part of the flow-through.The fractions marked with dashed lines were collected for further purification. 
GST-chTPH1 was collected from the eluate, concentrated and loaded onto a gel-filtration column, resulting 
in the chromatogram shown in Figure 16. The major peak (P3) contains GST-chTPH1. P1 and P2 also contain 
GST-chTPH1 and must be oligomer forms of the protein. According to the calibration curve of the column 
and the elution volume, GST-chTPH1 exists as a dimer or even trimer with an approx. size of 170 kDa (GST-
chTPH1: 62.5 kDa). As GST is known for dimerizing(105), GST-chTPH1 most likely exists as a dimer.  
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Figure 16: Chromatogram from the gel-filtration of GST-chTPH1 on a HiLoad Superdex 200 26/60 prep grade column. The 
fractions marked with dashed lines were collected for cleavage and further purification. 
The purified GST-chTPH1 was cleaved overnight using GST-3CP. The cleaved sample was loaded on the 
affinity column again, and the flow-through containing chTPH1 was collected, as shown in Figure 17. In this 
step the sample is loaded very slowly (1 mL/min) to allow for all GST species to bind to the column. Earlier 
purifications have shown that if the loading flow-rate is 2.5 mL/min, some GST does not bind to the column, 
and is thus found in the flow-through together with chTPH1. GST and chTPH1 cannot be separated in the 
last gel-filtration step due to their very similar sizes (36 kDa for chTPH1 vs. 26 kDa for GST), and thus it is of 
great importance that the sample is loaded slowly. In the protocol for the GST column it is also 
recommended to keep the flow rate low during sample loading for maximum binding capacity, due to the 
relatively slow binding kinetics between GST and gluthathione. A lower flow rate thus ensures a longer 
residence time.  
 
Figure 17: Chromatogram from the affinity purification of cleaved GST-chTPH1 on a GST FF 16/10 column. FT1: First part of the 
flow-through. FT2: Last part of the flow-through. The fractions marked with dashed lines were collected for further purification. 
The flow-through of the last affinity step is collected, concentrated and loaded on a gel-filtration column. 
As chTPH1 is expected to be monomeric, a superdex 75 column is used instead of superdex 200 as in the 
first gel-filtration step. The chromatogram in Figure 18 shows only one peak (P4), which contains chTPH1. 
 4 Purification   
   
  
  
29 
 
The protein solution was thus pure already before the last gel-filtration step, which could be omitted. 
However, if buffer exchange is needed, the gel-filtration step can be included. Also, the chromatogram 
confirms that chTPH1 exists as a monomer (approx. 40 kDa according to elution volume) and is 
monodisperse before freezing. 
 
Figure 18: Chromatogram from the gel-filtration of cleaved GST-chTPH1 on a HiLoad Superdex 75 26/60 prep grade column. The 
fractions marked with dashed lines were collected as the final product. 
The SDS-PAGE analysis of the entire purification is shown in Figure 19. GST-chTPH1 is partly soluble as a 
relatively large amount is found in the pellet after sonication. The pellet has been resuspended in the same 
volume of buffer as the raw extract, so the bands can be directly compared. However, approx. 60 % of the 
expressed GST-chTPH1 is soluble and found in the supernatant. 
 
Figure 19: SDS-PAGE analysis of the purification of GST-tagged chTPH1. M: Molecular weight standard. R: Raw extract. S: 
Supernatant. P: Resuspended pellet. FT1: First part of the flow-through from the GST-column during sample loading. FT2: Last 
part of the flow-through. E: Eluate. P1-P3: Peaks from the first gel-filtration. BC: Before cleavage. AC: After cleavage. Pr: 
Precipitate observed after cleavage. FT: Entire flow-through mixed. P4: Peak from the second gel-filtration. 
 In the first affinity step, minor amounts of GST-chTPH1 are found in both the first and last part of the flow-
through. This suggests that the loading speed (2.5 mL/min) is too fast to ensure a complete binding of GST-
chTPH1. If the column had been overloaded, GST-chTPH1 would only be seen in the last part of the flow-
through. The loading speed of this first affinity step was kept at 2.5 ml/min despite the loss of sample, as 
the step would otherwise be very time-consuming (the sample size is 120 mL). The loss of target protein in 
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this first step does not affect the purity of the final sample but merely the yield of the purification. In the 
eluate from the first affinity column, most GST-chTPH1 is found. All three peaks (P1, P2, and P3) from the 
first gel-filtration contain GST-chTPH1, and P1 and P2 must thus represent oligomer species (soluble 
aggregates). The sample of GST-chTPH1 from the first gel-filtration appears pure, and can be completely 
cleaved. In some purifications, precipitation was observed after cleavage. This precipitate apparently 
contains chTPH1, and thus the precipitation should lower the final yield. The flow-through from the second 
affinity step contains pure chTPH1, while GST and GST-3CP is found in the eluate. P4 from the last gel-
filtration contains pure chTPH1. 
The purity of the final product was also investigated with SDS-PAGE by loading different volumes of the 
product. Figure 20 shows, that the chTPH1 solution is completely pure, as no impurities are seen on the gel.  
 
Figure 20: SDS-PAGE analysis of the final product of purified chTPH1. M: Molecular weight standard. Numbers: Volume in µL 
loaded on the gel. 
The purity was furthermore checked by mass spectrometry, and the mass spectrum of intact chTPH1 is 
seen in Figure 21. The calculated mass of the only species present is 36540.9 Da. This mass corresponds 
very well with the theoretical mass of holo-chTPH1, which is 36530.6 Da. It can once again be concluded 
that the sample is pure and contains chTPH1. Addition of EDTA to the sample gave a decrease in the mass 
of 57.9 Da corresponding to the removal of Fe(III) with a theoretical mass of 52.8 Da (data not shown). 
 
Figure 21: Mass spectrum of 4 µM chTPH1 in 600 mM NH4Ac/NH3, pH 7.5. The calculated mass is 36540.9 Da. 
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To further characterize purified chTPH1, it was denatured using 2 % formic acid. The resulting mass 
spectrum is seen in Figure 22. Again, only one species is present with a mass of 36479.4 Da. The theoretical 
mass of apo-chTPH1 is 36477.8 Da, so again the masses match very well. 
 
Figure 22: Mass spectrum of 4 µM denatured chTPH1 in 30 mM NH4OAc incubated with 2 % formic acid. The calculated mass is 
36479.4 Da. 
Finally, the purified product was tested in an activity assay (see section 4.4). Here, the specific activity is 
given as µmol 5-OH-trp/µmol TPH/min in units of min-1 as this allows for a direct comparison between 
different TPH variants. chTPH1 showed a specific activity of 92 ± 2.2 min-1 which is in the same range as 
previously determined(13). 
It can be concluded that the purification procedure gives pure and active chTPH1, and that the previous 
impurity is not present. 
The overall yield of the purification was in the range 10-11 mg/L culture. UV-Vis measurements were 
performed after each step in order to identify any critical steps in the purification, see Table 5. When 
calculating the yield, all absorbance at 280 nm is assigned to TPH, and thus removal of impurities will also 
result in a decrease in yield. The product from the first affinity purification is considered 100 %, as it is not 
possible to determine the amount of TPH in the raw extract by UV-Vis. From the SDS-PAGE analysis it is 
known that some GST-chTPH1 is lost in this first affinity step. This loss is most likely due to the high flow-
rate of 2.5 ml/min and not because the column is overloaded, as the yield of the first step is significantly 
lower than the binding capacity of the column (approx. 6-7 µmol). 
Table 5: Protein yield after each step in the purification of GST-tagged chTPH1. The yield was calculated from the absorption at 
280 nm assuming that the samples contained only GST-chTPH1 or chTPH1 (after cleavage). The yield in % is given assuming that 
the first affinity step corresponds to 100 %. 
Step 
GST-chTPH1 
Yield 
[µmol] [%] 
1st affinity step 2.4 100 
1st gel-filtration step 1.0 43 
2nd affinity step 1.0 42 
2nd gel filtration 0.6 25 
4.3 Results and discussion 
   
32 
 
Approx. half of the protein is lost in the first gel-filtration. The cleavage and second affinity step is very 
effective and retains almost all chTPH1, despite the observed precipitation. The last gel-filtration step again 
has some loss of protein most likely due to concentration of the sample by ultrafiltration prior to sample 
loading. The loss of protein in the last gel-filtration step suggests that if the yield of the process should be 
optimized, the last purification step should be omitted, as it does not increase the purity of the sample. 
4.3.2.1.1 Monodispersity 
For crystallization and most other characterization techniques, a monodisperse sample usually gives the 
best results(95). In the crystallization setup process, the purified protein is thawed and directly used. To 
test the monodispersity of the frozen protein solution, the final product from the purification was thawed 
and loaded onto an analytical gel-filtration column. The resulting chromatograms are shown in Figure 23. 
The first run reveals that the thawed chTPH1 solution is not completely monodisperse, as a small peak is 
seen in front on the main peak. The small peak most likely represents aggregated chTPH1. The main peak 
from the first run was collected and loaded on the analytical gel-filtration column again. This time there is 
only one visible peak in the chromatogram. From the chromatogram of the last gel-filtration in the 
purification shown in Figure 18 it is known that purified chTPH1 is monodisperse right after purification. 
Thus, it can be concluded that even though chTPH1 is monodisperse right after purification, it becomes 
slightly polydisperse upon freezing and thawing. The monodispersity of the sample can be regained by gel-
filtration. 
 
Figure 23: Chromatograms from the analytical gel-filtrations of thawed chTPH1 on a Superdex 75 10 300 GL column. Red: The 
first run of thawed chTPH1. Fractions marked with dashed lines were collected and loaded again for the second run. Blue: The 
second run of chTPH1 collected from the main peak in the first run. The slightly shifted positions of the two peaks arise from 
different loading volumes (250 µL in the first run, 500 µL in the second). 
4.3.2.2 Purification of MBP-tagged hTPH1 
The successful purification of GST-chTPH1 inspired to also test this new method involving affinity 
purification with full-length hTPH1. As GST was not suitable as affinity tag for the tetrameric hTPH1 (vide 
infra), MBP was instead used as the preferred tag. The purification method of hTPH1 presented here was 
developed through several stages. First, the method only contained an affinity step after the cleavage, but 
SDS-PAGE analysis revealed that MBP impurities were still found in the product. Thus, an extra gel-filtration 
step was added at the end of the purification.  
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from the MBP affinity-tag. The pH of the buffer was chosen to 8.0. The theoretical pI of hTPH1 is calculated 
to 6.8(109), and 8.0 is well above this, theoretically ensuring a more soluble protein. 
 
Figure 25: SDS-PAGE analysis of the solubility test of MBP-hTPH1. Left: Salt solubility test. In all samples the background buffer 
was 20 mM Tris/H2SO4, pH 8.0. Right: pH solubility test. In all samples the background buffer was 20 mM Tris/H2SO4, 300 mM 
(NH4)2SO4. M: Molecular weight standard. R: Raw extract. S: Supernatant. P: Resuspended pellet. 
MBP-hTPH1 was purified according to the procedure described in section 4.2.3.2. It was first attempted to 
leave out several steps in the process to get as simple a procedure as possible. However, most steps turned 
out to be necessary to avoid impurities in the final product. The gel-filtration after the first affinity step was 
included to remove maltose from the solution, which would otherwise disturb the second affinity step. 
Furthermore, soluble aggregates of MBP-hTPH1 were observed, which could not be effectively cleaved, and 
these could also be discarded in the first gel-filtration step to minimize consumption of protease. The last 
gel-filtration step was included as the second affinity step did not completely remove all MBP species from 
the solution. The chromatogram from the first affinity purification is found in Figure 26. MBP-hTPH1 is 
found in the eluate, and is collected for further purification.  
 
Figure 26: Chromatogram from the affinity purification of MBP-hTPH1 on a 20 mL Dextrin Sepharose HP 16/10 MBP column. FT1: 
First part of the flow-through. FT2: Last part of the flow-through. The fractions marked with dashed lines were collected for 
further purification. 
The product from the first affinity purification was concentrated and loaded on a gel-filtration column. The 
resulting chromatogram is seen in Figure 27. Both peaks (P1 and P2) contain MBP-hTPH1. According to the 
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calibration curve of the column, P2 corresponds to tetrameric MBP-hTPH1 and this peak is selected for 
further purification. The first peak (P1) elutes in the dead volume of the column and contains MBP-hTPH1, 
which is also active (data not shown). Thus, this peak might represent soluble aggregates of MBP-hTPH1. 
Attempts to minimize this peak by testing different buffers failed. SDS-PAGE analysis shows that MBP-
hTPH1 from this peak cannot be completely cleaved (data not shown), which supports the hypotheses that 
it contains large aggregates, where the protease might not be able to reach the inside to cleave effectively. 
 
Figure 27: Chromatogram from the gel-filtration of MBP-hTPH1 on a HiLoad Superdex 200 26/60 prep grade column. The 
fractions marked with dashed lines were collected for cleavage and further purification. 
SDS-PAGE analysis for the purification of MBP-hTPH1 up until cleavage is shown in Figure 28. It is seen that 
most MBP-hTPH1 binds to the affinity column and can be eluted. However, a small part is found in the flow-
through, especially in the last part of the sample loading, indicating that the binding capacity of the column 
is exceeded. The eluate from the first affinity purification contains almost exclusively MBP-hTPH1. The SDS-
PAGE analysis of the first gel-filtration shows that both peaks (P1 and P2) and the valley between them 
contain MBP-hTPH1. 
 
Figure 28: SDS-PAGE analysis of first part of the purification of MBP-hTPH1. Left: Sample preparation and first affinity step. M: 
Molecular weight standard. S: Supernatant. P: Resuspended pellet. FT1: First part of the flow-through during sample loading on 
the MBP affinity column. FT2: Last part of the flow-through. E: Eluate from the affinity column. Right: Gel-filtration. P1-P2: Peaks 
from first gel-filtration shown in Figure 27. V: Valley between P1 and P2. 
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The product from the gel-filtration containing MBP-hTPH1 was cleaved with MBP-3CP overnight, and 
loaded on the MBP column again. The chromatogram of this second affinity step can be seen in Figure 29. 
hTPH1 can be found in the flow-through, while most MBP and MBP-3CP binds to the column and is found in 
the eluate. 
 
Figure 29: Chromatogram from the affinity purification of cleaved MBP-hTPH1 on a 20 mL Dextrin Sepharose HP 16/10 MBP 
column. The fractions marked with dashed lines were collected for further purification. 
The flow-through containing hTPH1 is concentrated and loaded onto the gel-filtration column for the last 
purification step. The chromatogram is seen in Figure 30. The main peka P4 contains hTPH1, and according 
to the calibration curve the size corresponds to a tetramer as expected. 
 
Figure 30: Chromatogram from the gel-filtration of cleaved MBP-hTPH1 on a HiLoad Superdex 200 26/60 prep grade column. The 
fractions marked with dashed lines were collected as the final product. 
The SDS-PAGE analysis of the last part of the purification of hTPH1 is seen in Figure 31, and shows that the 
sample from the first gel-filtration containing MBP-hTPH1 is completely cleaved after 16 hours. 
Furthermore, the cleavage process seems rather fast, as it is almost complete after only 10 minutes. The 
flow-through from the second affinity step contains hTPH1 mixed with impurities of MBP and MBP-3CP. 
The last affinity step is thus not effective enough to remove all MBP species, all though a large part of the 
impurities have been removed. The SDS-PAGE analysis of the peaks from the last gel-filtration shows that 
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P4 contains hTPH1, and so does the shoulder on the left called P3. P5 contains MBP-3CP and P6 contains 
MBP, which have not been removed in the affinity step. The purity of the final product is confirmed by 
loading different volumes of the final product. No impurities are seen. 
 
Figure 31: SDS-PAGE analysis of the second part of the purification of MBP-tagged hTPH1. Left: The cleavage of MBP-hTPH1 using 
MBP-3CP. M: Molecular weight standard. BC: Product from the first gel filtration before cleavage. 10 m: 10 minutes after 
addition of protease. 16 h: 16 hours after addition of protease. Center: Second affinity and gel-filtration steps. FT: Flow-through 
from the second affinity step. P3-P6: Peaks from the last gel-filtration. Right: The final product of hTPH1. Numbers: µL loaded on 
the gel. 
To confirm the purity and identity of the final product, mass spectrometric measurements of the intact 
protein were made as described in section 4.2.5.4. The identification of large intact protein complexes such 
as tetrameric hTPH1 is a relatively new achievement, which represents state-of-the-art in protein mass 
spectrometry(118). The m/z spectrum obtained from 7 µM hTPH1 in 1 M NH4OAc is shown in Figure 32. It 
shows only one major species, which is assigned to tetramer hTPH1. The calculated mass is 204929 Da. This 
corresponds well with the theoretical mass of tetramer hTPH1 including Fe(III) which is 204820 Da. It can 
thus be concluded that the final product from the purification contains pure tetrameric hTPH1. 
 
Figure 32: Mass spectrum of 7 µM hTPH1 in 1 M NH4OAc. The calculated mass is 204929 Da. 
Further investigations of the final product were performed by analyzing a denatured sample of hTPH1 also 
with mass spectrometry. Using 5 (v/v)% formic acid hTPH1 was partly unfolded, and the resulting mass 
spectrum in Figure 33 nicely shows the breakdown of the tetramer to dimer, monomer and unfolded 
(denatured) monomer. Mass analysis on the unfolded monomer gave a calculated mass of 51156 Da. This 
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mass is very similar to the theoretical mass of apo hTPH1 monomer of 51152 Da. This confirms once again 
that the sample contains hTPH1. 
The final product of the purification was also tested in the activity assay, and purified hTPH1 showed 
significant activity for hydroxylation of tryptophan with a specific activity of 164 ± 3.1 min-1. 
It can be concluded that the purification method developed for hTPH1 gives pure, soluble and active 
hTPH1. 
 
Figure 33: Mass spectrum of 7 µM hTPH1 in 0.33 M NH4OAc and 5(v/v) % formic acid. The calculated mass of the unfolded 
monomer was 51156 Da. 
The overall yield from the purification was in the range 16-23 mg/L culture. Furthermore, the yield of 
protein after each purification step was calculated, see Table 6. The yield is shown for both a standard 
purification, and for a purification with low salt concentration in all buffers (50 mM (NH4)2SO4). The yield 
from the first affinity step was considered 100 %. From SDS-PAGE it is known that some MBP-hTPH1 is lost 
in the last part of the flow-through, probably due to the limited binding capacity of the MBP column. 
Comparison of the yield after the first affinity step (2.4 and 3.3 µmol) with the expected binding capacity of 
the MBP column (approx. 2.5 µmol depending on the protein) supports this hypothesis. However, if the 
flow-through is loaded on the affinity column again, almost no MBP-hTPH1 binds to the column, and 90 % is 
found in the flow-through again. The reason for this is unknown, but the phenomenon was also observed in 
purification of all other MBP-tagged TPH variants (vide infra).  
Table 6: Protein yield after each step in the purification of MBP-hTPH1 with high and low salt concentrations (300 mM and 50 
mM (NH4)2SO4, respectively). The yield was calculated from the absorption at 280 nm assuming that the samples contained only 
MBP-hTPH1 or hTPH1 (after cleavage). The yield in % is given assuming that the first affinity step corresponds to 100 %.  
Step 
MBP-hTPH1 
300 mM (NH4)2SO4 
MBP-hTPH1 
50 mM (NH4)2SO4 
Yield Yield 
[µmol] [%] [µmol] [%] 
1st affinity step 2.4 100 3.3 100 
1st gel-filtration step 1.1 48 1.8 28 
2nd affinity step 1.2 52 1.6 27 
2nd gel filtration 0.6 26 0.4 12 
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Appproximately half of MBP-hTPH1 is lost in the first gel-filtration step. This is most likely due to the 
aggregated species eluting in P1 in Figure 27. The increase in yield from the first gel-filtration to the second 
affinity step most likely originates from the presence of impurities in the flow-through of the affinity step 
after cleavage, which contributes to the absorption. The second affinity step is not completely effective, 
and some MBP and MBP-3CP impurities are still found in the flow-through. In the last gel-filtration almost 
half of hTPH1 is lost again. The decrease in yield could be caused by a combination of impurities that are 
removed and hTPH1 that precipitates or is lost during concentration.  
The purification method developed here is very similar to the one developed by McKinney et al(98). It 
differs mainly in the buffers used. McKinney et al uses 20 mM Na–HEPES buffer, pH 7.0, 20 % glycerol, 1mM 
PMSF (serine protease inhibitor) for the affinity step, and 15 mM Na–HEPES, pH 7.4, 200 mM NaCl for the 
gel-filtration step of MBP-hTPH1. They also observe a high molecular weight peak in the gel-filtration 
containing MBP-hTPH1. They cannot detect any activity in the peak and assigns it to aggregated protein. 
Upon cleavage using enteropeptidase, TPH1 precipitated and was identified in the insoluble fraction by 
SDS-PAGE. Since the main difference between the purification method developed here and the one 
developed by McKinney et al. is the salt concentration in the buffer system, and since earlier studies have 
shown that GST-rhTPH1 requires high salt concentrations to be stable, it is reasonable to assume that 
hTPH1 also requires high salt concentrations for solubility. To test this hypotheses, a purification of MBP-
hTPH1 was performed using only 50 mM (NH4)2SO4 in the buffer. As expected, a lower yield of the 
purification was seen, despite a higher initial yield from the first affinity step (see Table 6). However, 
cleavage does not seem to be the critical step, as almost no hTPH1 is lost between the first gel-filtration 
and the second affinity step, where the cleavage takes place. The most significant difference between the 
purifications was the visible precipitation in many fractions when using low salt concentration. Also, the 
protein could only be concentrated to 50 µM in low salt, while a concentration of 150 µM was achieved in 
high salt. These results suggest that even though a high salt concentration is not absolutely required for 
purification of hTPH1, it helps to stabilize hTPH1 and increases the yield. 
The purification method of hTPH1 can be optimized by excluding the second affinity step, and only 
performing a gel-filtration step after cleavage. The chromatogram in Figure 30 confirms that both MBP and 
MBP-3CP can be separated from hTPH1 using size-exclusion, so that the second affinity step is unnecessary. 
Also, it seems that the first affinity step is the limiting factor for the final yield. Thus, dividing the 
supernatant in two portions, and loading them in separate runs, could possible increase the yield of this 
first step. However, it would increase the time spent on purification significantly. Furthermore, the 
purification procedure can be shortened significantly by using on-column cleavage, which would shorten 
the purification procedure to just two steps that can be performed in one day.  
4.3.2.2.1 Monodispersity 
The chromatogram for the monodispersity test showed several shoulders besides the main peak indicating 
that the sample is not completely monodisperse, see Figure 34. The main peak was collected and loaded on 
the gel-filtration column again, in order to see if the monodispersity could be restored. The second run 
showed almost no shoulders and the sample can be considered monodisperse. It is not known whether the 
polydispersity is caused by the freezing/thawing process, the concentrating or simply by time. For 
crystallization purposes, the thawed protein solution should be loaded on a gel-filtration column before use 
or the drops should be set up directly after purification. 
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Figure 34: Chromatograms from the analytical gel-filtrations of thawed hTPH1 on a superdex 200 10 300 GL column. Red: The 
first run of thawed hTPH1. Fractions marked with dashed lines were collected and loaded again for the second run. Blue: The 
second run of hTPH1 collected from the main peak in the first run. 
4.3.2.3 Stability of chTPH1 and hTPH1 
chTPH1 and hTPH1 were studied by DSF to investigate the stability and effect of different  buffer 
compositions. DSF can detect the temperature at which the protein unfolds under different conditions 
testing the thermal stability of the protein(119). The unfolding is measured by an increase in fluorescence 
of a dye with affinity for hydrophobic parts of the protein, which are exposed as the protein unfolds. The 
fluorescent dyes that can be used for DSF are highly fluorescent in non-polar environment, such as the 
hydrophobic sites on unfolded proteins, compared to aqueous solution where the fluorescence is 
quenched. A typical DSF result with schematic drawings of the processes involved is shown in Figure 35, 
left. When the protein is folded, fluorescence is low, but as the protein unfolds fluorescence increases. 
After unfolding, the proteins will aggregate and/or precipitate and the fluorescence will decrease again. 
The unfolding or melting temperature is determined as the maximum point of the first derivative of the 
data. DSF only requires very low concentrations and small amounts of protein to test many different 
conditions. 
  
Figure 35: Left: A typical DSF result recording fluorescence as a function of temperature along with schematic drawings of the 
processes involved. UL and LL: Upper and lower level of fluorescence. Adapted with permission from (119). Copyright 2007 
Nature Publishing Group. Right: DSF result for hTPH1 in the reference buffer 100 mM Tris/H2SO4, 300 mM (NH4)2SO4, pH 8.0. 
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Fluorescence intensity as a function of temperature for hTPH1 is shown in Figure 35, right. It resembles that 
of a typical DSF curve in Figure 35, left, and shows only one major transition. Multi-domain proteins can 
show several unfolding transitions at different temperatures, as one domain can unfold without affecting 
the other domains, but this is not the case for hTPH1. 
In Figure 36, the effect on different pH values on melting temperature is shown. It is seen that both chTPH1 
and hTPH1 are stable in the entire pH range tested, and that pH does not have a great affect on the 
stability. For both proteins, pH 5.0 and 10.0 was also tested, but due to protein precipitation, the melting 
temperature could not be determined. The pH optimum is from 7.0 to 8.0 for both proteins, and the pH 
working range is from 6.0-9.0. 
By comparing the maximum melting temperature of chTPH1 (46 °C) and hTPH1 (54 °C), it is seen that the 
tetrameric structure or the presence of the regulatory domain in hTPH1 significantly stabilizes the protein. 
  
Figure 36: Results from DSF studies of the pH optimum of chTPH1 (left in orange) and hTPH1 (right in red). 22 mM citric acid, 33 
mM HEPES, 44 mM 2-(Cyclohexylamino)ethanesulfonic acid (CHES)/NaOH, 300 mM (NH4)2SO4 was used as background buffer. 
The effect of different salts on the stability was also tested, as seen in Figure 37. All salt concentrations 
were adjusted so the ionic strength matches that of 300 mM (NH4)2SO4, meaning that the concentrations of 
NaCl, KCl and NH4Cl were 900 mM.  
  
Figure 37: Results from DSF studies on the effect of different types of salt on chTPH1 (left in orange) and hTPH1 (right in red). 100 
mM Tris/H2SO4 or HCl, pH 8.0 was used as background buffer. All salt concentrations were adjusted so the ionic strength 
matched that of 300 mM (NH4)2SO4. 
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For chTPH1, a large effect of salt type is seen, with a difference of 20 °C in melting temperature of the most 
(Na2SO4) and least (NH4Cl) stabilizing salt. It can be speculated that certain ions could stabilize the protein 
by specific interactions, but there does not seem to be any trend in the results indicating such an effect.  
Based on the results above, hTPH1 was purified using 300 mM Na2SO4 instead of 300 mM (NH4)2SO4. 
However, this decreased the yield of the purification from 16 to 8 mg/L culture, suggesting that the 
increased stabilization of hTPH1 does not lead to a greater yield. 
The effect of the concentration of (NH4)2SO4 was also investigated, and the results are seen in Figure 38 
below. Both chTPH1 and hTPH1 display higher melting temperatures as the (NH4)2SO4 concentration 
increases. However, when studying the data closely, it is also revealed that the start fluorescence increases 
and the difference between the upper and lower levels of fluorescence decreases, indicating that a 
significant part of hTPH1 is precipitated or aggregated at high (NH4)2SO4 concentrations. A purification of 
hTPH1 using 900 mM (NH4)2SO4 correspondingly decreased the yield from 16 to 7 mg/L culture. 
 
Figure 38: Results from DSF studies on the effect of different (NH4)2SO4 concentrations on chTPH1 (left in orange) and hTPH1 
(right in red). 100 mM Tris/H2SO4, pH 8.0 was used as background buffer. 
4.3.2.4 Purification of MBP-tagged rchTPH1 
The successful purification of MBP-tagged full-length hTPH1 inspired to also test the purification of other 
variants with MBP-tag. MBP-rchTPH1 was purified as described in section 4.2.3.3 generally following the 
same procedure as for MBP-hTPH1. The chromatogram from the first affinity step is not shown, while the 
chromatogram from the first gel-filtration step is seen in Figure 39.  
As with MBP-hTPH1, a peak (P1) appears in the dead volume of the column corresponding to species with a 
size that exceeds the exclusion limit of the column. The peak contains MBP-rchTPH1 and so do both P2 and 
P3. Due to the lack of tetramerization domain, rchTPH1 is expected to be monomeric. However, comparing 
elution volumes of P2 (146 mL) and P3 (154 mL) with the column calibration curve, these would correspond 
to species with sizes of approx. 175 and 230 kDa. MBP-rchTPH1 has a molecular weight of 90.6 kDa, and a 
monomer would be expected to elute around 175 mL. Based on this information, it seems that the 
regulatory domain causes some kind of oligomerization, possibly dimerization. Another possibility is that 
the regulatory domain is not compactly folded like globular proteins (which is what the calibration curve is 
based on), but maybe extends far out. This would also cause an increase in hydrodynamic radius.  
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Figure 39: Chromatogram from the gel-filtration of MBP-rchTPH1 on a HiLoad Superdex 200 26/60 prep grade column. The 
fractions marked with dashed lines were collected for cleavage and further purification. 
Both P2 and P3 were collected and cleaved with MBP-3CP overnight. Again, the chromatogram from the 
second affinity step is not shown here, while the chromatogram from the second gel-filtration is shown in 
Figure 40. Three main peaks are seen in the chromatogram, P4, P5, and P6. P4 contains rchTPH1 and elutes 
at 156 mL corresponding to a molecular weight of 165 kDa. P4 is the only peak in the chromatogram that 
displays activity in the tryptophan hydroxylation assay (data not shown). The molecular weight of rchTPH1 
is 47.8 kDa, and it is thus likely that rchTPH1 also after cleavage exists as a dimeric or trimeric species. The 
P4 peak has some tailing, which could be caused by the existence of smaller species, as e.g. monomers. 
 
Figure 40: Chromatogram from the gel-filtration of cleaved MBP-rchTPH1 on a HiLoad Superdex 200 26/60 prep grade column. 
The fractions marked with dashed lines were collected as the final product. 
SDS-PAGE analysis of the purification is shown in Figure 41. It is seen that most MBP-rchTPH1 is soluble and 
is found in the supernantant, while a small part is insoluble found in the pellet. Like for MBP-hTPH1, no 
MBP-rchTPH1 is seen in the first part of the flow-through when loading on the affinity column. There is 
however some MBP-rchTPH1 in the last part of the flow-through from the loading, which is lost. All 3 peaks 
(P1, P2 and P3) in the first gel-filtration chromatogram contain MBP-rchTPH1, and must thus represent 
different oligomers of the protein. MBP-rchTPH1 is completely cleaved using MBP-3CP. The last part of the 
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purification is somewhat difficult to follow by SDS-PAGE, as MBP has a mass of 43 kDa and rchTPH1 48 kDa. 
They can thus be hard to separate on the SDS-PAGE. 
 
Figure 41: SDS-PAGE analysis of the purification of MBP-tagged rchTPH1. Left: Purification of MBP-rchTPH1. M: Molecular weight 
standard. R: Raw extract. S: Supernatant. P: Resuspended pellet. FT1: First part of the flow-through from the affinity step. FT2: 
Last part of the flow-through. E: Eluate. P1-P3: Peaks from the first gel-filtration. Right: Purification of rchTPH1. BC: Before 
cleavage. AC: After cleavage. FT: Flow-through mixed. E: Eluate. P4-P6: Peaks from the second gel-filtration.  I: The final 
concentrated product (1 µL). II: The final product right after gel-filtration (20 µL): 
It is seen that the flow-through of the second affinity step contains impurities of MBP-3CP, which means 
that the step is not 100 % effective. This is also seen in the chromatogram from the gel-filtration, where 
several peaks appear. Only one peak (P4) showed activity. Based on this and the SDS-PAGE it is concluded 
that P5 contains MBP-3CP and P6 free MBP. Regarding the size and oligomerization state of rchTPH1, the 
fact that it elutes before MBP-3CP and MBP supports the fact that rchTPH1 exists as a dimer. The final 
product of rchTPH1 is pure as judged from SDS-PAGE, but it should be noted that any potential MBP 
impurities would not be seen on SDS-PAGE due to the small difference in size. 
 
Figure 42: Mass spectrum of 23 µM rchTPH1 in 1 M NH4OAc. The calculated masses can be seen in Table 7. 
Purified rchTPH1 was investigated by intact mass spectrometry, in order to identify the oligomerization 
state of the protein. The resulting spectrum is seen in Figure 42. It is clear that rchTPH1 exists in several 
different oligomer states in the sample. The rchTPH1 dimer is the dominating species followed by 
monomer, tetramer and trimer. The calculated and theoretical masses of the different species can be seen 
in Table 7, and corresponds very well. From mass spectrometry studies the rchTPH1 sample is found to be 
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highly polydisperse. It should be mentioned that the sample had been exchanged into 1 M NH4OAc before 
mass spectrometry measurements. 
Table 7: Theoretical masses of rchTPH1 oligomer species including iron compared to the masses calculated from the mass 
spectrum of rchTPH1 shown in Figure 42. 
rchTPH1 Theoretical mass 
incl. Fe [Da] 
Calculated mass 
(from MS) [Da] 
monomer 47868.3 47874 
dimer 95736.6 95744 
trimer 143604.9 143776 
tetramer 191473.2 191699 
The overall yield of the purification was in the range 16-20 mg/L culture. The yield of the purification was 
furthermore followed after each purification step. Half of the protein is lost in the first gel-filtration step. It 
seems that the yield increases drastically after the second affinity step, but this is caused by the large 
amount of impurities in the sample after cleavage. In the calculation of yield, all absorbance at 280 nm is 
assumed to be caused by rchTPH1, but after cleavage both MBP and MBP-3CP will also be present. The 
total yield of the purification is 21 %, which is comparable to the total yield in the purification of hTPH1, see 
Table 6. 
Table 8: Protein yield after each step in the purification of MBP-tagged rchTPH1. The yield was calculated from the absorption at 
280 nm assuming that the samples contained only MBP-rchTPH1 or rchTPH1 (after cleavage). The yield in % is given assuming 
that the first affinity step corresponds to 100 %. 
Step 
MBP-rchTPH1 
Yield 
[µmol] [%] 
1st affinity step 3.8 100 
1st gel-filtration step 1.9 51 
2nd affinity step 3.8 99 
2nd gel filtration 0.8 21 
4.3.2.4.1 Monodispersity 
The monodispersity of the purified rchTPH1 was tested after freezing and thawing. Upon thawing, 
precipitation of the sample was observed, and so the precipitate was removed by filtration. The resulting 
chromatogram in Figure 43 shows that rchTPH1 is monodisperse. This is in contrast to mass spectrometry 
results which showed a highly polydisperse sample. However, the mass spectrometry sample was 
exchanged into a different buffer for measurements, and also the vaporization process and high voltages 
involved in mass spectrometry could affect the oligomerization state. Based on the monodispersity test, the 
rchTPH1 sample should be suitable for crystallization purposes. It should be noted that the high tendency 
to precipitate might be a problem in crystallization even though the sample is monodisperse after filtration. 
From the elution volume of rchTPH1 and the calibration curve of the analytical column, the size should be 
around 80 kDa, which again indicates that rchTPH1 exists as a dimer (rchTPH1: 47.8 kDa). 
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Figure 43: Chromatogram from the analytical gel-filtration of thawed rchTPH1 on a superdex 200 10 300 GL column. As the 
sample was monodisperse, only one run was made. 
4.3.3 Purification of TPH2 
Variants of TPH2 were purified both with and without affinity tags. The results from the purification of 
chTPH2 and cthTPH2 were developed in earlier projects, and are only shown for future reference. 
4.3.3.1 Purification of chTPH2 
chTPH2 was purified according to the procedure described in section 4.2.4.1 consisting of an anion-
exchange step followed by a gel-filtration step. The chromatograms for both steps can be seen in Figure 44 
and Figure 45, respectively. Only one major peak appears in the anion-exchange chromatogram, where 
chTPH2 elutes at conductivity around 12 mS/cm.  
 
Figure 44: Chromatogram from the anion-exchange of chTPH2 on a Q Seph HP 26/10 column. The fractions marked with dashed 
lines were collected for further purification. 
The product from the anion-exchange was concentrated and loaded on a gel-filtration column. The 
chromatogram can be seen in Figure 45. Only one major peak appears corresponding to chTPH2 monomer 
with a size of 36 kDa. The gel-filtration step in the purification of chTPH2 has been performed in different 
buffers depending on the purpose that the product should be used for. The normally used buffer is 20 mM 
HEPES/NaOH, 100 mM (NH4)2SO4, pH 7.2. For mass spectrometry, chTPH2 has been purified in 300 mM 
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NH4OAc, no pH adjustment. For crystallization, chTPH2 has been purified in 20 mM HEPES/NaOH, 200 mM 
NaCl, pH 7.2 to avoid sulfate ions, which crystallizes with calcium ions present in many screens. The 
purification has also been performed with 5 (w/v) % glycerol in all buffers for an extra stabilizing effect. 
 
Figure 45: Chromatogram from the gel-filtration of chTPH2 on a HiLoad Superdex 75 26/60 prep grade column. The fractions 
marked with dashed lines were collected as the final product. 
Products from purifications using two different buffer systems are shown in Figure 46. The final product is 
pure, and thus seems suitable for crystallization. The yield of the purification is in the range 50-70 mg/L 
culture. The final product shows an activity of 219 ± 2.8 min-1. Mass spectrometric measurements shows 
that the mass of the denatured protein matches exactly that of apo-chTPH2 (36317 Da vs. 36316.5 Da). The 
mass spectrum of chTPH2 can be seen in Figure 47. 
 
Figure 46: SDS-PAGE analysis of the final product from purifications of chTPH2. M: Molecular weight standard. Numbers: µL 
loaded on the gel. NaCl: 20 mM HEPES/NaOH, 200 mM NaCl, pH 7.2. (NH4)2SO4: 20 mM HEPES/NaOH, 100 mM (NH4)2SO4, pH 7.2. 
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Figure 47: Mass spectrum of denatured chTPH2 in 5 (v/v)% formic acid. The calculated mass is 36317 Da. 
4.3.3.1.1  Monodispersity 
To check the monodispersity of the final chTPH2 product, it was thawed and loaded on an analytical gel-
filtration column. The resulting chromatogram can be seen in Figure 48, and shows that the sample is 
almost monodisperse with only a small shoulder left of the main peak. The main peak was collected and 
loaded on the column again for a second run, which is also shown in Figure 48. Most of the small shoulder 
has been removed in the second run, and the sample can be considered monodisperse. 
 
Figure 48: Chromatograms from the analytical gel-filtrations of thawed chTPH2 on a superdex 75 10 300 column. Red: The first 
run of thawed chTPH2. The fractions marked with dashed lines were collected and loaded again for the second run. Blue: The 
second run of chTPH2 collected from the main peak in the first run. The broader peak in the second run is caused by a larger 
sample volume. 
4.3.3.2 Purification of cthTPH2 
cthTPH2 was also purified according to the same simple procedure as chTPH2, with the only exceptions that 
a different gradient was used in the anion-exchange step and that a different gel-filtration column was 
used, due to the larger size of tetrameric cthTPH2. In Figure 49, the chromatogram from the anion-
exchange is seen. cthTPH2 elutes at a conductivity around 19.5 mS/cm. 
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Figure 49: : Chromatogram from the anion-exchange of cthTPH2 on a Q Seph HP 26/10 column. The fractions marked with 
dashed lines were collected for further purification. 
The collected fractions were concentrated and loaded on a gel-filtration column, giving the chromatogram 
shown in Figure 50. The only major peak contains cthTPH2 and is collected as the final product. The elution 
volume of cthTPH2 on the gel-filtration column correspond to a mass of approx. 150 kDa, which is in 
agreement with the theoretical mass of a cthTPH2 tetramer (158 kDa). 
 
Figure 50: Chromatogram from the gel-filtration of cthTPH2 on a HiLoad Superdex 200 26/60 prep grade column. The fractions 
marked with dashed lines were collected as the final product. 
The last gel-filtration step was performed in several different buffers including 0.3 M NH4OAc /NH3, pH 7.2, 
10 mM HEPES/NaOH, 200 mM NaCl, pH 7.2, and with 10 (w/v)% glycerol in all buffers for an extra 
stabilizing effect. 
SDS-PAGE analysis of cthTPH2 products from purifications using two different buffer systems are shown in 
Figure 51. The product is relatively pure; however some high molecular weight species are seen. These 
could represent impurities or cthTPH2 dimers and tetramers that have not been completely dissociated in 
the SDS-PAGE pretreatment. The overall yield from the purification was in the range 43-54 mg/L culture, 
which is slightly lower than for chTPH2. 
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Figure 51: SDS-PAGE analysis of the final product from purifications of cthTPH2. M: Molecular weight standard. Numbers: µL 
loaded on the gel. (NH4)2SO4: 20 mM HEPES/NaOH, 100 mM (NH4)2SO4, pH 7.2. NH4OAc: 0.3 M NH4OAc /NH3, pH 7.2. 
The final product of cthTPH2 was studied by intact mass spectrometry. The resulting mass spectrum 
showed only one species suggesting that the sample is pure. The mass was calculated to 159187.5 Da, 
which corresponds well with the theoretical mass of tetrameric cthTPH2 (159500.4 Da). It can thus be 
concluded that cthTPH2 exists as a tetramer. 
 
Figure 52: Mass spectrum of cthTPH2 in 0.65 M NH4OAc. The calculated mass is 159187.5 Da. 
4.3.3.2.1 Monodispersity 
The monodispersity of purified cthTPH2 has been tested before(11), and it was concluded that the cthTPH2 
sample containing 10 % glycerol was completely monodisperse as judged by dynamic light scattering and 
static light scattering experiments. Static light scattering includes an analytical gel-filtration step, which 
showed one main peak with no shoulders. In this project, the monodispersity of purified cthTPH2 with no 
glycerol was tested using analytical gel-filtration. The resulting chromatogram is seen in Figure 53, and 
shows a shoulder on the left side of the main peak. The sample without glycerol is thus not completely 
monodisperse. 
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Figure 53: Chromatogram from the analytical gel-filtration of thawed cthTPH2 on a superdex 200 10 300 GL column without 
glycerol in the buffer. 
To test if presence of glycerol has an effect on monodispersity, a purification was performed with 10 
(w/v)% glycerol in all buffers. The final product was frozen as usual and thawed for the monodispersity test. 
The result is seen in Figure 54. The shoulder is also present in the sample with 10 (w/v)% glycerol and thus 
glycerol does not seem to affect the monodispersity of the sample. The product from the main peak of the 
first run was collected and loaded again for the second run. The small shoulder on the left appeared again, 
suggesting that it exists in some kind of equilibrium with tetrameric cthTPH2 and cannot be removed. The 
shoulder is however very small, so the sample can be considered almost monodisperse. 
 
Figure 54: Chromatograms from the analytical gel-filtration of thawed cthTPH2 on a superdex 200 10 300 GL column with 10 
(w/v)% glycerol in the buffer. Red: The first run of thawed cthTPH2. The fractions marked with dashed lines were collected and 
loaded again for the second run. Blue: The second run of cthTPH2 collected from the main peak in the first run. 
The reasons for the difference between present and past results on the monodispersity of cthTPH2 are 
unknown. In earlier purification methods cthTPH2 was put directly in the -80 °C freezer without being flash-
frozen in liquid nitrogen first. The different freezing methods might affect the monodispersity. 
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4.3.3.3 Stability of chTPH2 and cthTPH2 
Even though successful purification protocols for chTPH2 and cthTPH2 have been developed, the buffers 
were chosen rather arbitrarily based on knowledge of theoretical pI values and some experimental 
evidence. By using differential scanning fluorimetry, the stability of the two TPH variants has been 
investigated in different buffers with varying pH, salt type and concentration. This gives a clear picture of 
the optimal buffer conditions, and can be used to improve the purification methods. 
The melting/unfolding temperature was tested in a pH range from 5.0-9.0 using a citric acid/HEPES/CHES 
buffer combination with 300 mM (NH4)2SO4. The results can be seen in Figure 55. Both chTPH2 and cthTPH2 
have the highest melting temperature around pH 7.0. This corresponds well with the pH of 7.2 chosen for 
the purification methods, and is also in agreement with pH in the cytosol of cells(120), where TPH is mainly 
located(121). Furthermore, cthTPH2 is generally more stable than chTPH2 under the conditions used in the 
screen, as seen from the slightly higher melting temperature. An explanation could be that cthTPH2 exists 
as a tetramer, whereas chTPH2 is a monomer, and the addition of the quaternary structure could stabilize 
the subunits. This effect was also seen from TPH1, were hTPH1 was significantly more stable than chTPH1. 
From DSF experiments it is also seen that cthTPH2 is more stable at higher pH than chTPH2. It can be 
concluded that the optimum pH is 7 for both variants, and that the pH working range for chTPH2 is 6.0-7.5 
and for cthTPH2 it is 6.0-8.5. 
  
Figure 55: Results from DSF studies of the pH optimum of chTPH2 (left in blue) and cthTPH2 (right in green). 22 mM citric acid, 33 
mM HEPES, 44 mM 2-(Cyclohexylamino)ethanesulfonic acid (CHES)/NaOH, 300 mM (NH4)2SO4 was used as background buffer. 
When comparing the stability of TPH2 variants to TPH1 variants in section 4.3.2.3, the most striking 
difference is the low melting temperature of chTPH1 (46 °C at pH 7.5) compared to chTPH2 (53 °C at pH 7.5) 
at high salt concentration (300 mM (NH4)2SO4). The lower stability of chTPH1 also corresponds well with the 
fact that chTPH2 can be concentrated to 2.5 mM, while chTPH1 only can be concentrated to 0.2 mM. The 
large difference between the catalytic domains of the two isoforms is unexpected, as they only differ at 
very few amino acids. The melting temperature of full-length hTPH1 and cthTPH2 is in the same range (54 
and 56 °C at pH 7.5, respectively). However, it seems that TPH2 is much more sensitive to changes in pH 
than TPH1, as the highest difference in melting temperature in the pH range tested is 18 °C and 14 °C for 
chTPH2 and cthTPH2, respectively, and only 5 °C and 3 °C for chTPH1 and hTPH1, respectively. 
To study the effect of different ions on the stability of chTPH2 and cthTPH2, several different salts were 
tested. The ionic strength is the same for all salts tested and corresponds to 100 mM (NH4)2SO4. 
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Figure 56: Results from DSF studies on the effect of different types of salt on chTPH2 (left in blue) and cthTPH2 (right in green). 
20 mM HEPES/NaOH, pH 7.0 was used as background buffer. All salt concentrations were adjusted so the ionic strength matched 
that of 100 mM (NH4)2SO4. 
 From Figure 56 it is seen that even though some salts seems to stabilize slightly better than (NH4)2SO4, the 
melting temperature is in the same range for all salts. Thus it can be concluded that the type of ions does 
not have any significant effect on the stability of chTPH2 and cthTPH2. Whether the ionic strength has an 
effect was tested with 5 different (NH4)2SO4 concentrations.  
 
Figure 57: Results from DSF studies on the effect of different (NH4)2SO4 concentrations on chTPH2 (left in blue) and cthTPH2 
(right in green). 20 mM HEPES/NaOH, pH 7.0 was used as background buffer. 
It is clear that the higher the ionic strength, the higher the melting temperature. However, both chTPH2 
and cthTPH2 are stable in solution also without any salt present. It should be noted that at (NH4)2SO4 
concentrations of 300 mM the melting temperature is only 44 °C for chTPH2, while the same concentration 
of (NH4)2SO4 also with a pH of 7.0 but a 100 mM citric acid/HEPES/CHES combination buffer instead of just 
20 mM HEPES gave 54 °C. Thus, the buffer system or concentration must have some effect on the melting 
temperature independent of pH and salt concentration. Compared, the melting temperature of cthTPH2 is 
only 4 °C higher in the citric acid/HEPES/CHES combination buffer than in the HEPES only buffer (56 vs. 52 
°C). To investigate this effect further three different buffers (HEPES, Bis Tris Propane and 3-(N-
morpholino)propanesulfonic acid (MOPS)) with the same pH and salt concentration were tested, but 
showed no significant effect on stability as the melting temperature varied with only 1 °C (data not shown). 
Possibly, the higher buffer concentration in the combination buffer (100 mM vs. normally 20 mM) could 
have affected the stability. 
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Finally, some typical protein stabilizing molecules (glycerol, sucrose, polyethylene glycol (PEG) 400 and 
sorbitol) were studied and gave an increased melting temperature as expected. These stabilizers can be 
used as additives for future experiments. 
 
Figure 58: Results from DSF studies on the effect of different stabilizers on chTPH2 (left in blue) and cthTPH2 (right in green). 20 
mM HEPES/NaOH, 100 mM (NH4)2SO4, pH 7.0 was used as background buffer and reference. 
4.3.3.4 Purification of hTPH2 
In my master project, hTPH2 was purified using the method developed for chTPH2 and cthTPH2 consisting 
of an anion-exchange step followed by a gel-filtration step. The result was an apparently pure (judged by 
SDS-PAGE) and active product, however in a very low yield (4.8 mg/L culture)(11). Dynamic light scattering 
measurements of the purification product revealed several different sized species in the sample upon 
concentration(11). Thus the hTPH2 purification product was investigated further. 
First, the chromatogram from the anion-exchange of hTPH2 is shown in Figure 59. hTPH2 elutes together 
with several other proteins  in the first peak (see SDS-PAGE in Figure 62).  
 
Figure 59: Chromatogram from the anion-exchange of hTPH2 on a Q Sepharose FF 16/10 column. The fractions marked with 
dashed lines were collected for further purification. 
The selected fractions from the anion-exchange were concentrated and loaded onto a gel-filtration column, 
which resulted in the chromatogram shown in Figure 60. 
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Figure 60: Chromatogram from the first gel-filtration of hTPH2 on a HiLoad Superdex 200 26/60 prep grade column. The fractions 
marked with dashed lines were collected and loaded on the gel-filtration column again, see Figure 61. 
P1 from Figure 60 seem to contain pure hTPH2 (56 kDa) as judged from the SDS-PAGE shown in Figure 62. 
However, when the sample from P1 was concentrated and loaded on the gel-filtration column again, a 
chromatogram very similar to that from the first gel-filtration appeared. The chromatogram from the 
second gel-filtration is shown in Figure 61. The 4 main peaks from the first gel-filtration appear again in the 
second gel-filtration, despite the fact that only P1 was concentrated and loaded on the column. The peak 
intensities relative to each other are also the same in both gel-filtrations. This indicates that hTPH2 exists in 
some sort of equilibrium with other species. Activity test of the peaks from the first gel-filtration shows that 
only P1 displays activity, and western blotting confirms that only P1 contains TPH(11). Mass spectrometric 
identification also confirms that P1 contains hTPH2. 
 
Figure 61: Chromatogram from the second gel-filtration of hTPH2 on a HiLoad Superdex 200 26/60 prep grade column. 
SDS-PAGE analysis was used to investigate the situation further. The anion-exchange product (AP) contains 
at least 4 other proteins than hTPH2 as shown in Figure 62. The 18 % SDS-PAGE gel shows 2 proteins with 
sizes between 31 and 45 kDa, and two other proteins with sizes between 21.5 and 31 kDa in AP. However, 
P1 from the first gel-filtration appears pure and does not show any other bands than the one representing 
hTPH2 around 50 kDa. Even though the bands from the second gel-filtration are very weak, it can still be 
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concluded that P5 contains protein with a size of approx. 55 kDa, P6 and P7 contain approx. 40 kDa 
proteins, and P8 contains a protein with a size of approx. 25 kDa. The bands from the SDS-PAGE gel were 
cut out and send for mass spectrometric identification. The results showed that P6 contains 
glyceraldehyde-3-phosphate dehydrogenase (GAPD – 35.5 kDa) and P8 contains superoxide dismutase 
(SOD – 21.3 kDa), both from E. coli.  GAPD catalyzes a step in glycolysis and SOD convert superoxide into 
oxygen and hydrogen peroxide. They are both considered “house-keeping” proteins.  
 
Figure 62: SDS-PAGE analysis of the purification of hTPH2. GAPD: glyceraldehyde-3-phosphate dehydrogenase. SOD: Superoxide 
dismutase. M: Molecular weight standard. AP: Anion-exchange product. P1-P8: Peaks from the first and second gel-filtration. 
Left: 7.5 % Tris-HCl gel. Right: 18 % Tris-HCl gel. 
From the results is seems that the compound isolated from P1 in the first gel-filtration is in equilibrium with 
several smaller species different from TPH, which turned out to be SOD and GAPD. However, the SDS-PAGE 
analysis of P1 shows only one single band. The explanation could be that TPH forms a heterotetramer with 
a mixture of GAPD and SOD. When only one band is present on the SDS-PAGE gel, it could be because SOD 
and GADP linked together has almost the same mass as hTPH2. If SOD and GAPD are covalently linked they 
might not be separated in the SDS-PAGE pretreatment.  According to the calibration curve of the column, 
the species in P1 should have a size of approx. 250 kDa corresponding with a hTPH2 homotetramer (224 
kDa) or a mixed tetramer where each hTPH2 molecule could be replaced by SOD+GAPD (56.8 kDa). The two 
small peaks left of P1/P5 in the chromatogram also contain TPH and displays activity (data not shown). 
From the calibration curve, they could correspond to hTPH2 8-mers and 16-mers, respectively. If 
equilibrium exists between a mixed tetramer and the free species of SOD, GAPD and TPH in different 
oligomer states, it makes sense that the mixed tetramer dissociates in order to reestablish the equilibrium 
when isolated from the rest of the solution as in the first gel-filtration step. The exact kind of interaction 
between hTPH2, GAPD and SOD cannot be elucidated from these results. However, it appears that hTPH2 
cannot be isolated, and thus a new purification method should be developed. Furthermore, the fact that 
hTPH2 interacts with other proteins during purification implies that it might also interact with and be 
stabilized by other proteins in vivo. This has been also been suggested in the literature(98), due to the 
instability of TPH in vitro. 
4.3.3.5  Purification of MBP-tagged rchTPH2 
As the purification of hTPH2 without affinity tag was unsuccessful, a new approach was taken. The success 
of purifying hTPH1 and rchTPH1 with MBP as affinity tag made the attempt to purify rchTPH2 and hTPH2 in 
the same way a natural choice. First, the purification of MBP-rchTPH2 was studied, and the results are 
presented here.  
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In the purification of MBP-rchTPH2, only one tube of cells was used (corresponding to 0.65 L culture). The 
purification follows the general procedure for affinity-tagged TPH variants shown in Figure 12, and the 
specific method described in section 4.2.4.4. The results from the DSF stability studies on chTPH2 and 
cthTPH2 described in section 4.3.3.3 shows a pH optimum around 7. Thus, pH 7 was used in all buffers in 
the purification of MBP-rchTPH2. The MBP-column has a pH working range >7. 
 
Figure 63: Chromatogram from the gel-filtration of MBP-rchTPH2 on a HiLoad Superdex 200 26/60 prep grade column. The 
fractions marked with dashed lines were collected for further purification. 
The first affinity step was performed on a MBPTrap HP 5 mL column. The elution fraction contained TPH 
and was concentrated and loaded on a gel-filtration column. The resulting chromatogram can be seen in 
Figure 63. As for MBP-hTPH1 and MBP-rchTPH1, two major peaks appear in the chromatogram, one 
representing a high molecular weight species eluting in the dead volume of the column (P1), and one with a 
size corresponding to a dimer of MBP-rchTPH2 (P2). P1 also contains MBP-rchTPH2.  
 
Figure 64: Chromatogram from the gel-filtration of rchTPH2 on a HiLoad Superdex 200 26/60 prep grade column. The fractions 
marked with dashed lines contained mainly rchTPH2. 
P2 was collected and added MBP-3CP for cleavage overnight. After cleavage, precipitation was observed in 
the sample, so it was filtrated and then loaded on the affinity column. rchTPH2 was found in the flow-
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through, which was collected, concentrated and loaded on the gel-filtration column for the last purification 
step. The resulting chromatogram is found in Figure 64.  
Several peaks appeared and from the calibration curve it was not clear which peak contained rchTPH2. 
Thus, activity measurements were performed in order to identify the peak containing TPH. 
Table 9: Results from the activity measurements of the 3 main peaks from the gel-filtration of rchTPH2 shown in Figure 64. 
[int/min] is an arbitrary unit, which can be used for internal comparison between different samples. 
Assay 
temperature 
Blank 
[int/min] 
P4 
[int/min] 
P5 
[int/min] 
P6 
[int/min] 
15 °C 5 49 23 11 
26 °C 8 85 41 13 
As seen in Table 9, P4 and P5 both show activity, while P6 does not. The activity of P5 is approx. half of that 
in P4, and could arise from the overlapping of P4 with P5. Because of the low concentration of protein, the 
activity measurements were performed at two temperatures to get a significant difference in activity 
between the inactive and active samples. From the activity measurements, it can be concluded that P4 
contains rchTPH2, and that P5 also contains some rchTPH2, however in a lower concentration.  
The purification was analyzed by SDS-PAGE as seen in Figure 65. Starting with the sample preparation, SDS-
PAGE shows that approx. 70 % of MBP-rchTPH2 is found in the supernatant as a soluble protein. MBP-
rchTPH2 is less soluble than MBP-rchTPH1. In the first affinity step, only a very small amount of MBP-
rchTPH2 is found in the flow-through, while most binds to the column and is eluted in a pure solution. Gel-
filtration separates the aggregated species of MBP-rchTPH2 from the dimer. Most MBP-rchTPH2 is cleaved, 
however a small amount is left uncleaved. During the cleavage, precipitation is seen, and the uncleaved 
protein might originate from this precipitate. The cleavage is rather fast and is almost complete after 10 
minutes, as was also seen for cleavage of MBP-hTPH1. rchTPH2 is found in the flow-through of the second 
affinity step, together with some minor impurities of MBP and MBP-3CP. The SDS-PAGE of the last gel-
filtration complements the activity measurements showing that P4 indeed does contain rchTPH2.  P5 
mainly contains MBP-3CP, but an impurity of rchTPH2 can be spotted on the SDS-PAGE. This impurity must 
be the cause of the activity of P5. P6 contains only MBP which is in agreement with the lacking activity, see 
Table 9.    
 
Figure 65: SDS-PAGE analysis of the purification of MBP-tagged rchTPH2. M: Molecular weight standard. P: Resuspended pellet. 
S: Supernatant. FT: Flow-through. E: Eluate. P1-P6: Corresponding peaks in Figure 63 and Figure 64. V: Valley between P1 and P2. 
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It was attempted to concentrate the sample from P4 using ultrafiltration, but the protein precipitated and 
the final concentration was only 4.2 µM.  
The purification of rchTPH2 was not successful. rchTPH2 cannot be separated completely from MBP-3CP in 
the last gel-filtration step as the resolution is too low. If a pure product should be achieved, the last affinity 
step should be 100 % effective removing all MBP species from the solution. Due to the instability of the 
final product causing precipitation, the purification was not optimized any further. chTPH2 is very stable 
during purification and can be concentrated to 2.5 mM. The addition of the regulatory domain thus 
decreases the stability of the protein significantly. Furthermore, the regulatory domain apparently causes 
dimerization. The elution volume of rchTPH2 corresponds to a molecular size of 85 kDa, and rchTPH2 has a 
molecular weight of 53 kDa. From these results it cannot be conclusively determined if rchTPH2 exists as a 
dimer or if the regulatory domain has a structure/fold which significantly increases the size of the protein. 
However, as both rchTPH1 and rchTPH2 apparently exist as dimers, the regulatory domains of both 
isoforms seem to cause dimerization. As chTPH1 could be successfully purified using GST-tag, future work 
on purification of rchTPH2 should include testing GST as affinity tag.  However, the apparent dimerization 
of rchTPH2 combined with the dimerization of GST might lead to insoluble aggregated species, as was the 
case for GST-hTPH1. 
4.3.3.6 Purification of MBP-tagged hTPH2 
As hTPH1 was successfully purified using MBP-tag, it was only logical to also attempt to purify hTPH2 using 
MBP-tag. The results can be seen in this section and follows the procedure described in section 4.2.4.5.  
First, MBP-hTPH2 was loaded on the affinity column, resulting in the chromatogram shown in Figure 66. 
The eluate contained MBP-hTPH2 and was collected for further purification.  
 
Figure 66: Chromatogram from the affinity purification of MBP-hTPH2 on a 20 mL Dextrin Sepharose HP 16/10 MBP column. FT1: 
First part of the flow-through. FT2: Last part of the flow-through. The fractions marked with dashed lines were collected for 
further purification.  
In the flow-through an increase in absorbance is seen at approx. 45 mL, between the marks FT1 and FT2. 
Activity test revealed that FT1 had no activity, while FT2 showed a high activity (data not shown). This 
indicates that all MBP-hTPH2 binds in the first part of the loading process, but after 45 mL, all MBP-hTPH2 
no longer binds and is thus found in the flow-through. SDS-PAGE confirms this hypothesis showing no 
bands for MBP-hTPH2 in FT1, while a clear band is seen in FT2 (vide infra, see Figure 69). To test if the MBP-
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column had simply been overloaded, the FT was loaded on the column again in a new run, but nothing 
bound to the column and no elution peak was seen. This behavior was also seen in the purification of MBP-
hTPH1 and all other MBP-tagged TPH variants. No explanation for the phenomenon has been found. 
Despite the great loss of protein in this first step, the eluate was concentrated and loaded on a gel-filtration 
column. The chromatogram seen in Figure 67 shows two major peaks (P1 and P2), as for the other MBP-
tagged TPH variants, and one minor peak at higher elution volume (P3). P2 which corresponds to tetrameric 
MBP-hTPH2 was collected and cleaved using MBP-3CP. The cleaved sample was loaded on the affinity 
column, and hTPH2 was collected from the flow-through.  
 
Figure 67: Chromatogram from the gel-filtration of MBP-hTPH2 on a HiLoad Superdex 200 26/60 prep grade column. The 
fractions marked with dashed lines were collected for further purification.  
 
Figure 68: Chromatogram from the gel-filtration of cleaved MBP-hTPH2 on a HiLoad Superdex 200 26/60 prep grade column. The 
fractions marked with dashed lines were collected as the final product. 
The flow-through was concentrated and loaded on the gel-filtration column again in the last purification 
step giving the chromatogram shown in Figure 68. Only one major peak is seen, and according to the 
elution volume it contains tetrameric hTPH2. The peak showed significant activity in the activity assay. The 
collected fractions from this peak were concentrated using ultrafiltration, but only up to 9 µM. The final 
yield of the purification of hTPH2 was 0.6-4 mg/L culture, which is a very low yield especially compared to 
hTPH1 (16 mg/L culture). 
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The SDS-PAGE analysis of the entire purification is seen in Figure 69. First, the solubility of MBP-hTPH2 is 
even less than for MBP-rchTPH2 and significantly worse than MBP-hTPH1. Approx. half of the expressed 
MBP-hTPH2 is found in the supernatant, while the rest is insoluble and found in the pellet. In the first 
affinity step, the first part of the flow-through does not contain MBP-hTPH2, while the last part does, as 
described earlier. The reason for this lack of binding is not known. However, some MBP-hTPH2 is bound 
and eluted with minor impurities. The first gel-filtration has MBP-hTPH2 in both P1 and P2. The cleavage is 
almost complete, and hTPH2 elutes in the FT of the second affinity step without any visible impurities. The 
small shoulder, P5, left of the main peak in the last gel-filtration, contains hTPH2 as does the main peak P6. 
The latter was collected and concentrated, and from the SDS-PAGE analysis the final product of hTPH2 
appears pure.   
 
Figure 69: SDS-PAGE analysis of the purification of MBP-hTPH2. M: Molecular weight standard. R: Raw extract. P: Resuspended 
pellet. S: Supernatant. FT1 and FT2: Flow-through fractions as defined in Figure 66. E: Eluate. P1-P6: Peaks in the gel-filtration 
chromatograms in Figure 67 and Figure 68. BC: Before cleavage. AC: After cleavage. Numbers refers to µL loaded on the gel. 
The instability of hTPH2 and hence the low yield gave rise to several optimization trials, but none gave 
positive results. The yield of each purification step for the original purification procedure can be seen in 
Table 10.  
Table 10: The protein yield after each step in the purification of MBP-hTPH2. The yield was calculated from the absorption at 280 
nm assuming that the samples contained only MBP-hTPH2 or hTPH2 (after cleavage). The yield in % is given assuming that the 
first affinity step corresponds to 100 %. 
Step 
MBP-hTPH2 
Yield 
[µmol] [%] 
1st affinity 0.32 100 
1st gel-filtration 0.11 35 
2nd affinity 0.14 44 
2nd gel-filtration 0.02 6 
Compared to the yields for MBP-hTPH1 seen in Table 6, the percentage yields are comparable. However, 
the amount of µmol protein is approx. a factor 10 smaller for MBP-hTPH2. This indicates that the first 
affinity step where large amount of MBP-hTPH2 is lost also is the main factor in limiting the yield. The yield 
from the first affinity step is significantly lower that the expected binding capacity of the MBP column (2.5 
µmol). As the hTPH2 sample has no impurities after the second affinity step (shown by SDS-PAGE) the last 
gel-filtration step can be omitted. This would also increase the final yield. 
  
In conclusion, the fusion to MBP allows purification of active
MBP-hTPH2 are lost in the flow-through of the 
affinity tag is highly unstable and precipitates easily, and canno
yield of the purification was 0.6-4 mg/L culture.
4.4 Overall discussion 
Several different variants of TPH have successfully been purified in this project. Here, a comparison 
between the variants is given in terms of expression levels, solubility, yields and activity.
Figure 70. SDS-PAGE analysis of the raw extracts (left) and supernatant
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can only be concentrated to very low concentrations. It seems that the high salt concentration stabilizes 
the regulatory domain of TPH1, but does not give the same stabilizing effect for the regulatory domain of 
TPH2. The two isoforms differ significantly in the regulatory domain, and thus it is not unlikely that the two 
regulatory domains are stabilized by different factors. 
Table 11: Overview of the purification method, yield and final concentration for the TPH variants purified in this project. *: The 
rchTPH2 sample was not completely pure. **: Activity was measured on a different day using different protein concentration 
compared to the other variants. 
Variant Purification  
method 
Yield  
[mg/L culture] 
Concentration 
[mM] 
Activity 
[min-1] 
chTPH1 Affinity using GST-
tag and gel-filtration 
11  0.18 mM 92 ± 2.2 
hTPH1 Affinity using MBP-
tag and gel-filtration 
23  0.16 mM 164 ± 3.1 
rchTPH1 Affinity using MBP-
tag and gel-filtration 
20  0.20 mM 95 ± 4.2 
chTPH2 Anion-exchange and 
gel filtration 
70  2.5 mM 219 ± 2.8 
cthTPH2 Anion-exchange and 
gel-filtration 
54  0.29 mM 187 ± 7.5 
rchTPH2* Affinity using MBP-
tag and gel-filtration 
0.06 0.004 mM 16** 
hTPH2 Affinity using MBP-
tag and gel-filtration 
0.6  0.009 mM 29 ± 8.3** 
The tryptophan hydroxylation activities of the purified variants were also measured as described in section 
4.2.5.2, and the results can be seen in Table 11 and Figure 71. The activities of rchTPH2 and hTPH2 were 
measured on different days with different protein concentrations, while all other variants were measured 
on the same day using a protein concentration of 1.5 µM. rchTPH2 and hTPH2 displayed activity compared 
to blank samples, but the protein concentrations were very low, and the protein was unstable and 
precipitated easily, so the results for these two should not be compared to the other variants. 
The most striking result from the activity measurements is the difference in specific activity between 
chTPH1 (92 min-1) and chTPH2 (219 min-1). The catalytic domains of TPH1 and TPH2 have a sequence 
identity of 81 % and a sequence homology of 91 %(13), and thus it is intriguing to observe such differences 
in specific activity. However, this observation has been made before(13). Another interesting feature is the 
lack of effect of the regulatory domain on activity of TPH1. chTPH1 and rchTPH1 have similar specific 
activities, despite the fact that rchTPH1 exists as a dimer and includes the regulatory domain. This result 
suggests that the regulatory domain of TPH1 does not directly influence catalytic activity in its native state, 
but may do so upon phosphorylation or binding of regulators. The higher specific activity of hTPH1 
compared to chTPH1 and rchTPH1 indicates that the tetrameric structure improves the catalytic activity of 
TPH1. This could be caused by e.g. cooperativity between different subunits. However, for TPH2, the 
addition of the tetrameric structure slightly lowers the specific activity for cthTPH2 (187 min-1) as compared 
to chTPH2 (219 min-1). 
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Figure 71: The specific activity of different TPH variants measured by activity assay. All measurements were made on the same 
day and the protein concentration was 1.5 µM for all variants. *: The unit of the blank sample is [int/min]. 
4.5 Conclusions 
Successful purification procedures were developed for a number of TPH variants. A new purification 
method for chTPH1 using GST affinity-tag was developed, which eliminated impurities identified by mass 
spectrometry in earlier projects. Furthermore, purification methods for rchTPH1 and hTPH1 using MBP 
affinity-tag were developed. It is the first time a purification method which yields pure, active and stable 
hTPH1 has been presented. This allows for a thorough characterization of the full-length human enzyme, 
which has not been possible before. hTPH1 displayed a significantly higher specific activity than chTPH1 and 
rchTPH1, suggesting that the tetramerization increase reactivity, possibly by cooperativity. Furthermore, 
rchTPH2 and hTPH2 were attempted purified using the same general method as for hTPH1, but the yields 
were very low and the products were unstable and could not be concentrated. The stability of chTPH1, 
hTPH1, chTPH2 and cthTPH2 were studied by differential scanning fluorimetry, and the results gave 
information on the effect of pH, salt type and ionic strength.   
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5 Crystallization 
Despite the recent development of high-throughput crystallization methods and impressive increase in 
available protein structures, production of high-quality crystals remains a major bottleneck in structure 
determination(122). Even when pure, soluble protein is available, the production of crystals which diffract 
can be a hard and sometimes impossible job, because crystallization is a complex multi-parametric process. 
So far, there are no complete guidelines of how to achieve well-diffracting crystals, and most of the advice 
found in the literature is based on empiric observations(95). The first step in crystallization is to scan a 
variety of precipitation agents, to find hits or leads, which may be optimized to produce crystals. These 
leads can be crystals, crystalline precipitate or even phase separation(122). When a lead is identified, the 
crystallization conditions can be fine-tuned by varying protein concentration, type and concentration of 
precipitant, pH or temperature or by adding additives as e.g. substrates. The most commonly used screens 
for initial screening of crystallization conditions are sparse matrix screens that consist of compilations of 
conditions that have previously led to successful crystallization(123). It is estimated that <300 trials for each 
protein should be sufficient to find crystallization conditions(124). Instead of testing even more conditions, 
the time and resources should rather be put into testing for different organisms, optimizing the constructs 
or looking for orthologs. When working with proteins that have potential as drug targets, it can be 
important to keep focus on the human variant, and instead try to optimize different constructs. With the 
use of high-throughput robotics, a vast amount of conditions can easily be tested without wasting large 
resources, time or protein, and thus this technique has also been used in this project. When a concentrated 
effort is put into the crystallization of a protein, the overall success rate is estimated to 30-40 %(125).  
Even when protein crystals have been produced, there are still many obstacles before the structure can be 
determined. The crystals should be mounted and tested for diffraction. The collection of high-quality 
diffraction data is yet another bottleneck in protein crystallization, where many crystals fail, either in terms 
of no diffraction at all or by giving such low-quality diffraction data in terms of e.g. resolution or 
completeness, that the structure cannot be solved. However, when protein crystallization does succeed, 
the results can be of great importance for science. 
This chapter will present the attempts to make a structural characterization of some of the purified variants 
of TPH by crystallization. First, an introduction to the already published structures of TPH will be given. 
5.1 Introduction and background 
Due to the difficulties in purification of TPH and problems with instability of the full-length protein, the 
structural characterization in form of crystal structures is very limited. Only crystal structures of the 
catalytic domain of isoform 1 exist. In comparison, PAH and TH has been characterized to a greater extent 
including structures of both the tetramerization and regulatory domains. However, the structure of a full-
length AAAH has not yet been determined. In Table 12 an overview of all the published crystal structures of 
the AAAHs found in the PDB database can be seen. 
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Table 12: Overview of all structures of the aromatic amino acid hydroxylases found in the PDB database. r: Regulatory domain. c: 
Catalytic domain. t: Tetramerization domain. Cv: Chromobacterium violaceum. Cp: Colwellia psychrerythraea 34H. 
PDB ID Organism Domains Resolution Comments Ref. 
Tryptophan hydroxylase 1 
1MLW Human c 102-402 1.7 Å Fe(III), BH2 (47) 
3E2T Chicken c 101-414 1.9 Å Fe(III), trp, imidazole (12) 
3HF8 Human c 104-393 1.9 Å Fe(III), inhibitor LP-533401 (48) 
3HFB Human c 104-393 1.9 Å Fe(III), inhibitor LP-534193 (48) 
3HF6 Human c 104-393 1.8 Å Fe(III), inhibitor LP-521834 (126) 
Tyrosine hydroxylase 
1TOH Rat ct 156-177, 200-498 2.3 Å Fe(III) (63) 
2TOH Rat ct 160-182, 186-498 2.3 Å Fe(III), BH2 (127) 
2XSN Human ct 193-527 2.7 Å Zn(II), 8 mutations  
Phenylalanine hydroxylase 
1PAH Human c 117-424 2.0 Å Fe(III) (128) 
3PAH Human c 117-424 2.0 Å Fe(III), adrenaline (129) 
4PAH Human c 117-424 2.0 Å Fe(III), noradrenaline (129) 
5PAH Human c 117-424 2.0 Å Fe(III), dopamine (129) 
6PAH Human c 117-424 2.0 Å Fe(III), dopa (129) 
1PHZ Rat rc 19-136, 143-427 2.2 Å Fe(III), phosphorylated (49) 
2PHM Rat rc 19-136, 143-427 2.6 Å Fe(III), dephosphorylated (49) 
2PAH Human ct 118-136, 143-452 3.1 Å Fe(III) (64) 
1DMW Human c 118-424 2.0 Å Fe(III), BH2 (130) 
1J8T Human c 118-424 1.7 Å Fe(II) (65) 
1J8U Human c 118-424 1.5 Å Fe(II), BH4 (65) 
1LRM Human c 118-424 2.1 Å Fe(II), BH2  
1LTU Cv 2-285 1.7 Å  (131) 
1LTV Cv 9-283 2.0 Å Fe(III) (131) 
1LTZ Cv 7-253, 257-284 1.4 Å Fe(III), BH2 (131) 
1KWO Human c 118-424 2.5 Å Fe(II), BH4, thienylalanine (132) 
1MMK Human c 117-425 2.0 Å Fe(II), BH4, thienylalanine (66) 
1MMT Human c 117-424 2.0 Å Fe(II), BH4, norleucine (66) 
1TDW Human c 117-424 2.1 Å Fe(III), A313T (133) 
1TG2 Human c 117-424 2.2 Å Fe(III), BH2, A313T (133) 
2V27 Cp 4-267 1.5 Å Fe(III) (134) 
2V28 Cp 7-267 2.0 Å  (134) 
 
 
 
 
 
As mentioned in section 2.1, the AAAHs are believed to share a similar reaction mechani
iron in the resting state is 6 coordinated
coordination changes to 5 coordinated (5C)
before and after binding of both substrate and cofactor are referred to as the open and closed 
conformation, respectively. The structure of the catalytic domain of human TPH1 with BH
(1MLW)(47) represents the open structure with iron being 
and ready for tryptophan to bind. The structure of the catalytic domain of chicken (
(3E2T)(12) on the other hand represents the closed structure. Tryptophan is bound, the binding pocket is 
closed and only a small opening in the structure gives access to the active site. This structure 
structure of the ternary complex of PAH in the closed conformation (1MMK)
in the open confirmation (1MLW)
cofactor is bound. An imidazole molecule from the crystallization conditions is coordinated to the active 
site iron, which is 5C. Although the imidazole is not binding exactly in the cofactor binding pocket, it might 
mimic the cofactor(12), thus inducing the change from the open to the closed confirmation. Another option 
is that TPH does not follow the general mechanism of PAH and TH and changes from the open to the
conformation when binding only the substrate. In order to investigate this, a new crystal structure of
cgTPH1 with tryptophan but without imidazole bound is needed.
Figure 72: The structure of the catalytic domain
coordination in 3E2T at the active site. Iron is shown as an orange sphere, BH
green sticks, imidazole is shown in cyan sticks 
3E2T structure. The small entrance to the active site is marked with a red ring. Amino acids coordinating
The two images are not seen from the same orientation. 
The recently published structures of the cata
are all very similar.  The  amino acid moiety of the inhibitors bind in the active site pocket of tryptophan, 
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 (6C), but upon substrate and cofactor binding the iron 
 and large overall structural changes are seen. These two states 
6C. The substrate binding pocket is accessible 
 more
(12). However, in the structure of cgTPH1 only tryptophan and 
 
 of gallus gallus TPH1 with tryptophan bound (PDB ID: 
4 aligned from the 1MMK structure is shown in 
and tryptophan is shown in magenta sticks. Right: Surface representation of the 
The figure was made using PyMOL
lytic domain of human TPH1 with designed inhibitors bound 
  
sm. The active site 
2 bound 
gallus gallus) TPH1 
resembles the 
 than the TPH structure 
no 
 closed 
 
 
3E2T). Left: The iron 
 iron are colored yellow. 
(50). 
  
but the inhibitors do not restrict the access to the cofactor binding pocket
monodentate glutamate and 2 histidines, as in a typical resting state open con
inhibitors (PDB ID: 3HF6 and 3HFB). For the last inhibitor (PDB ID
molecule and featuring a bidentate binding from glutamate
active site, even though the tryptophan binding pocket is closed
3HF6 with 1MLW (open conformation)
0.553 and 0.966, respectively, which
conformation structure. This is in contrast to the
structures represent some kind of intermediate between the open and closed conformations.
To obtain a greater knowledge on the structural characteristics of TPH as well as the structure
relationship, more crystal structures of TPH are needed. Especially structures of isoform 2 or structures 
containing the tetramerization or regulatory domains would fill in a large gap in the current knowledge. 
Structures of the catalytic domain with different
also shed light on structural changes compared to PAH. Thus, in this project attempts were made to 
produce crystal structures of the purified TPH variants. Furthermore, the crystallization of
optimized. 
Figure 73: The structure of the catalytic domain of human TPH1 with inhibitor bound (PDB ID: 
sphere, water as red spheres, the inhibitor in cyan sticks and BH
The iron coordination in 3HF6 at the active site
both the inhibitor, the cofactor binding pocke
The two images are not seen from the same orientation. 
5.2 Crystallization of cgTPH1
cgTPH1 has been purified and crystallized earlier by members of the Metalloprotein Chemistry and 
Engineering Group(12). However, the crystallization procedure was very time
months for the crystals to appear. Furthermore,
conditions is coordinating to the active site
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(48). Iron is 
: 3HF8), iron is 
. The overall structure is open
, see Figure 73. Alignment of 
 and 3E2T (closed conformation) gives a root mean square
 supports that the inhibitor bound structure is most similar to the open 
 authors opinion in reference (48). 
 combinations of tryptophan and/or cofactor bound could 
 
3HF6)
2 aligned from the 1MLW structure is shown in green sticks 
. Right: Surface representation of the 3HF6 structure. The active site is open, and 
t (marked by BH2 in green sticks) and iron coordinating three
The figure was made using PyMOL
 
-demanding, as it took 3
 in the cgTPH1 structure imidazole from the crystallization 
 iron. This gives some uncertainties in the analysis of the 
 
6C with 3 waters, a 
firmation for 2 of the 
5C to only one water 
 with access to the 
α C-atoms of 
 (RMS) of 
Most likely the inhibitor 
 
-function 
 cgTPH1 was 
 
. Iron is shown as an orange 
Left: 
 waters are visible. 
(50). 
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structure regarding structural changes upon substrate binding (see section 5.1). In this project the 
procedure for crystallization of cgTPH1 was optimized, so crystals appeared after 3-7 days, and the 
diffraction quality of the resulting crystals were tested with the goal of solving the structures. 
5.2.1 Experimental procedures 
cgTPH1 was purified as described in reference (96), split in two portions, concentrated to 3.3 and 6.3 
mg/mL, and frozen at -80 °C until further use. Optimization screens were developed based on the initial 
crystallization conditions, which were 22.5 (w/v)% PEG 10000, 0.2 M imidazole malate, pH 8.5. Different 
protein concentrations, addition of substrates, type and concentration of PEG, different additives, as well 
as temperature variation was tested. For a detailed description of the optimization screens, see appendix 
9.2-9.7. Some screens were set up on ice, and stored in a cooled incubator, model 3101 from RUMED set to 
5 °C. In general, the sitting-drop trays used were CombiClover Plates from Jena Bioscience, sealed with 
Crystal Clear sealing tape from Hampton Research. 250 µL screen solution was added into each reservoir. 2 
µL protein solution was added in each drop chamber, and was subsequently mixed with 2 µL screen 
solution from the reservoir by pipetting up and down three times. The drops were inspected using a M205C 
microscope equipped with a DFC290 camera and the LAS software, v 3.1.0, all from Leica Microsystems. 
The crystals were mounted primarily in litho loops from Molecular Dimensions using cryo solutions that 
were as close to the drop conditions as possible (for exact description of the cryo solutions used for the 
best diffracting crystals, see section 5.2.3). 
The diffraction data were collected by either of two means: I) By testing the crystals ourselves at MaxLab 
beamline I911-3(135). II) By submitting the crystals to the Mail-In service at Brookhaven National 
Laboratory(136). For processing of data images, indexing, cell refinement and integration the software 
iMosflm 1.0.5(137) or XDS(138) were used. For molecular replacement and following refinement, CCP4i 
application suite programs(139) Scala, MolRep or Phaser and RefMac were used together with 
WinCoot(140). Molecular replacement was performed with the 3E2T structure where everything except for 
the amino acid chain had been removed. Alignment between different structures were performed using the 
align command in PyMOL(50). 
5.2.2 Crystallization results 
The initial crystallization conditions for cgTPH1 were: 22.5 (w/v)% PEG 10000, 0.2 M imidazole malate, pH 
8.5 and 2.8 mg/ml (78 µM) cgTPH1 stored at 4 °C(12). No substrates were added. The structure contained 
tryptophan and imidazole bound in the active site. As the crystallization conditions for cgTPH1 were already 
known, only the fine-tuning of parameters was investigated. 
5.2.2.1 1st optimization screen  
First, an optimization screen based on the initial crystallization conditions of cgTPH1 was made and set up 
at room temperature and 5 °C. The screen varied protein concentration and PEG type and concentration. 
The conditions used in the screen can be seen in appendix 9.2. Tryptophan and BH2 were added both 
individually and combined. BH2 is added instead of the natural cofactor BH4, to avoid the reaction occuring, 
and because BH4 is not stable at room temperature at neutral pH. Tryptophan and BH2 was added in at 
least 2 fold molar excess from 7 mM stock solutions. Crystals appeared in the screen set up at room 
temperature after only 7 days, but only in drops containing imidazole and added tryptophan or tryptophan 
and BH2. The crystals all grew from precipitate. Most of the crystals seemed flat rather than 3 dimensional, 
but some conditions gave very nice crystals. The screen at 5 °C only produced crystals in the drops with 
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conditions similar to the original, but with added tryptophan. These crystals appeared after 14 days and 
looked very three dimensional. Thus, it can be concluded that adding tryptophan to the crystallization 
conditions decreases the crystallization time significantly, and that incubation of the screen at room 
temperature speeds up the crystallization process even more. Some of the crystals from the first screen can 
be seen in Figure 74. Several crystals were tested, but none gave diffraction data good enough for structure 
solving as the resolution was too low (4-8 Å). 
   
Figure 74: Pictures of cgTPH1 crystals from the 1st optimization screen. The left picture is from the screen at 5 °C, while the other 
3 pictures are from the screen at room temperature. The white scale bar in the bottom right corner of each picture is 0.1 mm. 
5.2.2.2 2nd optimization screen  
To check if any additives would speed up the crystallization process, an additive screen from Molecular 
Dimenions was tested with the original crystallization conditions (22.5 (w/v)% PEG 10000, 0.2 M imidazole 
malate pH 8.5) and a protein concentration of 2.8 mg/mL at room temperature. The additives were added 
according to the screen application note. Tryptophan and BH2 were added both individually and combined. 
A description of the additive screen can be found in appendix 9.3. No crystals appeared in this screen. 
5.2.2.3 3rd optimization screen  
In the 1st optimization screen, only conditions with imidazole gave crystals. In order to obtain crystals from 
conditions without imidazole, a new optimization screen was set up. The screen can be seen in appendix 
9.4 and was set up at room temperature. 
Crystals appeared after only 3 days in several conditions, which all had been added tryptophan or 
tryptophan and BH2. 7 conditions without imidazole gave crystals.  The drops mainly contained many small 
crystals, but some larger crystals also appeared. Several crystals were tested with X-ray diffraction, but only 
3 gave diffraction data good enough for structure solving (see section 5.2.3.1 and 5.2.3.2). Most of the 
crystals gave only low resolution data (4-8 Å). The 3 crystals that diffracted to high enough resolution for 
structure solving all came from this screen. Furthermore, it can be concluded that cgTPH1 crystals can be 
grown without imidazole in the crystallization conditions. 
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Figure 75: Pictures of cgTPH1 crystals from the 3rd optimization screen. The white scale bar in the bottom right corner of each 
picture is 0.1 mm. 
5.2.2.4 4th optimization screen  
In an attempt to get larger and better quality crystals without imidazole, a 4th optimization screen was set 
up, based on the previous results. The screens can be seen in appendix 9.5, 9.6, and 9.7. Larger drop 
volumes and different kind of crystallization trays/plates including hanging drops were tested in order to 
get larger crystals. Tryptophan or tryptophan and BH2 were added to all conditions, and the screen was set 
up at room temperature.  
Approx. half (38) of the conditions tested gave crystals, many of which looked suitable for structure 
determination in terms of size and three dimensional shape. Especially, the screen with hanging drops 
produced many crystals. The crystals appeared after 3-4 days. Many of the crystals from this screen were 
sent for analysis at Brookhaven National Laboratory, but unfortunately none gave data of high enough 
quality for structure determination (resolution around 4 Å). It can be speculated that the shorter 
crystallization times gives crystals of poorer quality compared to the original crystals, which were grown 
over 3-6 months. The literature only gives sparse information on the correlation between crystal growth 
rate and crystal quality(141, 142). However, it seems reasonable that faster crystal growth rates would 
increase the amount of defects incorporated into the crystal. 
   
Figure 76: Pictures of cgTPH1 crystals from the 4th optimization screen. The white scale bar in the bottom right corner of each 
picture is 0.1 mm. 
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5.2.3 Structures of cgTPH1 
Of the many crystals produced, several were tested by X-ray diffraction. Most crystals gave low resolution 
data (4-8 Å), which could not be used to solve the structure. 30 crystals were shipped to Brookhaven 
National Laboratory for analysis, but of these 30 crystals only 2 diffracted well enough for structure solving. 
These two crystals were the only two that contained imidazole in the crystallization conditions. Based on 
this, it seems that imidazole affects the crystallization and helps creating crystals that gives high resolution 
diffraction data. One crystal without imidazole was measured at MaxLab in Lund, Sweden and gave 
diffraction data with high enough resolution for structure solving. The two structures are presented in the 
following two sections. 
It should be noted here that there was no correlation between the crystal appearance and diffraction data 
quality. Many large and edgy crystals gave low resolution data, while small and seemingly flat crystals 
resulted in the best diffraction data.  
5.2.3.1 Structure of cgTPH1 with no imidazole and tryptophan bound 
The first crystal of cgTPH1 which gave reasonable diffraction data was obtained from the 3rd optimization 
screen. It will be referred to as crystal-1 and grew in the following conditions: 22.5 (w/v)% PEG 10000, 0.1 
M Tris acetate pH 8.5. The protein concentration was 2.5 mg/ml and tryptophan was added in 4.5 times 
excess (310 µM) compared to cgTPH1 (70 µM). The crystals appeared after 3 days at room temperature. 
           
Figure 77: Crystal-1 (cgTPH1) from the 3rd optimization screen. The white scale bar in the bottom right corner of each picture is 
0.1 mm. 
The crystal was mounted and frozen in cryo-solution containing 22.5 (w/v)% PEG 10000, 20 (v/v)% PEG 400, 
0.1 M Tris acetate pH 8.5, 155 µM tryptophan. The diffraction data was collected at MaxLab, Lund, Sweden 
at beamline I911-3. The results of the diffraction data collection can be seen in Table 13. 
Because of the low quality data, only the overall structure was solved and the resolution was limited to 3.1 
Å. No attempts were made to refine the structure. From the initial map, electron density was seen in the 
position where iron usually is placed. Thus iron was added to the structure. However, on addition of iron 
the RFree factor increased, even though the R factor decreased, see Table 14. This effect is usually seen 
when the structure is over-refined(143).  
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Table 13: Parameters from the data collection of crystal-1 (cgTPH1) at MaxLab, Lund, Sweden. 
Space group C121 
X-ray source I911-3, MAXII, MaxLab Lund 
Detector Marmosaic 225 
Wavelength (Å) 1.00 
Data collection temperature (K) 100 
Resolution limit (Å) 47.7-2.5 
No. reflections 51678 
Unique reflections 19336 
Redundancy 2.7 
Completeness (%) 93.8 
Rmerge 0.297 
<I/σ(I)> 2.5 
Unit cell parameters 
a (Å), b (Å), c (Å) 
α (°), β (°), γ (°) 
 
171.5, 49.7, 67.6 
90.0, 91.9, 90.0 
Solvent content 38.4 
Matthews coefficient (Å3/Da) 1.99 
Nmol/assym. 2 
Average mosaicity 1.04 
The new electron density map then revealed excess electron density in the tryptophan binding pocket and 
thus tryptophan was added in this position. The electron density map of the active site from the final 
refinement can be seen in Figure 78. It should be noted that RFree increased for both addition of iron and 
tryptophan. An excess electron density blob in the coordination sphere of iron was seen in some of the first 
refinement rounds, however, when water was added it moved far away from iron during the following 
refinement (approx. 6 Å). Thus, no conclusions can be made on the complete coordination of iron.  
Table 14: Overview of the R and RFree values upon refinement of the structure of crystal-1 (cgTPH1 with tryptophan but no 
imidazole bound). 
Operation R RFree 
Rigid body refinement 0.3686 0.3630 
Restrained refinement 0.2587 0.3391 
Addition of iron 0.2456 0.3463 
Addition of tryptophan 0.2385 0.3558 
The overall fold of this newly solved structure is more similar to the closed confirmation of 3E2T than to the 
open confirmation of 1MLW. However, 3E2T was also used as search model during molecular replacement. 
Furthermore, the data are of such low quality and the R and RFree values are correspondingly high and 
separated by too many percent, to make any definite conclusions from this structure.  
In conclusion, the crystal did contain cgTPH1, but the diffraction data were not good enough to make any 
definitive conclusions on the overall or active site structure. 
  
         
Figure 78: Electron density map of the active sites in the 2 molecules in the asymmetric unit of the structure
with tryptophan but with no imidazole bound)
5.2.3.2 Structure of cgTPH1 with imidazole and 
Brookhaven National Laboratory Mail
optimization screen, and of those only 2 diffracted well. These two
crystal-3, came from the same drop from th
M imidazole malate pH 8.5. The protein concentration was 2.8 mg/ml and tryptophan and BH
in 2 times excess (156 µM) compared to
that both tryptophan and BH2 would have bound in the active site, and the structure thus would represent 
a ternary complex. The crystals had a different shape (triangular) compared to crystals with only 
tryptophan added (rhombic), and can be see
temperature. 
Figure 79: Crystal-2 and crystal-3 (cgTPH1) 
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The crystals were mounted and frozen in a cryo-solution containing 22.5 (w/v)% PEG 10000, 20 (v/v)% PEG 
400, 0.1 M imidazole malate pH 8.5, 156 µM tryptophan, 156 µM BH2. All measurements and data analysis 
including molecular replacement with 3E2T as search model and the following refinement was performed 
by the Mail-in service crew at Brookhaven National Laboratory and will not be described further. The 
parameters for the two structures can be seen in Table 15. The two structures were very similar, and thus 
only the one structure of crystal-2 will be presented here.  
Table 15: Parameters from the data collection of crystal-2 and crystal-3 of cgTPH1 at Brookhaven National Laboratory mail-in 
service, New York, USA. 
Parameter Crystal-2 Crystal-3 
Space group C121 C121 
Resolution limit (Å) 2.4 2.3 
Unit cell parameters 
a (Å), b (Å), c (Å) 
α (°), β (°), γ (°) 
 
170.5, 48.7, 135.1 
90.0, 91.7, 90.0 
 
170.7, 48.7, 134.9 
90.0, 91.6, 90.0 
Nmol/assym. 4 4 
No. of reflections 34324 40815 
Completeness 81.8 85.5 
RFree 0.27 0.25 
R 0.19 0.19 
The structure of crystal-2 was refined to RFree = 27 %. Iron and tryptophan are bound in the active site in the 
structure. An imidazole ring has also been added near the iron coordination sphere. From the electron 
density map in Figure 80 it is seen that a ring-like molecule binds in the vicinity of iron, but it is not possible 
to determine if a water molecule is also coordinated to iron.  
Imidazole is located near the cofactor binding pocket, but the imidazole ring does not overlay the rings of 
the cofactor in the 1MLW structure or 1MMK structure. Furthermore, the electron density does not allow 
for a precise positioning of imidazole, which differs somewhat in the 4 molecules in the asymmetric unit. 
Thus, it is hard to interpret whether imidazole mimics the cofactor. As seen by the electron density maps, 
tryptophan is clearly bound in the structure, and both tryptophan and iron are present with 100 % 
occupancy. In Table 16, the distances between the different molecules in the structure of crystal-2 are 
seen. It can be discussed if imidazole coordinates to iron, considering the long distances between the two. 
The overall fold of the structure is very similar to that of the previous cgTPH1 structure 3E2T, also with 
imidazole and tryptophan bound. The RMS value only aligning α carbon atoms is 0.3 for 3E2T and 1.3 for 
1MLW. The alignment with the ternary complex of PAH (PDB ID: 1MMK) gave an RMS of 0.6, suggesting 
that the structure is in the closed conformation. However, this structure does unfortunately not contribute 
with any new structural information on TPH. 
 
 
  
Figure 80: Electron density map of the active sites in the 4 
and imidazole bound). Iron is shown as an orange sphere
Table 16: Distances between different molecules in the structure of crystal
The values are given for each of the 4 molecules in the asymmetric unit.
Distance Molecule 1 [Å]
Fe -> imidazole 3.6 
Fe -> water 2.2 
Fe -> tryptophan 4.1 
Fe -> His278 2.0 
Fe -> His273 2.1 
Fe -> Glu318 1.7 (2.8)
5.2.4 Conclusions 
The crystallization procedure for 
significantly from 3-6 months to a few days by addition of tryptophan and 
Nice crystals of cgTPH1 can also be grown with
the cgTPH1 crystals all looked very edg
The best diffraction data came from crystals grown with imidazole, but the solved structures did not 
contribute with any new knowledge on the structure of
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made using PyMOL(50). 
-2 (cgTPH1 with tryptophan and imidazole bound)
 
 Molecule 2 [Å] Molecule 3 [Å] Molecule 4 [Å]
2.8 2.3 
2.5 3.7 
4.0 3.9 
1.7 2.0 
2.1 2.0 
 1.9 (2.4) 1.9 (2.5) 
cgTPH1 has been optimized to shorten the crystal growth period 
incubation
out imidazole in the crystallization conditions. Even though 
ed and three dimensional, the diffraction data were of poor quality. 
 cgTPH1. 
 
 
 
-2 (cgTPH1 with tryptophan 
. The figure was 
. 
 
2.7 
- 
4.0 
2.0 
2.1 
1.6 (2.8) 
 at room temperature. 
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5.3 Crystallization of chTPH2 
One of the main goals in this project was to obtain a structure of TPH2. Thus, large efforts were put into the 
attempts to crystallize chTPH2 and cthTPH2. Crystallization of chTPH2 was attempted using several 
different buffer systems for purification, different screens, protein concentrations, addition of substrates, 
and temperature variation. A total number of approx. 4000 drops with chTPH2 were set up manually. 
Crystals did appear, but they turned out to be organic molecule crystals, possibly from the buffer. Protein 
samples of chTPH2 were shipped to HT (high throughput) crystallization at EMBL in Hamburg through the P-
CUBE project(144). Here, 5 different screens of 96 conditions were tested with 3 different protein 
concentrations and 4 combinations of substrates added at 19 °C to a total of 5760 drops. No crystals were 
found. 
In my master thesis, experiments with different scattering techniques showed that purified chTPH2 is not 
completely monodisperse, and that part of the sample might be denatured or exist as dimers(11). On SDS-
PAGE the sample looks pure (see section 4.3.3.1). Despite the multiple attempts to crystallize chTPH2 no 
crystals were made. Therefore, a more strategic way for testing of the samples and crystallization was 
chosen (see section 5.5). 
5.4 Crystallization of cthTPH2 
Earlier projects investigated the monodispersity of a cthTPH2 solution, and found that it was monodisperse 
and that cthTPH2 exists as tetramers(11). cthTPH2 purified in this project also looked pure judged from the 
SDS-PAGE (see section 4.3.3.2). As with chTPH2 several different buffer systems for purification, different 
screens, protein concentrations, addition of substrates, and temperature variation were tested in a total of 
approx. 5000 drops. The only crystals that appeared turned out to be organic molecule crystals, most likely 
of BH2 or buffer. 
5.5 Crystallization pipeline 
Along the project course it was clear that several new variants of TPH could be purified and was thus ready 
for crystallization trials. Because of the many different variants of TPH and the unsuccessful crystallization 
trials of chTPH2 and cthTPH2, a more strategic and systematic way of analyzing the purified samples and 
testing for crystallization was set up, called the crystallization pipeline. Even though the strategy for 
reaching the desired results was changed, the overall goal remains the same: To crystallize and solve the 
structures for TPH variants where the structure is unknown or known structures in new combinations with 
substrate and cofactor. 
The TPH variants that can be purified in reasonable amounts and are thus available for crystallization are 
shown in Table 17. 
These 5 variants constitute the main candidates in the crystallization pipeline in this project. cgTPH1 has 
not been included as it has already been crystallized. chTPH1 has been included even though it has been 
crystallized in the group before(10) because an impurity has been removed in the new purification method 
(see section 4.3.2.1), and this might improve the crystallization process and crystal quality. 
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Table 17: Overview of TPH variants that can be purified in reasonable amounts suitable for crystallization. Concentration is the 
highest concentration of the protein tested without precipitation. The same data is given in Table 11. 
Variant Purification 
method 
Buffer Yield Concentration Section 
chTPH2 Anion-exchange 
and gel filtration 
20 mM HEPES/NaOH 
100 mM (NH4)2SO4 
pH 7.2 
70 mg/L 
culture 
2.5 mM 4.3.3.1 
cthTPH2 Anion-exchange 
and gel-filtration 
20 mM HEPES/NaOH 
100 mM (NH4)2SO4 
pH 7.2 
54 mg/L 
culture 
0.29 mM 4.3.3.2 
chTPH1 Affinity using GST-
tag and gel-
filtration 
1xPBS 
200 mM (NH4)2SO4 
pH 8.5 
11 mg/L 
culture 
0.18 mM 4.3.2.1 
rchTPH1 Affinity using MBP-
tag and gel-
filtration 
20mM Tris/H2SO4 
300mM (NH4)2SO4 
pH 8.0 
20 mg/L 
culture 
0.20 mM 4.3.2.4 
hTPH1 Affinity using MBP-
tag and gel-
filtration 
20 mM Tris/H2SO4 
300 mM (NH4)2SO4 
pH 8.0 
23 mg/L 
culture 
0.16 mM 4.3.2.2 
 
5.5.1 Strategic approach 
When a TPH variant can be purified, the purification product should be tested in order to ensure that the 
protein sample is pure, active, and stable. This is tested through SDS-PAGE, mass spectrometry, activity 
assay, and DSF measurements. The monodispersity of the sample after freezing can be tested using 
analytical gel-filtration. A pure and uniform sample is one of the most important parameters in 
crystallization(95). If these tests show a pure, active, stable, and monodisperse protein sample, it should be 
suitable for crystallization.  
The monodispersity of the different TPH variants was tested in chapter 4, and an overview of the results is 
seen in Table 18. Most samples are slightly polydisperse after freezing and thawing, and this could explain 
the difficulties with crystallization. The aggregates or unfolded proteins represented by the shoulder on the 
main peak in the chromatograms were not separated by centrifugation or filtration as they are too small 
and soluble. Whether it is the freezing/thawing or the concentration process that causes the low 
monodispersity is unknown. However, most samples gave chromatograms with only very small shoulders 
on the main peak, which indicates that by far the majority of the sample has the same size. For 
crystallization purposes, even small amounts of unfolded or aggregated protein can inhibit or complicate 
the process(95, 122). Thus, if crystallization fails, the monodispersity of the sample would be one of the 
first parameter that should be investigated and possibly improved. However, as aggregates in some cases 
might abet crystallization, centrifugation or filtration of a sample is generally not advised prior to 
crystallization(125). It can thus be discussed if a slightly polydisperse sample is good or bad for 
crystallization. Screening of a large number of proteins has shown that a symmetric gel-filtration 
chromatography profile in general seems to be required for successful crystallization(145). However, most 
gel-filtration chromatograms in the reference which resulted in crystal structures also displayed small 
shoulders near the main peak as most TPH variants. Known protein stabilizers such as glycerol might help 
increasing the monodispersity, however they might also interfere with the crystallization process or even 
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bind to the active site (vide infra, see section 6.3). For cthTPH2, the presence of 10 (w/v)% glycerol in the 
buffers did not improve the monodispersity (see section 4.3.3.2.1). To eliminate the possible negative 
effect of freezing and thawing, the TPH variants were purified and the screens for crystallization were set 
up directly after purification. 
Table 18: Overview of the characterization results from the purification products of each variant. Details about the individual 
results can be seen in chapter 4. 
Variant SDS-
PAGE 
Mass spectrometry Activity 
assay 
TM from DSF 
at pH 7.5 
Monodispersity after 
freezing 
chTPH2 Pure Pure monomer with 
iron bound 
Active 53 Small shoulder that cannot 
be removed 
cthTPH2 Pure Pure tetramer Active 56 Small shoulder that cannot 
be removed 
chTPH1 Pure Pure monomer with 
iron bound 
Active 46 Small shoulder that can be 
removed 
rchTPH1 Pure Mixture of several 
oligomer species 
Active - Monodisperse 
 
hTPH1 Pure Pure tetramer Active 54 Large shoulder that can be 
decreased but not 
completely removed 
 
5.5.2 Screens 
When the TPH variant has been purified and the purification product has been tested and found suitable 
for crystallization, the actual crystallization set-up process can begin. It was decided to test all variants at 
the same conditions to ensure a better comparison between variants, and to limit the number of variables. 
The sparse matrix screen Structure Screen 1 from Molecular dimensions was chosen as the main screen. 
Conditions containing calcium (condition 1, 11, 20, and 23) was removed, as the protein buffers contain 
sulfate which would crystallize with calcium as CaSO4. Instead, the crystallization conditions for cgTPH1 and 
condition 26 from Structure screen 2 similar to the crystallization conditions for chTPH1 were included, 
giving a total of 48 conditions. These 48 conditions were tested with 2 protein concentrations (2 mg/mL 
and 5 mg/mL) and either no addition of substrates or addition of both tryptophan and BH2 in 3 fold molar 
excess. One screen was set up at room temperature and the other at 5 °C. This gives a total of 384 drops for 
each TPH variant. Each drop contains 2 µl protein solution and 2 µl reservoir solution. Thus, 2.7 mg protein 
was used for the entire experiment for each variant.  
It was considered to add iron to the crystallization conditions. However, iron is very hard to keep soluble at 
pH above 5 when oxygen is present, as it precipitates as Fe(III) oxides. Thus, Fe(II) was added during 
purification and not in the crystallization conditions. 
5.5.3 Experimental procedures 
The experimental methods used in the crystallization pipeline will be presented in this section, divided into 
the protein sample preparation and the screen set-up procedure. 
5.5.3.1 Protein sample preparation 
chTPH2, cthTPH2, chTPH1 (from GST-chTPH1), rchTPH1 (from MBP-rchTPH1) and hTPH1 (from MBP-hTPH1) 
were purified as described in sections 4.2.4.1, 4.2.4.2, 4.2.3.1, 4.2.3.3, and 4.2.3.2, respectively. For each 
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variant, the following preparations were made. The final purification product from the last gel-filtration was 
concentrated using ultrafiltration to a concentration of 7-10 mg/mL or until precipitation was observed. 
The pressure was taken of the ultrafiltration cell and the solution was left for 15 min to allow the 
equilibrium between precipitated and soluble protein to adjust. The protein solution was centrifuged at 
16000 x g for 15 min at 5 °C. The supernatant was collected and the concentration was determined by UV-
Vis. At least three consecutive concentration measurements were performed. Frozen stocks of 7 mM BH2 
and 20 mM L-tryptophan were thawed. Each protein solution was divided into 4 different solutions for 
crystallization set-up by diluting in the gel-filtration buffer from the purification (see Table 17), and 
tryptophan and BH2 were added in 3 times molar excess. An overview of the 4 solutions can be seen in 
Table 19. The protein solutions were kept on ice during the entire process. 
Table 19: Overview of the 4 protein solutions for crystallization set-up that were made for each TPH variant. 
Solution A B C D 
Protein concentration 5 mg/mL 5 mg/mL 2 mg/mL 2 mg/mL 
Added substrates - BH2+trp - BH2+trp 
5.5.3.2 Screen set-up 
The screen used was the Structure Screen 1 from molecular dimensions, see appendix 9.8. Conditions 1, 11, 
20, and 23 were not set-up, and instead a premade solution of 22.5 (w/v)% PEG 10000, 0.2 M imidazole 
malate pH 8.5 from Molecular Dimensions and condition 26 from Structure Screen 2 containing 0.2 M 
(NH4)2SO4, 0.1 M MES (2-(N-morpholino)-ethanesulfonic acid), pH 6.5, 30 (w/v)% PEG 5000 MME 
(monomethylether) were included. The screen solutions were approx. 5 °C when setting up the 5 °C screen, 
but were allowed to equilibrate to room temperature as the room temperature screen was set up. For the 
5 °C screen, the crystallization plate was kept on a tray filled with ice during set-up, and afterwards it was 
transferred to a cooled incubator, model 3101 from RUMED set to 5 °C where it was stored.  
The sitting-drop trays used were CombiClover Plates from Jena Bioscience, sealed with Crystal Clear sealing 
tape from Hampton Research. 250 µL screen solution was added into each reservoir. 2 µL protein solution 
was added in each drop chamber, and was subsequently mixed with 2 µL screen solution from the reservoir 
by pipetting up and down three times. 
The drops were inspected using a M205C microscope equipped with a DFC290 camera and the LAS 
software, v 3.1.0, all from Leica Microsystems.  
5.5.4 Results and discussion 
In general, 80-90 % of the drops contained protein precipitate. This was common for all TPH variants, 
despite the relatively low protein concentrations used (2 and 5 mg/mL). However, crystals can also grow 
from precipitate as in the case for e.g. cgTPH1. 
The pipeline screening of chTPH2, cthTPH2, rchTPH1, and hTPH1 did not result in any crystals. However, for 
rchTPH1 crystalline precipitate as well as assemblies of precipitate which also appeared crystalline was 
observed in several conditions. Examples of this are shown in Figure 81. These leads should be optimized to 
check whether crystals can be obtained. 
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Figure 81: Examples of leads from the pipeline screening of rchTPH1. Left is what is believed to be crystalline precipipate, and 
right is an assembly of precipitate. The crystals appeared in screen conditions 30 and 26, respectively from left to right (see 
appendix 9.8 for exact conditions). The white scale bar in the bottom right corner of each picture is 0.1 mm. 
For chTPH1, several conditions yielded crystals. A total of 20 different screen conditions successfully 
produced crystals, while approx. half of them had more than 3 hits (meaning that at least 3 of the 8 drops 
set up with this condition produced crystals). Most crystals were needle-shaped, as has been observed for 
chTPH1 before(10). Due to the many nucleation points in these drops, the crystals will be hard to separate. 
Furthermore, several crystals often grew from the same nucleation point in a star like pattern.  
   
Figure 82: Needle-like crystals from the chTPH1 pipeline screening. The crystals appeared in screen condition 18, 36 and 7, 
respectively from left to right (see appendix 9.8 for exact conditions). The white scale bar in the bottom right corner of each 
picture is 0.1 mm. 
As the needles are most likely protein crystals, they offer a great starting point for fine-tuning and 
optimization to yield separate crystals that can be analyzed by diffraction. The number of nucleation points 
should be decreased, so larger crystals can grow. There are several strategies to overcome the problem of 
excess nucleation resulting in the formation of numerous low-quality crystals. One option is seeding with 
already-grown small crystals into a drop in the meta-stable zone, which facilitates crystal growth but not 
nucleation(125). 
Several other crystal types than needles were also observed, including spherulites, see Figure 83. However, 
some of these could be suspected to be salt crystals, due to the intense color when viewed through a 
polarizer(122). As the protein solution contains quite high salt concentrations, it is not unlikely that salt 
crystals will appear. 
5.6 Conclusions 
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Figure 83: Different types of crystals observed in the chTPH1 pipeline screening. The center picture shows spherulites. The 
crystals appeared in condition 22, 37 and 35, respectively from left to right (see appendix 9.8 for exact conditions). The white 
scale bar in the bottom right corner of each picture is 0.1 mm. 
Finally, two different conditions (16 and 24) produced very nice looking, edgy and three dimensional 
rectangular crystals, as seen in Figure 84. Again, the intense color of the crystals when viewed through the 
polarizer indicates that they might be salt crystals. However, the crystals should be mounted and tested by 
diffraction to confirm this. Alternatively, the drops can be added Izit crystal dye, which mainly colors 
protein crystals, and not salt crystals or it can be tested if a mixture of protein-free buffer and screen 
solution also result in crystals. As the crystals appeared shortly before the deadline of this project, none of 
the above tests were performed. 
                 
Figure 84: Rectangular crystals observed in the chTH1 pipeline screening. The crystals appeared in condition 16 (two first 
pictures) and 24, respectively from left to right (see appendix 9.8 for exact conditions). The white scale bar in the bottom right 
corner of each picture is 0.1 mm. 
5.6 Conclusions 
The crystallization procedure for cgTPH1 was optimized to faster crystal growth by addition of tryptophan 
and incubation at room temperature. Crystals without imidazole in the crystallization conditions could be 
obtained. Only one such crystal and two crystals with imidazole gave diffraction data good enough for 
structure solving. There was no correlation between crystal appearance and diffraction data quality, as the 
smallest and most flat-looking crystals gave the best diffraction data. 
A strategic approach to crystallization of TPH variants was developed, and the 5 suitable TPH variants were 
purified followed by immediate screen set-up eliminating the freezing-thawing step. No crystals of any 
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TPH2 variant were found. However, the pipeline screening produced leads for rchTPH1 and crystals for 
chTPH1. The initial crystallization conditions identified for chTPH1 should be optimized to yield single 
crystals. 
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6 Mechanistic studies 
In this chapter, the experiments that investigate the mechanism of TPH will be presented. Several different 
techniques can be used to investigate the mechanism of enzymes. Here, focus has been on the pre-reaction 
events, specifically substrate and cofactor binding including binding affinity and structural changes in the 
active site. Also, mutations have been made in the active site to investigate the importance of the mutated 
amino acids for the reaction mechanism. When studying mechanism and substrate binding, it is important 
to utilize several different techniques to get reliable results. Even though a crystal structure shows a 
specific feature, it might not represent the natural state of the free enzyme in solution. Hence, a 
combination of different techniques gives the most trustworthy results. Up until now, many of the available 
characterization methods could not be applied to TPH, due to the lack of pure and stable variants that can 
be concentrated to the high concentrations necessary. The development of the purification procedure for 
chTPH2, which results in high yields of a stable and pure product that can be concentrated to 2.5 mM, 
opened up the possibility to utilize many of these techniques. 
6.1 Mechanistic mutations 
In this project, mutations of amino acids in the active site of chTPH2 have been made in order to investigate 
their importance for the activity of the enzyme. chTPH2 was chosen as the preferred variant to make 
mutations in, due to the high stability and yield from purification. To decide which mutations should be 
studied, a screening of the relevant literature was performed. Some mutational studies performed on TPH, 
PAH, and TH will be presented here. First, the disease related mutations of TPH will be discussed, follow by 
a brief review of mutations of TPH, PAH, and TH which gives insight into the mechanism of the AAAHs. Last, 
the background for the 4 mutants made in this project, will be described. 
6.1.1 TPH disease related mutants 
Both TPH1 and TPH2 are linked to a number of disorders in humans. Thus, polymorphisms in TPH related to 
these disorders have been widely investigated. In 2009, McKinney et al reviewed and characterized all 
reported missense variants for TPH2(146). Four of these were present in the catalytic domain: Pro206Ser 
(bipolar disorder), Arg303Trp (ADHD), Ala328Val, and Arg441His. None of these 4 mutations were close to 
iron in the active site, but they still had a significant effect on activity(146)(102). As the reported disease 
related mutants of TPH2 have all be studied by other groups, they were not chosen for mutation in this 
project. 
6.1.2 Mutations for investigation of AAAH mechanism 
Mutational studies have been used to shed light on the reaction mechanism of AAAHs. In the following a 
few examples of this will be given.  
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Mutations of several amino acids in the active site of rat TH have been performed. The mutant Glu332Ala 
catalyzed the uncoupled reaction, where only the cofactor and not the amino acid is hydroxylated(70). 
Kinetic studies showed that this amino acid has an important role in directing protonation of the Fe-OO-
pterin bridge ensuring correct formation of the hydroxylating intermediate(70). Without Glu332 the 
hydroxylating intermediate is not formed, and tyrosine cannot be hydroxylated as in the coupled reaction. 
Another mutation study of rat TH on Glu332, finds that it greatly affects the binding affinity of the cofactor, 
and also is important for ensuring a coupled reaction(147). For PAH, the corresponding amino acid Glu286 
has also been mutated, which confirmed its importance in catalytic activity and correct positioning of the 
cofactor(130). For this important glutamate residue, several different techniques were used to confirm the 
importance for the reaction mechanism by mutation. 
Another example of mutational studies was performed on disease-related amino acids in the active site of 
PAH using spectroscopic techniques combined with kinetic analysis. The mutant PAH Glu280Lys remained 
6C in iron coordination upon substrate and cofactor binding in contrast to wild-type PAH, which changes 
from 6C to 5C(84). Another mutant, Arg158Gln, did change iron coordination to 5C, but still the reaction 
catalyzed was mainly uncoupled. This indicates that the first step of the mechanism is formation of a 
peroxy-pterin species, which subsequently reacts with the iron site if the pterin is properly oriented for 
formation of a Fe-OO-pterin bridge and an open coordination position is available on the iron. Otherwise, 
the reaction becomes uncoupled, as no hydroxylating intermediate is formed. 
As mentioned in section 2.3.2.1, mutational studies can also clarify the effect of different amino acids on 
substrate specificity(62). 
6.1.3 Background for the mutants made in this project 
Based on the screening of the literature, 2 mutations of each 2 amino acids in chTPH2 were chosen for this 
project.  
From the PAH crystal structures, Tyr325 was identified as a possible important amino acids, as it swings out 
with an iron-coordinated water when the geometry changes from 6C to 5C upon substrate and cofactor 
binding (see section 2.4.1, Figure 10). Earlier DFT studies have also confirmed the importance of this amino 
acid in the hydrogen bonding network in the active site of TPH(76). This tyrosine residue (Tyr358 in hTPH2 
numbering) is placed in the second coordination sphere from iron and is conserved in all AAAHs except for 
human TH, where it is replaced by serine conserving the hydroxyl-group functionality. This tyrosine residue 
has been mutated to Phe in PAH without any significant loss in activity(130) thus excluding any direct 
functional role in catalysis. For rat TH the corresponding amino acid has also been mutated to Phe and the 
mutant showed full activity in the hydroxylation of tyrosine, leading to the conclusion that it had no 
essential mechanistic role(148). However, in 2003 mass spectrometric analysis of human Tyr325Phe PAH 
showed that the mutated phenylalanine had been post-translationally hydroxylated back to tyrosine 
eliminating the difference between the mutant and wild-type proteins. For bacterial Tyr325Phe PAH there 
was no such repair mechanism, and the specific activity was reduced 30-fold compared to the wild-
type(149). These results suggest that Tyr325 might have an important role despite earlier results. This was 
investigated further in 2005, where Tyr325 in PAH was mutated to Leu, Ala, Ser and Phe(150). Only 
Tyr325Leu and Tyr325Phe mutations resulted in stable enzymes. Compared to wild-type PAH the 
Tyr325Leu showed decreased specific activity, decreased coupling efficiency and decreased iron content, 
suggesting that Tyr325 does indeed play an important role. The importance of this tyrosine residue for the 
 6 Mechanistic studies   
   
 
87 
 
catalytic activity in TPH can be investigated experimentally by making mutations of this amino acid and 
testing the mutants for activity. 
The chTPH2 mutants Tyr358Phe and Tyr358Ser were chosen for the mutational study. The overall goal was 
to investigate whether the results from PAH are also valid for TPH. Tyr358Phe chTPH2 was made in order to 
check for self-hydroxylation and effect on activity. Tyr358Ser chTPH2 was made because this mutant has 
conserved the OH group, which might be important for functionality, but has removed the aromatic ring, 
which might have an effect on stability. Furthermore, the corresponding residue in human TH is a serine. 
Mutational studies can also be used to investigate the plasticity of the iron coordinating amino acids in TPH. 
The 3 amino acids coordinating iron in the facial triad have been subject to mutations in both PAH and TH 
in earlier studies(151–154). Mutation of all three amino acids to glutamine, glutamate or histidine in PAH 
shows that the activity is most sensitive to mutations in the glutamate ligand, but that all mutations gave 
low activities and reduced affinity for iron binding(151). The iron ligands in TH are much less sensitive to 
mutations than the iron ligands in PAH(151). However, in both enzymes mutation of glutamate is more 
disruptive to catalysis than mutation of either of the two histidines. 
Here, the glutamate iron ligand mutants Glu363Gln chTPH2 and Glu363His chTPH2 were chosen. The 
mutation to glutamine was thought to partly conserve the bidentate binding functionality of glutamate, 
which is important in the conformational changes in the active site upon substrate and cofactor binding. 
The amide of glutamine could coordinate the iron through both the deprotonated nitrogen and the oxygen, 
although this is not a very likely scenario. The mutation of glutamate to histidine is inspired by the 
existence of other oxygen-activating enzymes with a 3-His binding iron motif(155, 156), and thus it was 
tested if TPH can hydroxylate tryptophan with a 3-His iron coordination.   
6.1.4 Experimental procedures 
Most of the experimental work was performed by bachelor student Anne Kathrine Nielsen and generally 
follows the same procedures as for wild-type chTPH2. 
6.1.4.1 Expression 
The 4 chTPH2 mutants Tyr358Phe, Tyr358Ser, Glu363Gln and Glu363His were expressed as described in 
section 4.2.1, following the procedure for wild-type chTPH2.  
6.1.4.2 Purification 
The 4 chTPH2 mutants were purified following the procedure and buffer systems for wild-type chTPH2, see 
section 4.2.4.1, using an anion-exchange step followed by a gel filtration step. Only one tube of cells 
corresponding to 650 mL culture was purified, and thus the smaller columns Q Sepharose High 
Performance 16/10 and HiLoad Superdex 75 16/60 prep grade were used. In the anion-exchange a less 
steep gradient was used (0-15 % buffer B over 20 CV), to increase resolution. Furthermore, the protein 
sample was stored overnight at 4 °C after the anion-exchange, to allow for SDS-PAGE analysis of the peaks 
in the chromatogram. 
Wild-type chTPH2 was purified as described in section 4.2.4.1. 
The protein concentration was determined using the theoretical extinction coefficients(157) seen in Table 
20 below by measurement on a Nanodrop 1000 spectrophotometer from ThermoScientific. 
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Table 20: Theoretical extinction coefficients used for protein concentration determination of the four chTPH2 mutants. 
Protein Extinction coefficient at 
280 nm 
Wild-type chTPH2 39310 M-1 cm-1 
Tyr358Ser chTPH2 37820 M-1 cm-1 
Tyr358Phe chTPH2 37820 M-1 cm-1 
Glu363His chTPH2 39310 M-1 cm-1 
Glu363Gln chTPH2 39310 M-1 cm-1 
 
6.1.4.3 SDS-PAGE 
See section 4.2.5.1. 
6.1.4.4 Mass spectrometric analysis 
Using Micro Bio-Spin 6 Chromatography columns from Bio-Rad, the purified protein was transferred to a 
0.6 M NH4OAc solution (diluted from a prefabricated 7.5 M NH4OAc solution in plastic bottle from Sigma 
Aldrich). For denatured samples, the protein was transferred to a 2 (v/v)% formic acid solution. The 
samples were filtered through a 0.22 µm Millex-GV syringe filter. The mass spectrometer used was a LCT 
premier instrument with a nano-ESI source. The following instrument settings were used: Capillary voltage 
1100-1600 V and ionguide voltage 70-150 V. The instrument was calibrated using 100 mg/mL cesium iodide 
in 50 (v/v)% isopropanol. The function MaxEnt1 in the software suite MassLynx 4.1 was used to determine 
the mass of the detected ions. 
6.1.4.5 Activity measurements 
The activity measurements were performed as described in section 4.2.5.2. Protein concentrations 
between 0.5 and 3.3 µM were used. For blank measurements, 20 mM HEPES/NaOH, 100 mM (NH4)2SO4, pH 
7.2 was used, and this buffer was also used for dilution of protein samples. 
6.1.5 Results and discussion 
In the following section the results from the experimental work with the 4 chTPH2 mutants will be 
presented and discussed.  
6.1.5.1 Solubility test 
In order to compare the expression levels and solubility between the different mutants, an SDS-PAGE 
solubility test was made loading raw extract, resuspended pellet and supernatant. The result is seen in 
Figure 85. The expression levels of the 4 mutants look similar based on the intensity of the band around 36 
kDa in the raw extract samples. As the samples were run on different gels with different staining/destaining 
solutions and times, the comparison can only be approx. A large difference in solubility is however seen 
between the mutants. The raw extract and pellet samples can be directly compared, as pellet was 
resuspended in an equal volume of buffer as the raw extract. Clearly, Tyr358Phe chTPH2 is the most soluble 
mutant, with only a small fraction of the protein in the pellet. Tyr358Ser chTPH2 is on the other hand not 
very soluble. This corresponds well with the fact that Tyr358 is placed in the hydrophobic interior of the 
protein, and mutation to a hydrophobic amino acid such as Phe does not alter the solubility as much as the 
mutation to Ser, which is a polar/hydrophilic amino acid. The introduction of a hydrophilic amino acid in the 
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interior of a protein can cause folding problems and change the overall structure. Tyrosine is itself defined 
as a polar amino acid due to the hydroxy-group, but the aromatic ring makes it partly hydrophobic. Another 
explanation for the difference in solubility could be that the aromatic ring structure found in both Tyr and 
Phe, but not in Ser, is important for the stability of the protein. Aromatic rings can participate in stacking 
interactions with other aromatic ring amino acids (see Figure 91), and can through this contribute to the 
structural stability of the protein. From the crystal structure of chTPH1 with BH2 bound (PDB ID: 1MLW) no 
clear π-stackings interactions are seen for the corresponding tyrosine. Either way, it can be concluded that 
Tyr325 is important for solubility of TPH. This is in agreement with the mutation studies of PAH from 2005, 
where mutation of the corresponding tyrosine to serine resulted in enzyme that aggregated quickly after 
purification, while mutation to Phe gave stable protein with similar yield as for wild-type PAH(150). 
 
Figure 85: SDS-PAGE analysis of the solubility test of the four mutants of chTPH2. M: Molecular weight standard, R: Raw extract, 
P: Pellet, S: Supernatant. For Tyr358Ser, Glu363His, and Glu363Gln, 0.5 µL R and P and 3 µL S was loaded, while for Tyr358Phe, 1 
µL R and P and 5 µL S was loaded. 
Glu363His chTPH2 and Glu363Gln chTPH2 are both not very soluble, with a large fraction of the protein in 
the pellet. However, there are clear bands of protein in the supernatant, which allows for purification. Since 
Glu363 is placed at the active site and is involved in iron binding, it is not surprising that this amino acid also 
has a great effect on solubility of the protein. The iron binding amino acids are conserved among all AAAHs, 
suggesting the importance of these. For PAH, mutation of the corresponding glutamate to histidine or 
glutamine also showed that a significant amount of protein was found in insoluble inclusion bodies(151). 
For wild-type chTPH2 approx. 90 % of the protein is found in the soluble fraction(13). 
6.1.5.2 Purification 
The 4 chTPH2 mutants were purified following the procedure for purification of chTPH2 consisting of an 
anion-exchange step followed by a gel-filtration step. The chromatograms from the anion-exchange can be 
seen in Figure 86. For all mutants, SDS-PAGE analysis was made of all peaks in the chromatogram in order 
to decide which peak(s) contained TPH. Only the SDS-PAGE for the purification of Tyr358Ser chTPH2 is 
shown in the figure. 
Due to the difference in solubility between the mutants, the peak height also differs in the anion-exchange. 
However, all chromatograms have the same overall features, and all 4 chTHP2 mutants elutes at 
conductivities around 10 mS/cm. Another common feature is the poor separation of peaks which is mainly 
due to the low concentration of target protein compared to impurities. 
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Figure 86: Anion-exchange of the four chTPH2 mutants. Left: Chromatogram and SDS-PAGE analysis from the anion-exchange of 
Tyr358Ser chTPH2 on a Q Sepharose High Performance 16/10 column. M: Molecular weight standard, P1-P7: Samples from the 
corresponding peaks in the chromatogram. Right: Chromatograms for the anion-exchange of the three other chTPH2 mutants. 
The fractions marked with dashed lines contain TPH and are collected for further purification. The negative values on the 
absorption axis in the chromatogram of Glu363Gln are due to an error in zero setting. 
 
Figure 87: Chromatograms from the gel-filtration of the four chTPH2 mutants on a HiLoad Superdex 75 16/60 prep grade column. 
The fractions marked with dashed lines contain TPH and are collected as the final product. Notice the difference in peak 
intensity between the four mutants. 
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In the gel-filtration, all mutants elute around 65-70 mL (see Figure 87) corresponding to a mass of approx. 
40 kDa calculated from calibration curves. This corresponds well with the molecular weight of chTPH2 
(approx. 36 kDa), suggesting that the mutants exists as monomers as expected.  
The yield of purifications of the four chTPH2 mutants can be seen in Table 21, where the yield of wild-type 
chTPH2 is included for comparison. It is clear that the yields of all mutants are significantly lower than for 
the wild-type, probably due to lower solubility. The most soluble mutant, Tyr358Phe, also gives the highest 
yield. If more protein is needed for further characterization, 3 tubes of cells should be purified at one time 
using larger columns.  
Table 21: Yields of the purifications of the four chTPH2 mutants. Concentration is defined as that of the final product after 
concentration with ultrafiltration. 
Protein Yield  
[mg/L culture] 
Concentration 
[µM] 
Wild-type chTPH2 70(13)   2500 
Tyr358Ser chTPH2 2 14 
Tyr358Phe chTPH2 36 90 
Glu363His chTPH2 3 19 
Glu363Gln chTPH2 1 7 
 
6.1.5.3 Characterization of purification products 
To check the purity of the purification products of the four chTPH2 mutants, an SDS-PAGE analysis was 
conducted. The result is seen in Figure 88. Based on the SDS-PAGE all 4 mutant solutions appear pure, but 
there are traces of some impurity in the Glu363His chTPH2 sample with molecular weight of approx. 40 
kDa. However, the samples are pure enough for kinetic analysis. 
 
Figure 88: SDS-PAGE analysis of the final products from the purifications of the four chTPH2 mutants. M: Molecular weight 
standard. Numbers: µL loaded. 
It was attempted to analyze all four mutant solutions with mass spectrometry. This did not succeed for 
Tyr358Ser chTPH2, Glu363His chTPH2, and Glu363Gln chTPH2 probably due to the very low concentrations 
of the purified products, see Table 21 . During exchange into NH4OAc buffer the sample was diluted, and 
attempts to re-concentrate the samples did not succeed. A concentration of approx. 5-10 µM is favorable 
for mass spectrometry.  
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For Tyr358Phe chTPH2, mass spectrums of both the denatured and intact protein were made. The 
spectrum of the denatured protein can be seen in Figure 89. The mass of denatured Tyr358Phe chTPH2 was 
calculated to 36300.3 Da, which corresponds very well with the theoretical mass of apo-Tyr358Phe chTPH2 
of 36300.5 Da. If the mutated Phe had been hydroxylated back to Tyr, the theoretical mass would be 
36316.5 Da. From the mass spectrometric measurement it can thus be concluded that Phe358 is not post-
translationally hydroxylated back to Tyr in chTPH2.  
 
Figure 89: Mass spectrum of 10.6 µM denatured Tyr358Phe chTPH2 in 2 (v/v)% formic acid. The calculated mass is 36300.3 Da. 
The spectrum of intact Tyr358Phe chTPH2 can be seen in Figure 90. The mass of the major species was 
calculated to 36362.7 Da. This is in agreement with the theoretical mass of holo-Tyr358Phe chTPH2 of 
36353.1 Da. The smaller peak left of the main peak (visible in the inset of Figure 90) represents apo-
Tyr358Phe chTPH2, with a calculated mass of 36300.0 Da. Thus, the protein is not fully loaded with iron, or 
some protein loses iron during the ionization process. 
 
Figure 90: Mass spectrum of 6.9 µM Tyr358Phe chTPH2 in 0.6 M NH4OAc. The calculated mass is 36362.7 Da. 
6.1.5.4 Activity measurements 
The purified samples of the four chTPH2 mutants were tested for tryptophan hydroxylation activity and 
compared to wild-type chTPH2. The results can be seen in Table 22. 
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Table 22: Results from the activity measurements of the four chTPH2 mutants. The specific activity is calculated by dividing the 
activity with the protein concentration of the sample. 
Sample Activity 
 [Int/min] 
Concentration  
[µM] 
Specific activity ± st. dev.  
[Int/min/µM] 
Blank 120 - - 
Wild-type chTPH2 
790 
590 
650 
490 
0.5 
0.5 
0.5 
0.5 
1300 ± 300 
Tyr358Ser chTPH2 
100 
220 
240 
260 
0.5 
2.5 
3.0 
3.0 
110 ± 50 
Tyr358Phe chTPH2 
510 
410 
310 
300 
0.5 
0.5 
0.5 
0.5 
800 ± 200 
Glu363His chTPH2 
20 
110 
0.5 
3.3 
40 ± 5 
Glu363Gln chTPH2 
30 
60 
0.5 
1.7 
50 ± 20 
From the activity measurements, it can be concluded that both Glu363 chTPH2 mutants are inactive in the 
hydroxylation of tryptophan, as the measured activities are not significantly higher than the blank. The 
nature of the assay and the low protein concentrations set limitations to how low activities that can be 
measured. Thus, it is possible that the two mutants have very low activities outside the range of this assay. 
Mutation of the corresponding glutamate in PAH resulted in very low affinity for iron with KFe in the mM 
range(151). In the assay used here, 25 µM iron is added to the assay. Assuming that iron affinity is the same 
as for PAH and using the protein concentration from the assay, only a very small fraction of the mutant 
proteins would bind iron. Thus, the lack of activity in the assay may be due to low affinity for iron. In future 
experiments, this should be tested using a large excess of iron in the assay. It can be concluded that 
glutamate in the 363 position of chTPH2 is essential for activity and/or iron affinity, and that chTPH2 cannot 
hydroxylate tryptophan with a 3-His triad.  
Both Tyr358Ser chTPH2 and Tyr358Phe chTPH2 show significant activities in the assay, but are still less 
active than the wild-type. Thus, Tyr358 is important, but not essential, for activity in chTPH2. Tyr358Phe is 
much more active than Tyr358Ser and has activity in the same range as wild-type, suggesting that the 
aromatic ring conserved in both Tyr and Phe is important for optimal activity. Earlier studies of PAH have 
shown that the corresponding tyrosine is involved in cofactor binding and positioning through hydrophobic 
interactions(130). It is also speculated that this tyrosine through the hydrogen bond to an iron coordinated 
water (see Figure 91) can affect the catalytic activity and stability of the iron active site(150). Based on the 
kinetic experiments in this project, these two effects cannot be distinguished. However, as the mutation 
that conserves the aromatic ring results in higher activity that the mutation that conserved the hydroxyl 
group, it can be speculated that the hydrophobic interactions between Tyr358 and the cofactor are more 
important than the hydrogen bond to the iron coordinated water. 
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6.1.6 Conclusions 
Four mutants (Tyr358Ser, Tyr358Phe, Glu363His, Glu363Gln) of
and purified using procedures for wild
Tyr358Phe chTPH2 as the most soluble. Mutation of the iron coordinating Glu363 to histidine or glutamine 
gave inactive protein, and shows that glutamate is essential for catalytic activity. Whether the inactivity is 
caused by a lower affinity for iron or catalytic dysfunc
serine or phenylalanine yielded active protein, with Tyr358Phe as the most active. Thus, it can be 
concluded that Tyr358 is important, but not essential, for catalytic activity. 
was not hydroxylated back to tyrosine
6.2 Circular dichroism and magnetic circular dichroism
As described in the introduction to TPH
coordinated (6C) to 5 coordinated (5
until now not been possible for TPH,
required mM concentrations. With the development of the purification procedure for
possibility of such investigations suddenly arose
Thus, in order to investigate the coordin
and/or cofactor, circular dichroism (CD) and magnetic circular dirchroism (MCD) experiments were 
performed on chTPH2. The experiments were made in collaboration with graduate student Lei V. 
Solomon Laboratory, Stanford University, Palo Alto, California, USA under supervision of Professor Edward 
I. Solomon. 
6.2.1 Introduction to the techniques
The utilization of CD and MCD to investigate Fe(II) in the active site of proteins is relatively n
introduction to the techniques will be given. The introduction is based on reference 
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6.2.1.1 Electronic configuration of Fe(II) in biological systems
Ferrous iron, which is the catalytically active species in th
paramagnetic high spin, due to a low ligand field
by weak nitrogen and oxygen ligands
iron complex. The Fe(II) free ion has a 5
degenerate (5T2g) ground state and a doubly degenerate 
(the excited electron cannot change spin in a transition) only the one electron with opposite/down spin in 
the ground state can be excited, since all excited state d
see Figure 92. Thus, LF transitions from one ground state to either of the two excited states may occur. 
the low-symmetry environment of non
energy dependent on the coordination number and geometry of the Fe(II) ligation sphere
Figure 92. For a distorted 6C site the 
from the 5T2g state to each of the two components of the 
oxygen and nitrogen ligands of non-
a 5 C square pyramidal site the 5E
~5000 cm-1, while distortion of the 5C site to trigonal pyramidal changes the LF and lowers the energies of 
the two LF transitions to <10000 and <5000 cm
energy LF transitions around 4000-7000 cm
Figure 92: The electronic transitions dependent of the coordination
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 (LF) splitting compared to electron pairing energy
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By determining the energy of the electron d-d (LF) transitions, the splitting of the exited state d-orbitals can 
be determined. This gives insight into the geometric structure as the splitting depends on the coordination 
geometry of iron according to ligand field theory. 
However, the splitting of the excited state d-orbitals can be hard to determine experimentally. The d-d 
transitions are difficult to observe in absorption due to the parity forbidden nature, low extinction 
coefficients and falling in the near infra-red (near-IR) region were they are disturbed by intense 
contributions from protein and buffer vibrations(160). Recently, experimental methods to probe these 
transitions have been developed using CD and MCD(158). 
6.2.1.2 Circular dichroism and magnetic circular dichroism spectroscopy 
Circular dichroism (CD) and magnetic circular dichroism (MCD) are techniques that can be used for studying 
electronic transitions in metal complexes. In this project near-IR CD and MCD have been used to study the 
electronic and geometric structure of the active site iron in the catalytic domain of chTPH2 by observing the 
d-d electron transitions described in the previous section.  
In both CD and MCD spectroscopy the difference in absorbance of left-handed versus right-handed 
circularly polarized light is measured. The difference is recorded as a function of wavelength, which in the 
near-IR case goes from 600-2000 nm. In MCD the sample is placed in a strong magnetic field parallel to the 
propagation direction of the circular polarized light. 
For a material to exhibit CD activity is must possess chirality(158), which means that the iron coordination 
moiety cannot be superimposed on its mirror image. Optical activity can also be induced by applying a 
magnetic field, so that all substances exhibit MCD activity(158). CD and MCD probe the same electronic 
transitions and the results from the two techniques should be comparable. 
6.2.1.2.1 Linearly and circularly polarized light 
Linearly or plane polarized light can be obtained as a superposition of a left circularly polarized (LCP) wave 
and a right circularly polarized (RCP) wave with identical amplitudes. For linearly polarized light the 
magnitude of the electric field vector oscillates only in one plane. For circularly polarized light the electric 
field vector has a constant length, but rotates around its propagation direction creating a helix or spring 
shaped wave. Circularly polarized light is defined as right-handed (or simply right) when the electric field 
vector rotates clockwise as viewed by an observer facing the direction of the light propagation. The 
magnetic field vector is always perpendicular to the electric field vector. Both the electric and magnetic 
fields oscillate in a plane perpendicular to the direction of propagation. 
CD  and MCD effects are observed when a substance has a different absorbance for RCP in comparison to 
LCP at a certain wavelength. The plane polarized light that is shone upon the sample will be affected by this 
and the outgoing light will be an elliptical wave instead of a plane polarized wave, see Figure 93. This 
phenomenon arises because the intensity and thereby the amplitude of the two circularly polarized waves 
no longer are identical, due to the difference in absorption. 
 6 Mechanistic studies   
   
 
97 
 
                              
Figure 93: A) The elliptical wave (pink) resulting from difference in amplitude of the two circularly polarized light vectors (green). 
B) Definition of ellipticity (θ) and optical rotation (OR) of the elliptical wave. Adapted from (163). 
The elliptic trajectory of the resulting wave can be described by θ called ellipticity and OR called optical 
rotation. As seen from Figure 93, θ gives the ratio of the minor to the major axis of the ellipse by the angle 
of the tangent. OR, sometimes referred to as α, is the angle between the initial plane of polarization and 
the major axis of the ellipse of the resultant light. 
The value that is usually measured in a CD/MCD experiment is ΔA, the difference in absorbance of LCP and 
RCP light. 
 ∆ =  −  
Lambert-beers law can be applied to give: 
 ∆ = ( − ) ∙  ∙  
where εL and εR are the molar extinction coefficients for LCP and RCP, respectively, c is the molar 
concentration and l is the path length in cm. The molar circular dichroism ∆ε is given as: 
 ∆ =  −  
Though ΔA is often the measured quantity, most CD/MCD results are reported in degrees of ellipticity for 
historical reasons. Molar ellipticity [θ] is proportional to molar CD Δε by the following equation: 
  = 3298.2 ∙ ∆ 
This relationship is derived from the definition of the ellipticity of the polarization(164) and the unit of Δε is 
M-1 cm-1. 
6.2.1.2.2 Circular dichroism 
In CD, the absorption of RCP and LCP light is caused by transitions of electrons from the ground state to the 
excited states. In order for an electronic transition to give rise to optical activity as measured by CD 
spectroscopy, the transition must be both electric and magnetic dipole allowed according to the selection 
rules(165). 
The first selection rule is the spin selection rule ΔS = 0 for spin-allowed transitions. This means that the 
excited electron cannot change spin in a transition. For high-spin Fe(II) d6 in an octahedral ligand field, this 
means that only the one electron with opposite spin in the ground state can be excited, since all excited 
state d-orbitals are already filled with electrons. This one transition is thus magnetic dipole allowed. 
However, it is electric dipole forbidden according to the second selection rule. 
A) B) 
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The second selection rule says that all d-d transitions are parity forbidden according to the LaPorte 
selection rule, where transitions within the same subshell are forbidden in a centrosymmetric environment. 
However, metal sites in proteins usually have low symmetry with no inversion, which removes the parity 
restriction and splits the 5Eg excited state into two non-degenerate states that can be probed by CD(158). 
For free iron ions in solutions, the environment is centrosymmetric (6 octahedrally coordinated waters) and 
thus the d-d transitions in these complexes are parity forbidden and will not be observed with CD. 
6.2.1.2.3 Magnetic circular dichroism 
In MCD, the difference in absorption of LCP and RCP light is also measured, but the sample is placed in a 
strong magnetic field (up to 7 T) parallel to the propagation direction of the circularly polarized light.  
The MCD intensity is dependent on three different contributions, called the A, B and C-terms. A is any 
feature with a derivative bandshape caused by degenerate ground or excited states. B is any feature with 
absorption bandshape and temperature-independent intensity caused by intermediates states (mixing). 
And C is any feature with absorption bandshape that increases in intensity with decreasing 
temperature(158). In the experiments performed here we focus on the C-term.  
                                    
Figure 94. MCD C-term mechanism. (a) With no applied field, the RCP and LCP transitions from a doubly degenerate ground state 
to an excited state cancel, resulting in no observed MCD intensity. (b) When a magnetic field is applied, the degeneracy of the 
two ground states is lifted. At low temperatures the ground states become unequally populated corresponding to the Boltzmann 
distribution. This results in an MCD transition with an absorption bandshape, called a C-term. Adapted with permission from 
(158). Copyright 1995 Elsevier. 
The C-term arises from a degenerate ground state which is split in the magnetic field due to the Zeeman 
effect. Only paramagnetic compounds exhibit C-term signals. As shown in Figure 94 LCP and RCP light 
induce different electronic transitions. With no magnetic field, the ground states are degenerate and the 
RCP and LCP induced transitions cancel out resulting in no observed MCD intensity (see Figure 94, a). In the 
presence of a magnetic field the degeneracy of the ground state is lifted. At low temperature the two levels 
of the ground state doublet are unequally populated corresponding to the Boltzmann distribution. Hence, 
(b) (a) 
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the intensities of the RCP and LCP transitions do not cancel anymore, leading to an absorption band shape 
for the C-term. A further decrease in temperature or an increase in magnetic field results in a further 
increase in the population of the lowest-energy sublevel and therefore, the C-term MCD intensity also 
increases. 
All MCD intensity should increase linearly with magnetic field. A- and B-terms are temperature 
independent, while the C-term is highly dependent on the temperature. Because the C-term intensity is 
proportional to 1/T it is greatly enhanced at low temperatures compared to A- and B-term signals and 
dominates for paramagnetic transition metal complexes(159). A-terms can generally be excluded as a 
source of MCD intensity for high-spin ferrous centers(158). The field and temperature dependence of MCD 
features should be checked during experiments to differentiate between B- and C-terms. 
6.2.1.3 Model complexes 
The C-term feature will be observed for both transitions to the two excited state orbitals of AAAH Fe(II). 
This results in 2 positive peaks for a 6C octahedral Fe(II) complex within the near-IR region. In Figure 95 
experimental MCD spectra are shown for different iron complexes with 6, 5 or 4 ligands. 
 
Figure 95: Low temperature MCD spectra of structurally defined Fe(II) model complexes. A: 6C octahedral [Fe(H2O)6]. B: 5C 
square pyramidal [Fe(HB(3,5-iPr2pz)3)(OAc)]. C: 5C trigonal bipyramidal [Fe(tris(2-(dimethylamino)ethyl)amine)Br]
+. D: 4C 
tetrahedral [Fe(HB(3,5-iPr2pz)3)(Cl). Adapted with permission from (161). Copyright 2000 American Chemical Society. 
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From the experimental MCD spectra in Figure 95, the changes in LF transitions with changing geometry are 
clearly seen. Thus, the method can be used to determine the coordination of Fe(II) in non-heme iron 
enzymes such as the AAAHs. 
6.2.1.4 Experimental considerations 
The combination of CD and MCD has several advantages over e.g. absorption spectroscopy. Because of the 
parity-forbidden nature of the d-d transitions they exhibit low extinction coefficients and can therefore be 
hard to observe in absorption spectroscopy. However, CD and MCD spectroscopy are governed by different 
selection rules than absorption, which greatly favor the ligand field transitions. For CD, the magnetic dipole 
character of the d->d transitions of Fe(II) greatly enhances their CD intensity in the near-IR region relative 
to that of buffer and protein vibrations.  Also, transitions in the CD spectrum have a sign as well as a 
magnitude which makes it easier to resolve overlapping bands contributing to an absorption feature(159).  
The relevant transitions for Fe(II) complexes fall in the near-IR region where they are complicated by 
intense contributions from protein, H2O and buffer vibrations in the <12000 cm
-1 region. By exchanging 
protons with deuterium the vibrational overtone bands of O-H and C-H stretches are eliminated, which 
extends the transmission window from around 7000 cm-1 to 5300 cm-1. Otherwise, the vibrational overtone 
bands of O-H and C-H stretches dominate the transmission spectra and can block light transmission 
throughout much of the near-IR region. 
For MCD, high-spin paramagnetic Fe(II) will exhibit a C-term MCD signal which at low temperature is 2-3 
orders of magnitude more intense than the MCD signals associated with the diamagnetic protein 
background. 
It is a requirement that the samples for CD and MCD must transmit light and must not depolarize the 
incident light. When measuring MCD at low temperatures (5K), the icing of aqueous protein samples will 
result in both loss of light transmission and depolarization. Therefore, a glassing agent, such as glycerol or 
sucrose, must be used to prevent icing. It should be checked that the glassing agent does not chemically 
alter the protein by comparing room temperature CD spectra with and without glassing agent.  
As CD and MCD probe the same transitions, the peak positions should be comparable. However, due to the 
low temperature in MCD the peaks should be narrower in MCD than in CD, which is recorded at 5 °C. 
As free Fe(II) ions in solution are octahedrally coordinated to six water molecules, they are not chiral and 
can therefore not be observed in CD spectroscopy. Thus, only features from the distorted active site iron 
will be visible in the spectrum, and there is no need to worry about excess iron. In MCD, however, features 
from all iron ions will be probed, and thus it is very important not to have free Fe(II) ions in the protein 
solution, as they will mix with the Fe(II)-active site signal, and make the results hard to interpret. 
6.2.2 CD and MCD studies on AAAHS 
Both PAH and TH have been studied by CD and MCD previously. The most important results from these 
studies will be presented here, along with the motivation for why a study of the geometric changes in TPH 
upon substrate binding is interesting.  
The first AAAH to be investigated with CD and MCD was PAH in 1997(69). Solomon et al. studied PAH with 
and without substrate bound, and found that Fe(II) in PAH is 6C distorted octahedral. Binding of L-Phe in 
the active site resulted in geometric and electronic structural change at the iron center. The comparison of 
the PAH-resting and PAH-L-Phe spectra show that both are consistent with a distorted octahedral 
coordination. However, the transitions shift to higher energy for the substrate bound PAH corresponding to 
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a stronger ligand field. The presence of substrate in the active site pocket thus induces a stronger ligand 
field. The difference in energy between the two excited states decreased upon substrate binding. 
In 1999, the interaction between the active site of PAH and the pterin cofactor was investigated again using 
CD and MCD(67). The addition of cofactor analogue 5-deaza-6-MPH4 did not perturb the active site in the 
absence of substrate. However, in the presence of substrate the active site changed from 6C to 5C as seen 
by an intense low energy (~5000 cm-1) peak indicative of a square pyramidal 5C iron site (see Figure 96, D). 
This was strong evidence that only when both substrate and cofactor have bound, an open coordination 
position on the iron is formed for dioxygen to react. 
The 4 MCD spectra for the four PAH substrate/cofactor combinations can be seen in Figure 96 , A-D. 
 
Figure 96: MCD spectra of the 4 substrate/cofactor combinations of PAH and TH. All spectra are measured at 5 K and 7 T. 
 A-D: MCD spectra of the 4 PAH combinations. A: PAH. B: PAH + L-phenylalanine. C: PAH + 5-deaza-6-MPH4. D: PAH +L-
phenylalanine + 5-deaza-6MPH4. Adapted with permission from(69) and (67). Copyright 1997+1999 American Chemical Society. 
E-H: MCD spectra of the 4 TH combinations. E: TH. F: TH + L-tyrosine. G: TH + 6MPH4. H: PAH + L-tyrosine + 6MPH4. Adapted with 
permission from (70). Copyright 2009 American Chemical Society 
Later, in 2003, two phenylketonuria inducing mutants were investigated, also using MCD and XAS(84). This 
study showed that one of the mutants did not make the coordination sphere change of iron from 6C to 5C 
upon binding of substrate and cofactor analogue, and this could explain the lacking hydroxylation activity of 
the amino acid seen in kinetic analysis of this mutant. 
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Wild-type TH and two mutants have also been investigated using the above mentioned techniques(70). The 
results were very similar to the PAH results and can be seen in Figure 96, E-H. For the substrate only (F) and 
cofactor only (G) bound TH combinations, the MCD spectra showed distorted 6C geometry with slightly 
stronger ligand fields and less axial distortion compared to TH-resting sample, seen from the smaller 
distance between the two peaks. XAS was used to confirm the 5C configuration of the substrate and 
cofactor bound sample, as the low energy transition could not be observed in the MCD spectrum. 
6.2.2.1 Motivation for studies of TPHs electronic and geometric structure 
PAH and TH have both been extensively studied, while results on TPH are very limited due to the inherent 
instability of the enzyme and thus the difficulty to purify it. The iron coordination of both PAH and TH in the 
active site has been studied using CD, MCD, and XAS(67–70), as described in the previous section. The 
studies showed that the resting state iron is 6 coordinated (6C) with 2 His, 1 Glu and 3 waters, but changes 
to 5C (2 His, bidentate Glu and 1 water) upon binding of both substrate and cofactor/cofactor analogue. 
This opens a coordination position for O2 to react with iron. So far the active site of TPH has not yet been 
studied using CD and MCD, and even though the high sequence identity between the AAAHS suggests a 
similar mechanism, a recent crystal structure of TPH questions this. The crystal structure of doubly 
truncated gallus gallus TPH1 had the natural amino acid substrate bound and showed a 5C iron in the 
active site(12). However, an imidazole from the crystallization solution was also bound to iron, and it can be 
speculated whether this could mimic the function of the cofactor to induce the changes in iron 
coordination. Furthermore, the crystal structure contained Fe(III) and is thus not electronically consistent 
with the catalytically relevant species. In order to determine whether the binding of tryptophan alone 
triggers the iron coordination change from 6C to 5C, the active site of TPH should be analyzed with CD and 
MCD. Such a study would also elucidate whether TPH follows the general reaction mechanism of the other 
pterin-dependent hydroxylases.  
6.2.3 Experimental procedures 
All experiments except expression and purification were performed at Stanford University. 
6.2.3.1 Protein expression and purification 
The catalytic domain of human TPH2 (chTPH2) was expressed and purified as previously described (see 
section 4.2.1 and 4.2.4.1). Protein purified for initial experiments were added 5 mM EDTA in order to 
remove iron from the active site. The apo-protein samples were primarily used for iron titration 
experiments (data not shown). All results featured in this chapter are made on protein samples that were 
saturated with iron during purification by addition of 1.5 molar equivalent of (NH4)2Fe(II)(SO4)2 before gel-
filtration. Several purifications (~12) were made and the products from all purifications were mixed to 
achieve a homogeneous sample pool. A deuterated buffer was made by dissolving 20 mM HEPES and 300 
mM NaCl in D2O and adjusting pD to 7.2 with NaOD. To exchange hydrogens in the HEPES molecules for 
deuterium, the buffer was vacuum evaporated and subsequently dissolved in D2O 3 times. The purified 
protein was exchanged into the deuterated buffer by 6 times ultrafiltration from 6 ml down to 1 ml 
following addition of 5 ml deuterated buffer. 
SDS-PAGE and mass spectrometry was performed as described in section 4.2.5.1 and section 4.2.5.4, 
respectively. chTPH2 concentrations between 1-10 µM in 0.6 M NH4OAc were used. The spectrum of 
chTPH2+Fe was smoothed using the Spectrum smooth option in the software suite MassLynx 4.1. 
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6.2.3.2 Preparation of CD and MCD samples 
Solutions and solids were made anaerobic by purging with argon on a Schlenk line.  Anaerobic reagents 
were transferred into a nitrogen atmosphere maintained in a Vacuum Atmosphere Nexus-1 glovebox 
(<5ppm oxygen). A fresh solution of sodium dithionite was made every day in deuterated buffer. Solutions 
of tryptophan were made in deuterated buffer, frozen and thawed each day before use. The BH4 solution 
was made in a deuterated buffer with strong buffer capacity (100 mM HEPES) and subsequently pH was 
adjusted to 7.2 using NaOH in D2O, as no NaOD was available. Dissolving BH4 in the normal deuterated 
buffer without subsequent pH adjustment resulted in a very low pH, which caused protein precipitation 
upon mixing. The BH4 samples were frozen and thawed each day before use. 
Enzyme samples were made anaerobic by purging with argon. Inside the glovebox, 5 equivalents of sodium 
dithionite were added to the enzyme sample and it was incubated for 10 min while kept on a cold gel. 3 
equivalents of  tryptophan and/or BH4 were then added and the samples were incubated for another 10 
min. Samples for CD were injected into a 1 cm path length Infrasil quartz cuvette adapted with a ChemGlass 
stopcock to prevent air oxidation during the experiment. CD samples were kept on ice.  Samples for MCD 
were added a glassing agent, which were either deuterated sucrose or deuterated glycer-3-ol. Deuterated 
sucrose was added to saturation, while deuterated glycer-3-ol was added to a concentration of 50 (v/v)%. 
The enzyme samples were injected into MCD cells, which consisted of two Infrasil quartz disks that were 
separated by a neoprene spacer (0.2-0.3 cm path length) and held in place by two fitted copper plates. 
After removal from the glovebox the MCD samples were directly frozen in liquid nitrogen and stored at 77 
K.  
The protein concentration varied in the samples between 1.0 and 2.0 mM. The natural substrate and 
cofactor were used for the experiments, which is only possible in an oxygen free environment, as the 
reaction would otherwise proceed. 
6.2.3.3 Circular dichroism experiments 
Near-IR CD spectra (278 K, 600-2000 nm) were obtained by using a Jasco J200D spectropolarimeter with a 
liquid nitrogen cooled InSb photodiode detector. The sample temperature was maintained by a 
recirculating water bath attached to the cell holder. Data acquisition was achieved using routines written 
within the software package LabVIEW (National Instruments). Contributions to the CD intensity due to 
buffer and cell backgrounds were subtracted from the protein CD spectra. 
6.2.3.4 Magnetic circular dichroism experiments  
Low-temperature near-IR MCD data (5-15 K, 1-7 T, 600-2000 nm) were collected on a Jasco J200D 
spectropolarimeter equipped with a liquid nitrogen cooled InSb photodiode detector and fitted with an 
Oxford Instruments SM 4000-7T superconducting magnet along the beam path. Each sample was measured 
at 7 T, 3.5 T, 0 T, -3.5 T, and -7 T and at two different temperatures (5 K and 15 K). For some conditions the 
scan rate was varied. MCD spectra were corrected for zero-field baseline effects either by subtracting the 
corresponding 0 T scan or by averaging the positive and negative field data (by subtracting the negative 
field data from the positive field data and dividing by 2). Gaussian fitting of the MCD spectra was performed 
using the program PeakFit v4.12 (SPSS Science).  
6.2.4 Results and discussion 
In this section the results from the CD and MCD measurement on chTPH2 will be presented and discussed. 
It should be clarified here that this is the first time the active site of TPH is investigated using CD and MCD, 
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and the first time any CD and MCD study of the AAAHs uses the natural cofactor BH4. The results have been 
divided into CD and MCD experiments. First, the purification product of chTPH2 for the measurements is 
characterized. 
The product from the chTPH2 purifications was investigated by SDS-PAGE and mass spectrometry after 
exchange into the deuterated buffer. The results can be seen in Figure 97 and Figure 98. From the SDS-
PAGE the sample looks pure, and it is thus suitable for use in CD and MCD measurements.  
 
Figure 97: SDS-PAGE analysis of the purified chTPH2 in deuterated buffer (diluted) for CD and MCD experiments. M: Molecular 
weight standard. Numbers: µL loaded 
Mass spectra were taken of both chTPH2 purified according to the general procedure, and chTPH2 where 
either 5 mM EDTA or 1.5 molar equivalent (NH4)2Fe(II)(SO4)2 were added in the purification. When 
purification was performed according to the general procedure, chTPH2 contains both the apo- and holo-
form in a 40:60 ratio. The calculated masses of the apo and holo forms are 36325 Da and 36379 Da, 
respectively. The theoretical masses of apo and holo chTPH2 are 36316.5 Da and 36369.3 Da (Fe(III)). The 
masses correspond quite well, however there is a constant difference of approx. 10 Da between the 
measured and theoretical masses. This could be caused by errors in the calibration. However, the mass 
difference between the apo and holo forms is 54 Da, which is in agreement with the theoretical mass of 
Fe(III) of 52.8 Da. Addition of 5 mM EDTA during purification effectively removes iron from the active site of 
chTPH2, so the sample mainly contains the apo form. Addition of iron completely restores the holo form of 
chTPH2. This last sample with added iron was used for all the CD and MCD measurements described in this 
chapter. It was decided to use the chTPH2 sample that was saturated with iron during purification, as this 
eliminates the chance of any excess iron in the solution, which will disturb the active site iron signal in MCD 
measurements. As iron is added prior to gel-filtration, this purification step will remove the excess iron that 
has not been bound in the active site of chTPH2. The earlier procedure for TH samples was to remove all 
iron from the enzyme sample after purification and subsequently titrate iron into the sample until approx. 
85 % saturation was reached(70). However, this last option is experimentally quite difficult and requires 
very precise protein concentration measurements. Merely using a protein sample that already from 
purification is saturated with iron seems a much simpler way of avoiding excess iron in the sample. 
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Figure 98: Mass spectra of chTPH2 for MCD measurements. Top: chTPH2 purified according to the general procedure. Center: 
chTPH2 with 5 mM EDTA added in the purification. Bottom: chTPH2 with 1.5 molar equivalent of (NH4)2Fe(II)(SO4)2 added in the 
purification.  
6.2.4.1 Circular dichroism experiments 
In this section the results from the CD experiments on the 4 substrate/cofactor combinations will be 
presented and discussed. The differences in intensities between samples should not be given any great 
importance, as the intensity depend on protein concentration, which is less accurately determined. 
6.2.4.1.1 Glycerol samples 
The 4 combinations (TPH-resting, TPH-trp, TPH-BH4, and TPH-trp-BH4) were measured in 50 (v/v)% 
deuterated glycer-3-ol at 5 °C and the results can be seen in Figure 99. The peak positions resulting from 
the Gaussian fitting can be seen in Table 23.  
The spectrum of TPH-resting shows a positive peak around 8200 cm-1 and a negative peak around 11100 
cm-1 indicative of a 6C coordination, where two peaks centered around ~10000cm-1 split by ~2000 cm-1 are 
expected(160). The split for the TPH sample is somewhat higher (~3000 cm-1) indicating a loose 6th ligand, 
most likely water. 
Addition of the cofactor BH4 does not perturb the ligand field significantly since the peak positions are more 
or less identical to TPH-resting. This is also the case for PAH(67). When the substrate trp is added the peak 
pattern is the same, however the peaks shift to slightly lower energies. The split of the peaks is still ~3000 
cm-1. For PAH, binding of L-Phe also has an effect on the peak positions compared to the resting sample, 
however they move to higher energies(69). 
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Figure 99: CD spectra for the 4 TPH substrate/cofactor combinations. The samples were all prepared with 50 (v/v)% deuterated 
glycer-3-ol as glassing agent. 
When both trp and BH4 are added, the peak pattern completely changes. A low energy peak appears, and 2 
smaller peaks are seen at higher energies. The low energy peak is directly indicative of a 5C iron, which 
supports a 6C to 5C change of the active site iron only upon binding of both substrate and cofactor. A 5C 
square pyramidal site would give two transitions around 5000 and 10000 cm-1, while a 5C trigonal 
pyramidal site theoretically gives transitions <5000 and <10000 cm-1(160). As the third positive peak for 
TPH-trp-BH4 is located around 10000 cm
-1 this suggests a square pyramidal site, which is also consistent 
with the position of the low energy peak, that is clearly visible in the spectrum. For a 4C sample, two low 
energy peaks would be expected around 5-7000 cm-1. The peak at 10000 cm-1 rules out this coordination. 
The presence of 3 peaks indicates a mixed sample, where not all TPH has been converted to the 5C form. 
Extra substrate and cofactor were added to the sample to test this, as described in the next section.  
Table 23: Peak positions from the fitting of the CD spectra shown in Figure 99 for the 4 TPH substrate/cofactor combinations. 
The samples were all prepared with 50 (v/v)% deuterated glycer-3-ol as glassing agent. 
Sample Peak 1 Peak 2 Peak 3 
TPH-resting - 8245 cm-1 11109 cm-1 
TPH-trp - 7498 cm-1 10758 cm-1 
TPH-BH4 - 8534 cm
-1 11193 cm-1 
TPH-trp-BH4 < 6000 cm
-1 7254 cm-1 10008 cm-1 
6.2.4.1.2 Buffer samples 
In order to check for any effect on the active site configuration of the glassing agent (deuterated glycer-3-
ol) the 4 combinations were also made in deuterated buffer. The result is seen in Figure 100. Even though 
there are small changes in peak positions and intensities, the general picture and the trend are the same. It 
is especially important to notice that the samples with deuterated buffer also show a low energy peak 
when both trp and BH4 are added. The spectra for the samples with deuterated buffer are smoother due to 
a stronger signal from the higher protein concentration of the undiluted sample. 
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Figure 100: CD spectra for the 4 TPH substrate/cofactor combinations. The samples were all prepared in deuterated buffer with 
no glassing agent. 
As the TPH-trp-BH4 sample looks like a mixed sample, more substrate and cofactor were added to see if this 
had any effect on the spectrum. If the binding of trp or BH4 is weak, a higher ratio than 1:3 might be needed 
to completely saturate the protein. The spectrum did not change upon addition of up to 9 equivalents of 
trp and BH4 (data not shown).  
6.2.4.1.3 Sucrose samples 
From the MCD data (vide infra, see section 6.2.4.2) it was seen that there were differences between 
samples made in glycerol and sucrose, especially for combinations TPH-resting and TPH-trp. Therefore, 
these two combinations were made with both glycerol, sucrose and buffer to check for differences in the 
CD spectra. It is not possible to compare MCD data of the buffer sample, since a glassing agent is needed to 
prevent icing. Thus, CD data often is the best way to determine which of the glassing agents that best 
mimic the natural state of the protein in buffer. 
Generally, the spectra for all 3 samples have the same features; A positive peak around 8000 cm-1 and a 
negative peak around 11000 cm-1 (see Figure 101). However, there are small differences in the shape of the 
curves, especially for TPH-resting sample. The sucrose sample has a kink around 9000 cm-1 not seen for the 
other two samples. Based on the spectra shown here it is not possible to determine which of the two 
glassing agents best represent the natural state of the protein. The effect of glycerol and sucrose on the 
active site will be discussed further in section 6.2.4.2 and 6.3. 
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Figure 101: CD spectra of the TPH-resting sample (left in black) and TPH-trp sample (right in red). The full line is the sample with 
deuterated sucrose as glassing agent, the dashed line is the sample with deuterated glycer-3-ol as glassing agent, and the dotted 
line is the sample in deuterated buffer with no glassing agent.  
6.2.4.2 Magnetic circular dichroism experiments 
In this section the results for the magnetic circular dichroism experiments will be presented. If nothing else 
is mentioned, the spectra are all recorded at 5 K with a magnetic field of 7 T. 
6.2.4.2.1 Glycerol samples 
The MCD spectra were first recorded with 50 (v/v)% deuterated glycer-3-ol as the glassing agent for the 4 
TPH substrate/cofactor combinations (TPH-resting, TPH+trp, TPH+BH4 and TPH+trp+BH4). The result is seen 
in Figure 102. Compared to the MCD data for PAH and TH in the literature (see Figure 96), the TPH data are 
of very high quality including strong signals with minimal noise. This can be attributed to both pure protein 
samples of high concentrations and effective exchange of hydrogen for deuterium. 
TPH-resting shows two clearly separated peaks at around 8500 cm-1 and 10800 cm-1, which corresponds 
well with a 6 coordinated (6C) iron and also is similar to corresponding samples for TH (8720 and 10750 cm-
1)(70) and PAH (8500 and 10300 cm-1)(69). When tryptophan binds the ligand field is slightly perturbed but 
iron remains 6C. This is seen from the two peaks at 8200 and 10000 cm-1. The MCD data cannot be fitted 
with one peak and the CD data also supports the 6C as the two peaks can be clearly distinguished (one 
positive and one negative). Thus, binding of tryptophan alone does not trigger a change in iron 
coordination to 5C, which has been speculated based on the crystal structure of gallus gallus TPH with 
tryptophan bound. For TPH-BH4 the two peaks from the CD spectra are not obvious in the MCD spectra of 
the same sample. One peak at 9200 cm-1 is clearly seen, however the high energy peak apparently becomes 
negative, and is hard to distinguish. As the CD spectrum clearly shows two peaks, it is concluded that 
binding of BH4 to TPH does not change the coordination of iron significantly as it remains 6C. The major 
change in the spectrum is seen when both tryptophan and BH4 are added. A low energy peak emerges at 
<6000 cm-1 corresponding with the change in iron coordination to 5. At higher energy two peaks are seen at 
8700 and ~10000 cm-1. The two peaks at higher energy could be explained if the sample contains a mixture 
of iron 5C and 6C. This is the first time that MCD data of any AAAH with the natural cofactor BH4 has been 
presented. Earlier studies have used cofactor analogues such as the redox inactive 5-deaza-6-MPH4 or 
6MPH4. 
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Figure 102: MCD spectra for the 4 TPH substrate/cofactor combinations. The samples were all prepared with 50 (v/v)% 
deuterated glycer-3-ol as glassing agent. 
The small negative peak of the TPH-BH4 sample around 11200 cm
-1 was subject to further investigations, as 
it is not clear whether it represents an actual peak (or maybe one negative and one positive peak). This was 
investigated by recording spectra at different strengths of magnetic field and different temperatures. The 
result in seen in Figure 103, and does not clearly show whether the peaks are C-term or just baseline 
problems. As described earlier C-term transitions are both field and temperature dependent. The relatively 
weak signal of the TPH-BH4 sample made interpretation even harder. However, as the CD spectrum of the 
TPH-BH4 sample shows a negative peak at ~11200 cm
-1 corresponding more or less to the position of the 
small negative peak in the MCD spectra, it is likely that it represents an electronic transition.  
It was attempted to fit the peak positions and widths from both CD and MCD spectra combined, but this did 
unfortunately not succeed. The MCD data generally shows a smaller splitting between the two excited 
states than the CD data for the TPH-trp and TPH-BH4 samples. 
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Figure 103: MCD spectra of the TPH-BH4 sample. The sample was prepared with 50 (v/v)% deuterated glycer-3-ol as glassing 
agent. Left: The field effect. Right: The temperature effect. 
6.2.4.2.2 Sucrose samples 
In order to check whether glycerol has an effect on the active site geometry, another glassing agent was 
tested. Deuterated sucrose was chosen as this was standard in the Solomon Laboratory, and as sucrose 
usually gives a good glass in the sample upon freezing. The results of this test with sucrose were surprising, 
and can be seen in Figure 104. The overall trend in the experiment was the same as for glycerol samples; 
iron changed from 6C to 5C only upon binding of both tryptophan and BH4, shown by emerge of a low 
energy peak. However, there were clear changes in the ligand fields around iron as compared to the 
glycerol samples for all samples except TPH+trp+BH4. For TPH-resting in sucrose the peaks shift further 
away from each other, and the highest energy peak is almost indistinguishable. This could lead to some 
doubt on whether the TPH-resting sucrose sample is 6C, but variable temperature variable field MCD 
measurements performed by graduate student Lei V. Liu confirm that the coordination is 6C (data not 
shown). Furthermore, the CD spectrum of the TPH-resting sample in sucrose also displays two peaks with 
positions indicative of a 6C coordination. For TPH+trp the high energy peak becomes negative instead of 
positive and for TPH+BH4 the intensity relationship between the two peaks shifts.  
These data show that there is a difference in the iron coordination sphere depending on the glassing agent. 
It is hard to distinguish whether glycerol or sucrose binds directly to the iron or changes the ligand field by 
affecting/pushing the iron coordinated waters. Apparently, the glassing agents can only affect the active 
site in the open 6C conformation, as the TPH-trp-BH4 sample is not sensitive to the type of glassing agent. It 
can be speculated that when the active site of TPH is 6C and open, the glassing agents are free to 
coordinate to iron in competition with water molecules. However, when the coordination changes to 5C, 
the active site closes and does not allow any interaction between the glassing agents and iron, which is no 
longer freely accessible. 
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Figure 104: MCD spectra for the 4 TPH substrate/cofactor combinations. Full lines are samples prepared with deuterated sucrose 
as glassing agent. Dashed lines are samples prepared with 50 (v/v)% deuterated glycer-3-ol as glassing agent. 
  
Figure 105: MCD spectra of the TPH-trp sample. The sample was prepared with deuterated sucrose as glassing agent. Left: The 
field effect. Right: The temperature effect. 
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The TPH-trp sucrose sample was investigated further for field and temperature effect, to clearly distinguish 
the high energy negative peak. From Figure 105 it is seen that the peak does indeed represent the C-term 
as it shows both field and temperature dependence. 
For the TPH-BH4 sucrose sample, both the negative and positive peak is also field dependent as seen in 
Figure 106. 
 
Figure 106: MCD spectra of the TPH-BH4 sample. The sample was prepared with deuterated sucrose as glassing agent. The 
spectra demonstrates the field effect. 
The peak positions of the 4 TPH substrate/cofactor combinations in both glycerol and sucrose can be seen 
in Table 24. There are significant differences between similar samples in different glassing agents, except 
for the TPH-trp-BH4 sample. 
Table 24: Results from the Gaussian fitting of the MCD data for samples with 50 (v/v)% deuterated glycer-3-ol or deuterated 
sucrose as glassing agent. TPH-trp-BH4 was fitted with both 3 and 4 peaks, and both results are shown in the table. *: Negative 
peak. ():  insignificant peak. 
Sample Glassing agent Peak 1 Peak 2 Peak 3 Peak 4 
TPH-resting Glycerol - 8383 10397 - 
Sucrose - 8038 (11560) - 
TPH-trp Glycerol - 8182 9603 - 
Sucrose - 8164 *11006 - 
TPH-BH4 Glycerol - 9243 *(11228) - 
Sucrose - 9004 *11007 - 
TPH-trp-BH4 Glycerol (3 peaks) ~5531 8447 9412 - 
Glycerol (4 peaks) ~5903 8264 8804 9591 
Sucrose (3 peaks) ~5814 8370 9321 - 
Sucrose (4 peaks) ~5628 8285 8896 9648 
Comparison of CD results from samples with no glassing agent added and those with glycerol and sucrose 
gave no convincing results for which structures best represent the natural state (see section 6.2.4.1.3). 
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6.2.5 Conclusions 
The 4 TPH substrate/cofactor combinations were all investigated by CD and MCD. From CD experiments, a 
clear low-energy peak corresponding with a change in iron coordination from 6 to 5 is seen only when both 
substrate and cofactor are added. The same is the case for the MCD experiments. It can thus be concluded 
that the coordination of iron in TPH is 6C in the resting state and only changes to 5C when both substrate 
and cofactor bind. Small changes in the ligand field were seen when trp or BH4 binds separately, but iron 
remains 6C. The results obtained here are similar to results from PAH and TH supporting the assumption 
that they all share a similar reaction mechanism, in which the conformational change from open to closed 
upon substrate and cofactor binding is accompanied by a change in iron coordination from 6C to 5C. The 
binding of tryptophan does not lead to a change in iron coordination to 5C, as was otherwise implied by the 
recent crystal structure of gallus gallus TPH1 with tryptophan bound.  
This is the first time a MCD study has been performed on the AAAHs using the natural substrate and the 
natural cofactor. The data quality is very high and TPH is thus a promising candidate for further 
investigations of the AAAHs reaction mechanism. 
Deuterated sucrose and glycerol were tested as glassing agents, and even though TPH samples with both 
glassing agents showed the same overall trend, there were differences in the spectra indicating that either 
glycerol, sucrose or both has an effect on the active site iron. This is investigated further by other 
techniques in the next section. 
6.3 The glycerol effect 
Indications from MCD experiments lead to further investigations of the effect of glycerol on the active site 
of chTPH2. The results from these will be presented in this section. 
6.3.1 Experimental procedures 
6.3.1.1 Purification 
chTPH2 was purified according to the described procedures (see section 4.2.4.1) either in buffer with 5 
(w/v)% glycerol or without glycerol.  
6.3.1.2 Absorbance measurements 
The absorbance of chTPH2 samples with and without glycerol, and with glycerol added in concentrations 
ranging from 5∙10-7 (v/v)% to 20 (v/v)% was measured using a NanoDrop spectrophotometer. The 
corresponding buffer was used as blank and at least 2 consecutive measurements were performed for each 
sample. 0.05 M sodium dithionite was also added to the purification products with and without glycerol, 
and the absorbance before and after was measured. 
6.3.1.3 Iron and glycerol interactions 
To test the effect of glycerol on Fe(II) and Fe(III) in aqueous solution, the following experiment was 
conducted. 10 mM solutions of (NH4)2Fe(II)(SO4)2 and NH4Fe(III)(SO4)2, respectively  were made in MilliQ 
water. 20 (v/v)% glycerol was added to the solutions and the color change was observed. 
6.3.1.4 Activity assay 
The activity of chTPH2 with different glycerol concentrations were tested using the general activity assay 
described in section 4.2.5.2. The protein concentration was 0.5 µM and the temperature was 27-28 °C due 
to the lack of cooling equipment. Each sample was measured 8 times. 
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6.3.2 Results and discussion 
In the following section, the results from the experiments on the effect of glycerol on the active site of TPH 
will be presented and discussed. 
6.3.2.1 Purification 
Overall, the chromatograms for the purifications with and without glycerol were similar, except in the gel-
filtration step, where a peak at 416 nm is seen when chTPH2 elutes when using buffer with 5 % glycerol, 
and no peak at 416 nm is seen when using buffers without glycerol. This gave an indication that the 
difference between chTPH2 samples with and without glycerol can be observed by absorbance at 416 nm 
corresponding to a yellow color. Normally, purifications of TPH are monitored at 280 nm (aromatic amino 
acids), 416 nm (possible heme-containing contaminants) and 214 nm (peptide bonds), which is why this 
wavelength was chosen for the purification. Upon concentration of the two purification products, a visible 
color difference was also seen. The sample with 5 (w/v)% glycerol was clearly more yellow than the sample 
containing no glycerol, see Figure 107. The yields of the purifications with and without glycerol were 
similar. 
                    
Figure 107: Color difference between chTPH2 sample with and without 5(w/v) % glycerol. Left: Eppendorf tubes with glycerol 
(left, yellow) and no glycerol (right, colorless) chTPH2 solution with the same concentration. Center: Concentrated 5 (w/v)% 
glycerol chTPH2 solution with a clear yellow color. Right: Concentrated chTPH2 solution with no glycerol and an orange/brown 
color. 
6.3.2.2 Absorbance measurements 
The purifications with and without glycerol showed a difference in absorbance at 416 nm. Thus, the 
following analysis also used this wavelength to investigate the effect of glycerol on the protein samples. 
The absorption spectra for two samples with the same protein concentration, but with 0 % and 10 % 
glycerol, respectively, are shown in Figure 108. There is a clear difference in the absorption between the 
two samples from approx. 310 nm to 500 nm. Absorption in the range 420-430 nm would give a yellow 
substance, corresponding with the yellow color of the glycerol containing TPH sample. 
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Figure 108: Absorbance spectra of two chTPH2 samples without (red) and with 10 (v/v)% glycerol (blue). The dashed line marks 
416 nm. The two samples have the same protein concentration. 
The two concentrated products from the purifications were added glycerol in different concentrations and 
the absorption at 416 nm was measured. The results can be seen in Table 25. For the sample with 5 (w/v)% 
glycerol, no increase in absorption upon addition of extra glycerol is seen. The start absorption is however 
relatively high compared to the sample without glycerol. For the sample with no glycerol in the buffer, the 
results show a clear increase in absorbance at 416 nm upon addition of glycerol. Higher concentration of 
glycerol does not increase the absorption further. The absorptions measured were however very low, so 
the sample without glycerol was concentrated and measured again. The increase in absorption at 416 nm 
upon addition of glycerol is also seen in the concentrated sample.  
Table 25: Absorbance at 416 nm for samples of chTPH2 upon addition of different glycerol concentrations. Each sample was 
measured at least 3 times and the standard deviation is given. 
(v/v)% glycerol 
added 
Abs. 416 nm ± St. Dev. 
230 µM chTPH2 
5 (w/v)% glycerol 
Abs. 416 nm ± St. Dev. 
182 µM chTPH2 
No glycerol 
Abs. 416 nm ± St. Dev. 
590 µM chTPH2 
No glycerol 
0 0.024 ± 0 0.006 ± 0.001 0.016 ± 0.002 
5 0.027 ± 0.001 0.018 ± 0.001  
10 0.028 ± 0.002 0.018 ± 0.001 0.034 ± 0.005 
20 0.027 ± 0.002 0.017 ± 0  
 
To investigate how low a concentration of glycerol that would still cause the increase in absorption, two 
new experiments were set up with very low glycerol concentrations. The results can be seen in Table 26, 
and show somewhat ambiguous results. The 1st experiment shows an increase in absorption at the lowest 
glycerol concentration of 5∙10-5 (v/v)%, which corresponds to approx. 7 µM. In the 2nd experiment, the 
absorption does not increase until a glycerol concentration of 0.5 (v/v)% corresponding to approx. 70000 
µM. The goal of these experiments was to determine if glycerol was binding 1:1 with the protein suggesting 
a specific binding, however the data are not clear on this. 
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Table 26: Absorbance at 416 nm for samples of chTPH2 upon addition of low concentrations of glycerol. Each sample was 
measured at least 2 times and the standard deviation is given, except for the sample marked with *, which was only measured 
one time. 
(v/v)% glycerol 1st experiment 
Abs. 416 nm ± St. Dev. 
437 µM chTPH2 
2nd experiment 
Abs. 416 nm ± St. Dev. 
411 µM chTPH2 
0 0.028 ± 0.002 0.018 ± 0.003 
5∙10-7  0.019 * 
5∙10-5 0.051 ± 0.01 0.017 ± 0 
5∙10-4 0.051 ± 0.002  
5∙10-3 0.047 ± 0.003 0.019 ± 0.001 
5∙10-2 0.049 ± 0.004  
0.5 0.060 ± 0.006 0.029 ± 0.001 
1 0.053 ± 0.003  
2 0.057 ± 0.006  
5 0.051 ± 0.002 0.033 ± 0.001 
7.5 0.055 ± 0.001  
10 0.050 ± 0.004  
The two concentrated products from the purifications were added dithionite to see if any effect on the 
absorbance at 416 nm was seen. As seen from Table 27, there was a clear decrease in the absorbance at 
416 nm for the sample with 5 (w/v)% glycerol, whereas the dithionite had no effect on the sample without 
glycerol. 
Table 27: The absorbance at 416 nm for samples of chTPH2 upon addition of 0.05 M sodium dithionite. Each sample was 
measured 2 times. 
 Abs. 416 nm ± St. Dev. 
408 µm chTPH2 
5 (w/v)% glycerol 
Abs. 416 nm ± St. Dev. 
315 µM chTPH2 
No glycerol 
Before dithionite addition 0.049 ± 0.001 0.013 ± 0.001 
After dithionite addition 0.004 ± 0.001 0.018 ± 0.001 
The addition of dithionite to the glycerol containing sample was also followed by a clear color change from 
yellow to colorless. These results suggest that only Fe(III) shows the yellow color in combination with 
glycerol, while the reduced Fe(II) is colorless even in the presence of glycerol. From these experiments it 
cannot be determined whether the disappearance of the yellow color is due to the reduction of iron or 
because glycerol does not bind to Fe(II). 
Experiments with addition of Fe(III) and EDTA gave no conclusive results (data not shown). 
6.3.2.3 Iron and glycerol interactions 
To test the effect of glycerol on Fe(II) and Fe(III) in aqueous solution, solutions of (NH4)2Fe(II)(SO4)2 and 
NH4Fe(III)(SO4)2 were made in MilliQ water. The Fe(II) solution was colorless, while the Fe(III) solution was 
red/orange. Upon addition of 20 (v/v)% glycerol the Fe(II) solution remained colorless, while the Fe(III) 
solution changed color from red/orange to yellow/orange. The colors observed in this simple test 
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corresponded to the colors of the concentrated protein solutions with glycerol (yellow) and without 
glycerol (brown/red), see Figure 107. 
6.3.2.4 Activity assay 
If glycerol binds in the active site it could have an effect on the reaction rate. Thus, the initial rate was 
measured for chTPH2 samples with different concentrations of glycerol using the activity assay. 
Table 28: Activity of chTPH2 samples with different glycerol concentrations. The concentration of chTPH2 in the assay was 0.5 
µM. Each sample was measured 8 times. The unit for activity [int/min] is an arbitrary unit, but can be used for comparison 
between different samples. 
(w/v)% glycerol Activity  ± St. Dev. [int/min] 
0 515 ± 56 
0.4 545 ± 36 
0.8 567 ± 14 
The results from the activity measurements in Table 28 show that glycerol does not inhibit the 
hydroxylation reaction of TPH. Actually, it slightly increases the activity and significantly decreases the 
standard deviations. This is in agreement with the fact that glycerol is a known protein stabilizer(166), and 
that a more stable protein solution would give lower standard deviations. 
6.3.2.5 Theoretical calculations 
In an attempt to specify which of the two glassing agents used in MCD that affects the active site, a 
theoretical calculation study was carried out by master student Niels Theis Bendtsen under supervision of 
Associate Professor Günther H. J. Peters(167). A model of the binding pocket of TPH2 was computed based 
on the 1MLW structure of chTPH1 by point-mutating three amino acids. Several programs were used to 
dock sucrose and glycerol into the binding pocket and investigate their interaction with the active site iron. 
The calculations showed that both sucrose and glycerol can enter the active site of TPH and coordinate to 
iron. 
6.3.3 Overall discussion 
It is well known that catecholamines such as dopamine bind directly to iron in PAH(129) and TH(168) and 
inhibit catalysis. A crystal structure of PAH with bound dopamine shows a bidentate coordination to iron 
through two OH-groups(129). Glycerol could bind to iron in a similar binding mode. The light yellow color of 
the glycerol Fe(III)-TPH sample is also seen for Fe(III)-PAH in glycerol and disappears upon reduction(69). 
Furthermore, a glycerol effect was observed in some of the first PAH MCD experiments for the PAH sample 
with added tryptophan. The presence of tryptophan perturbed the iron active site, but upon addition of 
glycerol this effect was nullified and the peaks returned to the positions for the resting enzyme(69). It was 
speculated that glycerol displaces tryptophan from the active site pocket. However, the resting and L-phe 
bound PAH enzyme samples are insensitive to glycerol addition(69). Fe(III) in aqueous solution with glycerol 
is light yellow, suggesting that the color of the TPH samples arises from a direct interaction between iron 
and glycerol, and not from distant binding of glycerol in the active site. Glycerol is a smaller molecule than 
sucrose and it could more easily enter the active site, even though the theoretical calculations show that 
sterically both molecules fit. 
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6.3.4 Conclusions 
There is a clear color change to yellow when glycerol is added to a solution of chTPH2 in the Fe(III) form. 
The color disappears upon reduction to Fe(II) with sodium dithionite. Based on this it is reasonable to 
believe that glycerol is affecting the iron coordination, and that the sucrose samples used in MCD 
experiments most likely best represents the natural state of chTPH2. Glycerol is commonly used in 
preparation of AAAH samples and it is thus an important finding that it interacts with the active site iron. 
However, as activity is not inhibited by glycerol, it may not have large consequences for the kinetic analysis. 
Glycerol is a known protein stabilizer and has been used in protein preparation for many years. 
6.4 Differential scanning fluorimetry 
The unfolding/melting temperature of a protein can be measured by DSF as described in section 4.3.2.3, 
and if binding of substrates thermodynamically stabilizes the protein, this should be visible from a DSF 
experiment. Different substrates and substrate analogous were added to chTPH2 and cthTPH2 and the 
melting temperature was determined.  
6.4.1 Experimental procedures 
chTPH2 and cthTPH2 were purified as described in section 4.2.4.1 and 4.2.4.2. The samples were frozen in 
liquid nitrogen and stored at -80 °C. DSF experiments were performed at MaxLab, Lund University following 
the general procedure described in section 4.2.5.3. The protein concentration was 2 µM in the final screen, 
and the protein was diluted in 10 mM HEPES/NaOH, pH 7.0 before addition to the screen. For 1000 µL 
diluted protein solution, 3.0 µL 5000x SyPro Orange was used. The reference buffer was 100 mM 
HEPES/NaOH, 100 mM (NH4)2SO4, pH 7.0. 
The screen used was homemade, and was prepared by adding 1.5 mL reference buffer to each well in the 
deep well block. Substrates were added to the deep well block from frozen stocks solutions on the day of 
use, before the Tecan robot sat up the DSF screen. The final substrate concentrations were 100 µM. Iron-
compounds were dissolved immediately before use to 66 mM stock solutions and diluted if necessary. 1 µL 
iron-compound solution per well was added directly to the DSF screen right before protein addition, in 
order to prevent oxidation.  8 µL protein/SyPro orange solution was added to each well with 24 µL screen 
(and 1 µL iron-compound). 
6.4.2 Results and discussion 
Initial measurements showed a large increase in melting temperature (5 °C) upon addition of 
(NH4)2Fe(II)(SO4)2 (data not shown). The effect of different (NH4)2Fe(II)(SO4)2:protein ratios were thus tested 
along with addition of Fe(III) as NH4Fe(III)(SO4)2 and Fe(III)OAc. The results can be seen in Figure 109. 
Addition of Fe(III) as NH4Fe(III)(SO4)2 and Fe(III)OAc has no significant effect on the stability in terms of 
unfolding temperature. Mass spectrometric studies have shown that chTPH2 is fully loaded with iron after 
purification (see section 6.2.4), so addition of extra Fe(III) does not make any difference. A significant 
increase in melting temperature is however observed with increasing (NH4)2Fe(II)(SO4)2 concentration. It 
must be assumed that TPH in solution contains Fe(III), as Fe(II) would have been oxidized by oxygen in the 
air and buffers. Thus, it makes sense that addition of Fe(II), which is the catalytically active species, 
stabilizes the protein relative to Fe(III). The constant increase in melting temperature with Fe(II):protein 
ratios up to 30 could be explained by a low binding affinity for Fe(II), when Fe(III) is already bound, or by the 
slow electron transfer between Fe(II) in solution and Fe(III) bound in the protein. The finding that TPH in 
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the Fe(II) form is significantly more stable than in the Fe(III) form is important and should be considered for 
e.g. crystallization and other characterization techniques.  
  
Figure 109: Results from DSF studies on the effect of addition of iron. Reference is 100 mM HEPES/NaOH, 100 mM (NH4)2SO4, pH 
7.0. Numbers (e.g. 30 x) refers to excess of the compound relative to the protein concentration, which was 2 µM. Left in blue: 
chTPH2. Right in green: cthTPH2. 
Several types of reducing conditions were tested to investigate if the stabilizing effect could be achieved by 
reducing protein bound Fe(III) to Fe(II). No conclusive results were however seen, probably due to the 
negative effect of reducing agents on protein stability.  
Addition of substrates (trp, BH4), substrate analogue (BH2) and possible regulators (serotonin) to TPH gave 
no significant increase in melting temperature (max 1 °C, data not shown). Addition of BH4 gave a 
significant decrease in melting temperature probably caused by a low pH in the added BH4 solution. Thus, 
BH4 is not included in the following figures. 
  
Figure 110: Results from DSF studies on the effect of addition of substrates to samples with Fe(II) added. Reference is 100 mM 
HEPES/NaOH, 100 mM (NH4)2SO4, pH 7.0. Numbers (e.g. x 30) refers to excess of the compound relative to the protein 
concentration, which was 2 µM. All conditions with added substrates also contained (NH4)2Fe(II)(SO4)2 x 30. Left in blue: chTPH2. 
Right in green: cthTPH2. 
However, if substrates are added along with Fe(II) an effect is seen on the melting temperature for chTPH2, 
see Figure 110. Addition of BH2, which is a cofactor analogue and inhibitor, gives a 3 °C increase in melting 
temperature, while addition of both trp and BH2 gives an increase of 5 °C. Addition of trp alone does not 
have any effect. This suggests that BH2 and trp binds to the protein and energetically stabilizes it. 
Furthermore, it indicates that even if tryptophan can bind before BH2, it is energetically more favored when 
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binding after BH2. This stabilizing effect could be caused by the large structural changes and the closing of 
the active site upon cofactor and substrate binding. Furthermore, these results suggests that binding of 
substrates in the Fe(III) form does not stabilize the protein. For cthTPH2 the effect of substrates on the 
melting temperature is not significant. 
6.4.3 Conclusions 
Addition of Fe(II) increases the unfolding temperature of both chTPH2 and cthTPH2 with 9 and 7 °C, 
respectively. Addition of BH2 and trp+BH2 significantly stabilizes chTPH2 in the presence of Fe(II). Without 
addition of Fe(II) no effect of BH2 and trp+BH2 addition is seen. This suggests that binding of the substrates 
only stabilizes the structure in the catalytically active state. 
6.5 Isothermal titration calorimetry 
The binding of substrates can be studied using a steady state kinetic assay and michaelis menten kinetic 
theory. For TPH, several studies using kinetics comparing KM values and the differences between the 
isoforms have been published(13, 34, 51, 98, 102, 169, 170). In 2009, the Metalloprotein Chemistry and 
Engineering group investigated the kinetic differences between purified chTPH1 and chTPH2 at the exact 
same conditions, so the results can be directly compared(13). Despite the large sequence identity between 
the two catalytic domains of 81 %, several differences were seen. First, chTPH1 was inhibited at large 
concentrations of tryptophan, while chTPH2 was not. Second, the KM value for BH4 was more than 10 times 
larger for chTPH1 than for chTPH2. The latter is surprising, as none of the amino acids close to the BH4 
binding pocket differs between the isoforms. The results are in contrast to earlier studies of full-length 
TPH1 and TPH2(51), where the KM values for BH4 and Trp were in the same range for both isoforms. 
However, this study was performed on affinity-tagged TPH variants that were not completely pure. 
As KM values are difficult to compare and represent several factors beside the actual binding affinity, 
another technique was used to study the binding of substrate and cofactor to TPH. The technique is called 
isothermal titration calorimetry, and allows for direct determination of dissociations constants, which can 
be directly compared. 
Isothermal titration calorimetry (ITC) is a technique used to determine the thermodynamic parameters of 
biomolecular interactions in solution. For ligands binding to protein, both the binding affinity, number of 
binding sites, entropy and enthalpy of the reaction are determined in a single experiment(171).  
A representation of a typical ITC instrument can be seen in Figure 111. The ligand solution is placed in a 
syringe and added in small portions to the sample cell containing protein solution. The reference and 
sample cells are mounted in an adiabatic environment and can only be accessed through narrow tubes 
minimizing interaction with the outside world. The temperature difference between the two cells is 
measured by a thermoelectric device. When ligand is added to protein, the binding reaction occurs in the 
sample cell, and heat is generated or absorbed according to the thermodynamics of the reaction. The 
temperature difference between the sample and reference cell is kept constant at 0 by addition or removal 
of heat to the sample cell. The integral of the power required to maintain a constant temperature 
difference ∆T=0 between the reference and sample cell, is a measure of total heat resulting from the 
binding reaction. 
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Figure 111: Schematic representation of a typical power consumption ITC. The diagram shows an oversimplification of how the 
power applied by the instrument to maintain constant temperature between the reference and sample cell is measured 
resulting in the instrument signal. Reprinted with permission from (171). Copyright 2008 Elsevier. 
If the concentrations of protein and ligand are appropriate, the first peaks will be of similar size, 
corresponding to full binding of all the ligand added. As saturation is reached, less and less ligand will bind 
and the peaks will decrease in size. The last peaks will represent the heat of dilution, as all protein has 
ligand bound. The integral of the peaks per mole of ligand plotted against the molar ratio of ligand to 
protein, gives a complete binding isotherm. The binding affinity is determined by the slope at which the 
peaks fall when saturation is reached (see Figure 112). The enthalpy of the reaction is the total difference 
between the first and last integrated peaks, and the stoichiometric number is found at the inflection point.  
The advantages of ITC as a technique are that both ligand and protein are free in solution and do not have 
to be labeled or immobilized on a surface, as with e.g. surface plasmon resonance. Also, there are almost 
no buffer restrictions. The disadvantage is that high protein concentrations and significant amounts of 
protein are usually required to get reliable results, even through the protein consumption has been 
significantly lowered in the new equipment. Also, the vigorous stirring can cause precipitation of the 
protein if it is unstable. Furthermore, the use of reducing agents will cause some disturbance of the 
baseline due to the constant reaction. The producer of the ITC instrument (MicroCal) recommends the use 
of tris(2-carboxyethyl)phosphine (TCEP) or β-mercaptoethanol over DTT(172).  
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Figure 112: Typical ITC raw data (left) and integrated data (right) showing the binding isotherm and how the different 
parameters are determined. Reprinted with permission from (173). Copyright 2000-2009 GE Healthcare. 
6.5.1 Experimental procedures 
In this section the experimental procedures for the isothermal titration calorimetry experiments will be 
described. The experiments were performed at the Faculty of Pharmaceutical Sciences at Copenhagen 
University under supervision of Associate Professor Lars Olsen. 
The calorimetry experiments were performed using a microcalorimeter (ITC200, Microcal, MA, USA). The 
software ORIGIN 7.0 (Microcal, MA, USA) was used to determine the thermodynamic properties of ligand 
binding using non-linear least-squares fitting assuming a single-site model. For all experiments, the first 
peak was omitted from data analysis. 
6.5.1.1 Preparation of protein samples 
chTPH2 purified as described in section 4.2.4.1 was thawed and mixed. The total volume was approx. 3.2 
ml. The solution was added to a “Slide-A-Lyzer” cassette from Pierce (3-12 ml) with a molecular cut-off of 
10000 Da, after the cassette had been hydrated for 2 min. in buffer. The buffer used for all experiments 
weas: 100 mM HEPES/NaOH, 100 mM (NH4)2SO4, pH 7.00. The buffer used resembles that from the last 
step in the purification. The main differences are a higher buffer concentration, which should keep pH more 
stable when ligands are added, and a lower pH which is used in order to be able to compare the KD values 
with KM values determined previously using the kinetic assay(13). 
The dialyze-cassette was placed in 1 L of buffer with stirring at 4 °C for 2 hours. The dialysis buffer was 
discarded and 800 ml new buffer was added. The dialysis setup was left overnight. The dialyzed protein 
solution was removed from the cassette and filtered (there was visible precipitation). The protein 
concentration was measured by UV-Vis at the NanoDrop 1000 spectrophotometer using ε280nm = 39310 M
-1 
cm-1 to 225 µM (triple determination). The protein solution was frozen in aliquots of 350 µl in liquid 
nitrogen and kept at -80 °C until further use. 
6.5.1.2 Prepration of ligand samples 
The dialysis buffer from the second round of dialysis of the protein sample was used to make ligand 
solutions in order to ensure that the composition was exactly the same for protein and ligand samples. The 
ligands were weighed out and solubilized in buffer flushed with argon for 15 min to ensure a minimum of 
oxygen (BH4 is sensitive to oxidation). After solubilization, pH was adjusted to 7.00 if necessary, and the 
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final solution was flushed with argon for 10 min. The concentrations of tryptophan and BH2 were 
determined with UV-Vis at the NanoDrop 1000 spectrophotometer using the extinction coefficients shown 
in Table 29. The BH4 sample was measured, then added 1 mM TCEP and 2 mM (NH4)2Fe(II)(SO4)2 to simulate 
the reducing assay conditions, and subsequently measured again. As the concentration of the BH4 solution 
determined by UV-Vis did not correspond with the mass of BH4 solubilized, the concentration calculated 
from the mass is given in Table 29. 
Table 29: The concentration and extinction coefficients for ligand solutions for ITC experiments. 
Ligand Concentration Extinction coefficient 
Tryptophan 1.85 mM ε278nm = 5500 cm
-1 M-1(174) 
BH2 1.72 mM ε330nm = 6170 cm
-1 M-1(175) 
BH4 2 mM -
 
 
6.5.1.3 ITC experiments 
All experiments were performed at 15 °C, to ensure that the results can be compared to those from the 
kinetic assay, which is also performed at 15 °C.  
At the beginning of each day and between different samples, the sample cell was cleaned several times 
with water using the cleaning program in the software and a manual Hamilton syringe. Prior to addition of 
protein solution, the sample cell was washed with buffer. The syringe was washed by filling with water and 
emptying at least 3 times between different samples. Furthermore, the syringe was washed with one 
volume of the ligand solution before use. The reference cell was filled with water and the sample cell was 
filled with buffer, water or protein using a Hamilton syringe. Excess solution was removed from the top of 
the sample cell, to ensure a correct volume of 206 µL.  
Most experiments were run with 20 injections: the first of 0.5 µl to ensure that no air bobbles were trapped 
in the syringe and the following of each 2.0 µl. Generally, the time difference between each injection was 
180 s, however, this was occasionally changed. The stirring speed was 1000 rpm and the differential power 
(DP) was set to 6 µcal/s. These are standard running conditions.  
6.5.2 Results and discussion 
In this section results from the ITC experiments will be presented and discussed. 
6.5.2.1 Blanks 
All ligand solutions were added to the buffer without any protein present to check how big peaks arise from 
differences in the two samples and from the mixing. The results for tryptophan and BH2 can be seen in 
Figure 113. 
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Figure 113: Left: Tryptophan injected in buffer, both with 1 mM TCEP. The temperature was 15 °C and 2 ul injections (first 0.5 µl) 
were made every 180 s. Right: BH2 injected in buffer, both with 1 mM TCEP and 0.4 mM (NH4)2Fe(II)(SO4)2. The temperature was 
15 °C and 2 µl injections (first 0.5 µl) were made every 180 s. 
The small and almost indistinguishable peaks compared to the noise on the baseline for both tryptophan 
and BH2 indicates that the ligand and buffer solutions are very much alike, and that the heat from mixing is 
small.  
For BH4, the picture is somewhat different, see Figure 114. The large decrease in the baseline following 
each injection suggests that a reaction is taking place. This also corresponds with the fact that the 
decreases get smaller and smaller for each injection, which is typical for reactions(171). BH4 is prone to 
auto-oxidation by O2(176), especially in non-acidic solutions, where there is no protonation of N5(177).  
 
Figure 114: BH4 injected in buffer, both with 1 mM TCEP and 0.4 mM (NH4)2Fe(II)(SO4)2. The temperature was 15 °C and 2 ul 
injections (first 0.5 µl) were made every 240 s. 
The absorption spectrum of the BH4 solution suggests that the main content is not BH4, see Figure 115. 
Compared to the absorption spectrum of BH4 in acidic solution, the shoulder at 266 nm typical for BH4 is 
missing. Even upon reduction by addition of TCEP the shoulder does not appear. The spectrum of the BH4 
solution made in this project more resembles the spectrum of quinonoid dihydropterin q-BH2, which is the 
product of the auto-oxidation of BH4(176).  
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Figure 115: Left: Absorption spectrum of BH4 before and after addition of 1 mM TCEP and 2 mM (NH4)2Fe(II)(SO4)2. Right: 
Absorption spectrum of BH4 and quinonoid dihydropterin (q-BH2) in 2 M HCl. Adapted with permission from (174). Copyright 
1999 Elsevier. 
One possible explanation for the pattern seen in Figure 114 is the reduction of q-BH2 back to BH4, when the 
ligand solution is added to the buffer solution containing 1 mM TCEP. Whether this is the case or not, it can 
be concluded that the BH4 solution is not suitable for addition to protein samples, as the large reaction 
heats would disguise the binding heats. Furthermore, if the solution does contain q-BH2 instead of BH4 or a 
mixture of the two, the binding constants would be ambiguous. A solution to this problem could be to 
solubilize BH4 in acidic solution, but as ITC requires that the protein and ligand is in the same solution this 
cannot be performed, as chTPH2 is not stable at low pH, see section 4.3.3.3. Alternatively, the ITC 
experiment can be carried out under oxygen free conditions as in e.g. a glovebox. 
6.5.2.2 Determination of binding constants 
First, the binding constant of tryptophan to chTPH2 was determined in a solution with 1 mM TCEP. This 
means that no Fe(II) was added, and thus the protein might not have been saturated with iron. After the 
measurement, protein precipitation was observed, which means that the actual concentration will also be 
lower than the 225 µM determined before the measurement. The actual protein concentration during the 
experiment is thus hard to determine. For this particular experiment only, TCEP was added from a very 
concentrated solution which caused precipitation of the protein even before addition to the sample cell. A 
lower protein concentration must be anticipated than in the other ITC experiments described here, where 
the actual protein concentration was determined by UV-Vis after each ITC experiment. 
The protein precipitation, and following change in active protein concentration, should not affect the 
determination of the association constant for optimally designed experiments. However, if the 
precipitation process takes place during measurements, the baseline might be affected due to the constant 
release of heat from the phase change. After addition of protein to the sample cell, the stirring was started 
and after only 5 min, the protein solution was checked and precipitation was observed. This indicates that 
the fast stirring (1000 rpm) might be responsible for the precipitation. This hopefully means that most 
protein precipitation happens during temperature and baseline equilibration, and thus should not affect 
the actual measurement. For the rest of the samples, the protein solution was centrifuged after each 
measurement, and the actual protein concentration was determined by UV-Vis. Precipitation of protein due 
to stirring is a well-known problem when performing ITC.  
____ BH4, 2 M HCl 
- - - q-BH2, 2 M HCl 
 
6.5 Isothermal titration calorimetry 
   
126 
 
The baseline-corrected data for the ITC experiment of tryptophan binding to chTPH2 is seen in Figure 116, 
left, and displays a clear binding of tryptophan to the protein. The binding heat is negative (positive peaks), 
which means that the binding reaction of tryptophan to the protein is endothermic, and thus must be 
entropically driven. This corresponds well with the fact that tryptophan binds in a hydrophobic pocket. The 
design of the experiment is not optimal, as the protein concentration is too low (or the ligand 
concentration too high) and thus no plateau is seen for the integrated data of the first peaks. This makes 
determination of the dissociation constant difficult. Furthermore, the protein concentration was not 
measured after the experiment, so instead it was estimated. In order to fit the data, the stoichiometry 
parameter N had to be fixed to 1. The association constants determined from the fitting was dependent on 
protein concentration and varied between 9.987∙103 M-1 (1 µM protein) and 1.749∙104 M-1 (50 µM protein), 
corresponding to dissociation constants of 100 and 57 µM, respectively. These dissociation constants are 
within the same order of magnitude as the kinetically determined KM value for tryptophan, which is 15 
µM(13). In order to determine an exact dissociation constant by ITC, the experiment will have to be 
repeated with a higher protein concentration or lower tryptophan concentration, so the data integration 
can be performed independent of protein concentration. 
   
Figure 116: ITC experiments with tryptophan binding.  The top graph shows the baseline-corrected raw data, and the bottom 
graph the integrated data along with the fit. Left: Tryptophan injected in chTPH2 solution, both with 1 mM TCEP. The 
temperature was 15 °C and 2 µl injections (first: 0.5 µl) were made every 180 s. The data was fitted assuming a protein 
concentration of 50 µM and N fixed to 1, which gave a dissociation constant of 57 µM. Right: Tryptophan injected in chTPH2+BH2 
solution, both with 1 mM TCEP and 0.4 mM (NH4)2Fe(II)(SO4)2.. The temperature was 15 °C and 2 µl injections (first: 0.5 µl) were 
made every 180 s. No fitting could be made due to the widening of peaks at the end of the run and a steep change in baseline. 
To check if the binding of substrate and cofactor is independent, the binding of tryptophan to the protein 
with BH2 already bound was also investigated. As tryptophan and BH2 bind in separate binding pockets 
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according to the crystal structures(12, 47) this is not expected, but substrate binding induced 
conformational changes in the protein, could change the association constant. The result can be seen in 
Figure 116, right, where the general pattern suggests binding of tryptophan. Fitting of the data was not 
possible, due to a steep change in baseline and widening of the last peaks which made integration 
unreliable. The widening of the last peaks is possibly caused by air in the system. However, it can be 
concluded that tryptophan does bind to the protein with bound BH2, and the binding is endothermic. 
 
Figure 117: ITC experiments with BH2 binding. The top graph shows the baseline-corrected raw data, and the bottom graph the 
integrated data along with the fit. Left: BH2 injected in chTPH2 solution, both with 1 mM TCEP. The temperature was 15 °C and 2 
µl injections (first: 0.5 µl) were made every 180 s. The dissociations constant was determined to 6 µM for a protein 
concentration of 124 µM. Right: BH2 injected in chTPH2+tryptophan solution, both with 1 mM TCEP and 0.4 mM 
(NH4)2Fe(II)(SO4)2. The temperature was 15 °C and 2 µl injections (first 0.5 µl) were made every 180 s. The dissociations constant 
was determined to 15 µM for a protein concentration of 106 µM. 
BH2 was injected directly into a protein sample with no other ligands present. The baseline-corrected raw 
data and the integrated data can be seen in Figure 117, left. Fitting of the integrated data gave an 
association constant of 1.956∙105 M-1, which corresponds to a dissociation constant of 5 µM. For the 
protein concentration measured after the experiment (124 µM) N=0.97, which is very close to 1. It can thus 
be concluded that BH2 binds 1:1 with the protein, and that the reaction is exothermic (negative peaks). The 
binding of BH2 is significantly stronger than binding of tryptophan corresponding with the smaller 
dissociation constant, but this was also expected since BH2 is an inhibitor of TPH. Fitting of the integrated 
data could be performed without fixing any parameters, suggesting that the protein and BH2 
concentrations are suitable.  
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BH2 was also injected into a sample containing chTPH2 and tryptophan. The result is seen in Figure 117. 
right. The integrated data gives an association constant of 6.747∙104 M-1, which equals a dissociation 
constant of 15 µM. The protein concentration after this measurement and centrifugation was 106 µM, 
which gives N=0.74, corresponding with a 1:1 binding. The difference in the dissociation constant between 
the protein alone (5 µM), and the protein with bound tryptophan (15 µM) is too small to be significant, 
especially since the experiments were only performed once. More reliable data for BH2 binding to chTPH2 
with already bound tryptophan could be achieved by lowering the ligand concentration or increasing the 
protein concentration. 
In order to determine whether chTPH1 and chTPH2 differs significantly in binding affinity for the cofactor as 
suggested by the kinetic data, ITC measurements of TPH1 must be carried out. The recent development of 
purification procedures for chTPH1 and hTPH1 makes this possible, as both can be concentrated to around 
200 µM, which should be sufficient for ITC measurements. As the natural cofactor cannot be used for ITC 
experiments, the dissociation constants for BH2 or other cofactor analogues could be compared. 
6.5.3 Conclusions 
In general, protein precipitation made the ITC measurements difficult. Despite this several results were 
obtained. It can be concluded that both tryptophan and the inhibitor BH2 binds to chTPH2. The dissociation 
constant of BH2 is 5 µM, while the dissociation constant for tryptophan is somewhat higher and within the 
same order of magnitude as KM determined by a kinetic assay. The precise value cannot be determined 
from the experiments performed here. Furthermore, tryptophan and BH2 binds independently of each 
other, corresponding with different binding pockets also seen in crystal structures. Tryptophan binding is 
entropically driven, while binding of BH2 is exothermic.  
6.6 Conclusions 
In this chapter, chTPH2 has been investigated using several different techniques in order to provide 
information on the reaction mechanism. 
Four mutants of chTPH2 were made, and it could be concluded that Glu363, which is an iron ligand, is 
essential for activity, while Tyr358 affects the activity, but is not absolutely required. Both amino acids were 
important for the solubility of the protein. CD and MCD measurements were performed on chTPH2 samples 
added either tryptophan, BH4 or both. The results clearly demonstrated that the active site iron changes 
conformation from 6C to 5C only when both substrate and cofactor binds. A difference between samples 
made in glycerol and sucrose was observed, and this effect was tested further by absorption 
measurements. It was clear that addition of glycerol to chTPH2 with bound Fe(III) gave a yellow color 
indicative of interaction. DSF measurements demonstrated that chTPH2 and cthTPH2 is significantly more 
stable with Fe(II) bound than with Fe(III). Furthermore, the addition of substrates and cofactor only 
stabilizes chTPH2 when Fe(II) is present. ITC measurements were performed on chTPH2. Despite problems 
with protein precipitation, the dissociations constant of BH2 was determined to 5 µM, while the 
dissociation constant for tryptophan is somewhat higher. Tryptophan and BH2 bind independently of each 
other.
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7 Overall conclusions 
The two overall goals of this project were: I) To develop purification methods for full-length human TPH1 
and TPH2, and II) to characterize purified variants of TPH to achieve a better understanding of the 
structure-functional relationship.  
A successful purification method for full-length hTPH1 was developed, which resulted in pure, active and 
stable protein. The method includes affinity-purification using MBP tag and high salt concentrations in all 
buffers. It is the first time a successful purification method for hTPH1 has been presented, which also yields 
stable protein after cleavage from the affinity tag. This allows for a thorough characterization of the full-
length human enzyme, which has not been possible before. Furthermore, successful purification 
procedures were developed for a number of other TPH variants. A purification method for rchTPH1 similar 
to that of hTPH1 using MBP affinity tag was developed, and revealed that the regulatory domain causes 
dimerization. Also, a new purification method for chTPH1 using GST affinity-tag was developed, which 
eliminated impurities identified by mass spectrometry in earlier projects. rchTPH2 and hTPH2 were 
attempted purified using the same general method as for hTPH1, but the yields were very low and the 
products were unstable and could not be concentrated. The high salt concentration does thus not seem to 
stabilize the regulatory domain of TPH2. hTPH1 displayed a significantly higher specific activity than chTPH1 
and rchTPH1, suggesting that the tetramerization increase reactivity, possibly by cooperativity. The stability 
of chTPH1, hTPH1, chTPH2 and cthTPH2 were studied by differential scanning fluorimetry, and the results 
gave information on the effect of pH, salt type and ionic strength. 
The results from crystallization were unfortunately rather limited. The crystallization procedure for cgTPH1 
was optimized to faster crystal growth by addition of tryptophan and incubation at room temperature. 
Crystals without imidazole in the crystallization conditions could be obtained. The solved structures were 
however of poor quality and did not contribute with any new information on TPH. A strategic approach to 
crystallization of TPH variants was developed, and the 5 suitable TPH variants were purified followed by 
immediate screen set-up eliminating the freezing-thawing step. No crystals of any TPH2 variant were found. 
However, the pipeline screening produced leads for rchTPH1 and several crystals for chTPH1. 
In the mechanistic studies, several different techniques were used to investigate TPH. Four mutants of 
chTPH2 were made, and it could be concluded that Glu363, which is an iron ligand, is essential for activity, 
while Tyr358 affects the activity, but is not absolutely required. CD and MCD results on chTPH2 clearly 
demonstrated that the active site iron changes conformation from 6C to 5C only when both substrate and 
cofactor binds. It is the first time a MCD study has been performed any AAAH with the natural cofactor, and 
the quality of the data was very high. A difference between samples made in glycerol and sucrose was 
observed, and this effect was tested further by absorption measurements. It was clear that addition of 
glycerol to chTPH2 with bound Fe(III) gave a yellow color indicative of interaction. DSF measurements 
demonstrated that chTPH2 and cthTPH2 are significantly more stable in the Fe(II) form compared to the 
Fe(III) form. Furthermore, the addition of substrates and cofactor only stabilizes chTPH2 when Fe(II) is 
present. ITC measurements were performed on chTPH2. Despite problems with protein precipitation, the 
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dissociation constant of BH2 was determined to 5 µM, while the dissociation constant for tryptophan is 
somewhat higher. Tryptophan and BH2 bind independently of each other. 
Overall, the work performed in this project has made significant contributions to the research on TPH, both 
by providing new purification procedures as well as advancements in the knowledge on the mechanism of 
TPH. 
7.1 Future work 
The results presented in this thesis provide a good starting point for further research on TPH. The 
purification procedures involving affinity tags could be shortened significantly by introducing on-column 
cleavage. For purifications using the MBP column, a thorough investigation of the first affinity step should 
be performed in order to elucidate why a large portion of the MBP-tagged protein is found in the flow-
through and cannot subsequently bind to the column. Kinetic characterization of the purified TPH variants 
should also be made. The availability of pure and stable TPH variants containing the regulatory domain can 
be used for investigation of the regulatory mechanisms including possible feed-back regulation by e.g. 
serotonin or inhibition by substrates. 
Regarding crystallization, more crystals of cgTPH1 without imidazole in the crystallization conditions should 
be produced and tested for diffraction in the hope of achieving high resolution data. Furthermore, the 
leads for crystallization of chTPH1 should be pursued in order to solve the structure without any substrates 
bound, or with either tryptophan or tryptophan and BH2 bound. 
The ITC experiments with chTPH2 performed here were only preliminary, but provide information on how 
to design suitable experiments for determination of dissociation constants for tryptophan and BH2. Such 
experiments should be performed, and if possible compared to similar ITC experiments of TPH1 to 
determine any differences between the isoforms. The ITC experiments could also be performed with 
unnatural but redox-active cofactor analogues such as 6-methyltetrahydropterin for more reliable results 
as compared to BH4.  
7.2 Outlook 
It is the hope that the continued work on TPH regarding purification and characterization in time will lead 
to a thorough understanding of the structure, mechanism and regulation as well as shed further light on 
the differences between isoform 1 and 2. Even though the work is inhibited by the inherent instability of 
TPH, small steps of progress are made with each project. In the future, knowledge obtained from the 
research on TPH might aid in developing improved treatments for serotonin-related disorders. 
 
 i 
 
8 References 
1.  Lovenberg, W., Jequier, E., and Sjoerdsma, A. (1967) Tryptophan hydroxylation: measurement in 
pineal gland, brainstem, and carcinoid tumor, Science 155, 217-219. 
2.  Mockus, S. M., and Vrana, K. E. (1998) Advances in the molecular characterization of tryptophan 
hydroxylase, Journal of Molecular Neuroscience 10, 163-179. 
3.  Ganguly, S., Coon, S. L., and Klein, D. C. (2002) Control of melatonin synthesis in the mammalian 
pineal gland: the critical role of serotonin acetylation, Cell and Tissue Research 309, 127-137. 
4.  Lucki, I. (1998) The spectrum of behaviors influenced by serotonin, Biological Psychiatry 44, 151-
162. 
5.  Martínez, A., Knappskog, P. M., and Haavik, J. (2001) A structural approach into human tryptophan 
hydroxylase and its implications for the regulation of serotonin biosynthesis, Current Medicinal 
Chemistry 8, 1077-1091. 
6.  Walther, D. J., Peter, J.-U., Bashammakh, S., Hörtnagl, H., Voits, M., Fink, H., and Bader, M. (2003) 
Synthesis of serotonin by a second tryptophan hydroxylase isoform, Science 299, 76. 
7.  Walther, D. J., and Bader, M. (2003) A unique central tryptophan hydroxylase isoform, Biochemical 
Pharmacology 66, 1673-1680. 
8.  Carkaci-Salli, N., Flanagan, J. M., Martz, M. K., Salli, U., Walther, D. J., Bader, M., and Vrana, K. E. 
(2006) Functional domains of human tryptophan hydroxylase 2 (hTPH2), The Journal of Biological 
Chemistry 281, 28105-28112. 
9.  Nielsen, M. S. (2007) Expression, purification and characterization of tryptophan hydroxylase, Ph.D. 
thesis. Department of Chemistry, Technical University of Denmark. 
10.  Boesen, J. (2010) Cloning, expression, purification and characterization of tryptophan hydroxylase 
variants, Ph.D. thesis. Department of Chemistry, Technical University of Denmark. 
11.  Haahr, L. T. (2008) Expression, purification and structural studies of tetrameric variants of 
tryptophan hydroxylase isoform 2, Master thesis. Department of Chemistry, Technical University of 
Denmark. 
12.  Windahl, M. S., Petersen, C. R., Christensen, H. E. M., and Harris, P. (2008) Crystal structure of 
tryptophan hydroxylase with bound amino acid substrate, Biochemistry 47, 12087-12094. 
  
 
ii 
 
13.  Windahl, M. S., Boesen, J., Karlsen, P. E., and Christensen, H. E. (2009) Expression, purification and 
enzymatic characterization of the catalytic domains of human tryptophan hydroxylase isoforms, The 
Protein Journal 28, 400-406. 
14.  Fitzpatrick, P. F. (2003) Mechanism of aromatic amino acid hydroxylation, Biochemistry 41, 14083-
14091. 
15.  Thöny, B., Auerbach, G., and Blau, N. (2000) Tetrahydrobiopterin biosynthesis, regeneration and 
functions, The Biochemical Journal 347 Pt 1, 1-16. 
16.  Fitzpatrick, P. F. (1999) Tetrahydrobiopterin-dependent amino acid hydroxylases, Annual Review of 
Biochemistry 68, 355-381. 
17.  Fitzpatrick, P. F. (2000) The aromatic amino acid hydroxylases, Advances in Enzymology and Related 
Areas of Molecular Biology 74, 235-294. 
18.  Kaufman, S. (1957) The enzymatic conversion of phenylalanine to tyrosine, Journal of Biological 
Chemistry 226, 511-524. 
19.  Kaufman, S. (1993) The phenylalanine hydroxylating system, Advances in Enzymology and Related 
Areas of Molecular Biology 67, 77-264. 
20.  Flatmark, T., and Stevens, R. C. (1999) Structural insight into the aromatic amino acid hydroxylases 
and their disease-related mutant forms, Chemical Reviews 99, 2137-2160. 
21.  Fenylketonuri (PKU, Føllings sygdom) - Statens Serum Institut. 
http://www.ssi.dk/Diagnostik/Klinisk%20information/Blodproeve%20fra%20nyfoedte/Sygdomme%
20som%20indgaer%20i%20screeningen/Fenylketonuri.aspx, 27/4-2012. 
22.  Nagatsu, T., Levitt, M., and Udenfriend, S. (1964) Tyrosine hydroxylase - the initial step in 
norepinephrine biosynthesis, The Journal of Biological Chemistry 239, 2910-2917. 
23.  Knappskog, P., Flatmark, T., Mallet, J., Luedecke, B., and Bartholome, K. (1995) Recessively inherited 
L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene, 
Human Molecular Genetics 4, 1209-1212. 
24.  Bademci, G., Edwards, T. L., Torres, A. L., Scott, W. K., Züchner, S., Martin, E. R., Vance, J. M., and 
Wang, L. (2010) A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease, Human 
Mutation 31, E1767-E1771. 
25.  Lüdecke, B., Knappskog, P. M., Clayton, P. T., Surtees, R. A., Clelland, J. D., Heales, S. J., Brand, M. P., 
Bartholomé, K., and Flatmark, T. (1996) Recessively inherited L-DOPA-responsive parkinsonism in 
infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene, Human Molecular 
Genetics 5, 1023-1028. 
26.  Pavon, J. A., and Fitzpatrick, P. F. (2006) Insights into the catalytic mechanisms of phenylalanine and 
tryptophan hydroxylase from kinetic isotope effects on aromatic hydroxylation, Biochemistry 45, 
11030-11037. 
 iii 
 
27.  Slominski, A., Pisarchik, A., Johansson, O., Jing, C., Semak, I., Slugocki, G., and Wortsman, J. (2003) 
Tryptophan hydroxylase expression in human skin cells, Biochimica et Biophysica Acta (BBA) - 
Molecular Basis of Disease 1639, 80-86. 
28.  Patel, P. D., Pontrello, C., and Burke, S. (2004) Robust and tissue-specific expression of TPH2 versus 
TPH1 in rat raphe and pineal gland, Biological Psychiatry 55, 428-433. 
29.  Zill, P., Büttner, A., Eisenmenger, W., Möller, H.-J., Ackenheil, M., and Bondy, B. (2007) Analysis of 
tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study, Journal 
of Psychiatric Research 41, 168-173. 
30.  Hasegawa, H., Yanagisawa, M., Inoue, F., Yanaihara, N., and Ichiyama, A. (1987) Demonstration of 
non-neural tryptophan 5-mono-oxygenase in mouse intestinal mucosa, The Biochemical Journal 248, 
501-509. 
31.  Zhang, X., Beaulieu, J.-M., Sotnikova, T. D., Gainetdinov, R. R., and Caron, M. G. (2004) Tryptophan 
hydroxylase-2 controls brain serotonin synthesis, Science 305, 217. 
32.  Gutknecht, L., Waider, J., Kraft, S., Kriegebaum, C., Holtmann, B., Reif, A., Schmitt, A., and Lesch, K.-
P. (2008) Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout 
mice., Journal of Neural Transmission 115, 1127-1132. 
33.  Murphy, K. L., Zhang, X., Gainetdinov, R. R., Beaulieu, J.-M., and Caron, M. G. (2008) A regulatory 
domain in the N terminus of tryptophan hydroxylase 2 controls enzyme expression, The Journal of 
Biological Chemistry 283, 13216-13224. 
34.  Tenner, K., Walther, D., and Bader, M. (2007) Influence of human tryptophan hydroxylase 2 N- and 
C-terminus on enzymatic activity and oligomerization, Journal of Neurochemistry 102, 1887-1894. 
35.  Camilleri, M. (2011) LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic 
diarrhea associated with increased serotonin, Neurogastroenterology and Motility 23, 193-200. 
36.  Liu, Q., Yang, Q., Sun, W., Vogel, P., Heydorn, W., Yu, X.-qing, Hu, Z., Yu, W., Jonas, B., Pineda, R., 
Calderon-gay, V., Germann, M., Neill, E. O., Brommage, R., Cullinan, E., Platt, K., Wilson, A., Powell, 
D., Sands, A., Zambrowicz, B., and Shi, Z.-cai. (2008) Discovery and characterization of novel 
tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal 
tract, The journal of Pharmacology and Experimental Therapeutics 325, 47-55. 
37.  Margolis, K. G., Stevanovic, K. D., Yang, Q. M., Li, Z., Mazo, R., and Gershon, M. D. (2011) An inhibitor 
of tryptophan hydroxylase successfully ameliorates TNBS-induced colitis, Gastroenterology 140, S-
478. 
38.  Walitza, S., Renner, T. J., Dempfle, A., Konrad, K., Wewetzer, C., Halbach, A., Herpertz-Dahlmann, B., 
Remschmidt, H., Smidt, J., Linder, M., Flierl, L., Knölker, U., Friedel, S., Schäfer, H., Gross, C., 
Hebebrand, J., Warnke, A., and Lesch, K. P. (2005) Transmission disequilibrium of polymorphic 
variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder, Molecular 
Psychiatry 10, 1126-1132. 
  
 
iv 
 
39.  Cichon, S., Winge, I., Mattheisen, M., Georgi, A., Karpushova, A., Freudenberg, J., Freudenberg-Hua, 
Y., Babadjanova, G., Van Den Bogaert, A., Abramova, L. I., Kapiletti, S., Knappskog, P. M., McKinney, 
J., Maier, W., Jamra, R. A., Schulze, T. G., Schumacher, J., Propping, P., Rietschel, M., Haavik, J., and 
Nöthen, M. M. (2008) Brain-specific tryptophan hydroxylase 2 (TPH2): A functional Pro206Ser 
substitution and variation in the 5’-region are associated with bipolar affective disorder, Human 
Molecular Genetics 17, 87-97. 
40.  Zhang, X., Gainetdinov, R. R., Beaulieu, J.-M., Sotnikova, T. D., Burch, L. H., Williams, R. B., Schwartz, 
D. a, Krishnan, K. R. R., and Caron, M. G. (2005) Loss-of-function mutation in tryptophan 
hydroxylase-2 identified in unipolar major depression, Neuron 45, 11-16. 
41.  Zhou, Z., Roy, A., Lipsky, R., Kuchipudi, K., Zhu, G., Taubman, J., Enoch, M.-A., Virkkunen, M., and 
Goldman, D. (2005) Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major 
depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations, Archives of General 
Psychiatry 62, 1109-1118. 
42.  Van den Bogaert, A., Sleegers, K., De Zutter, S., Heyrman, L., Norrback, K.-F., Adolfsson, R., Van 
Broeckhoven, C., and Del-Favero Jr., J. (2006) Association of brain-specific tryptophan hydroxylase, 
TPH2, with unipolar and bipolar disorder in a Northern Swedish, isolated population, Archives of 
General Psychiatry 63, 1103-1110. 
43.  Mössner, R., Walitza, S., Geller, F., Scherag, A., Gutknecht, L., Jacob, C., Bogusch, L., Remschmidt, H., 
Simons, M., Herpertz-Dahlmann, B., Fleischhaker, C., Schulz, E., Warnke, A., Hinney, A., Wewetzer, 
C., and Lesch, K.-P. (2006) Transmission disequilibrium of polymorphic variants in the tryptophan 
hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder, The 
International Journal of Neuropsychopharmacology 9, 437-442. 
44.  Sheehan, K., Lowe, N., Kirley, A., Mullins, C., Fitzgerald, M., Gill, M., and Hawi, Z. (2005) Tryptophan 
hydroxylase 2 (TPH2) gene variants associated with ADHD, Molecular Psychiatry 10, 944-949. 
45.  Matthes, S., Mosienko, V., Bashammakh, S., Alenina, N., and Bader, M. (2010) Tryptophan 
hydroxylase as novel target for the treatment of depressive disorders, Pharmacology 85, 95-109. 
46.  Popova, N. K., and Kulikov, A. V. (2010) Targeting tryptophan hydroxylase 2 in affective disorder, 
Expert Opinion on Therapeutic Targets 14, 1259-1271. 
47.  Wang, L., Erlandsen, H., Haavik, J., Knappskog, P. M., and Stevens, R. C. (2002) Three-dimensional 
structure of human tryptophan hydroxylase and its implications for the biosynthesis of the 
neurotransmitters serotonin and melatonin, Biochemistry 41, 12569-12574. 
48.  Cianchetta, G., Stouch, T., Yu, W., Shi, Z. C., Tari, L. W., Swanson, R. V., Hunter, M. J., Hoffman, I. D., 
and Liu, Q. (2010) Mechanism of inhibition of novel tryptophan hydroxylase inhibitors revealed by 
co-crystal structures and kinetic analysis, Current Chemical Genomics 4, 19-26. 
49.  Kobe, B., Jennings, I. G., House, C. M., Michell, B. J., Goodwill, K. E., Santarsiero, B. D., Stevens, R. C., 
Cotton, R. G. H., and Kemp, B. E. (1999) Structural basis of autoregulation of phenylalanine 
hydroxylase, Nature Structural Biology 6, 442-448. 
 v 
 
50.  DeLano, W. L. (2002) The PyMOL Molecular Graphics System. http://www.pymol.org. Schrödinger 
LLC, San Carlos, CA, USA. 
51.  McKinney, J., Knappskog, P. M., and Haavik, J. (2005) Different properties of the central and 
peripheral forms of human tryptophan hydroxylase, Journal of Neurochemistry 92, 311-320. 
52.  Johansen, P. A., Jennings, I., Cotton, R. G., and Kuhn, D. M. (1995) Tryptophan hydroxylase is 
phosphorylated by protein kinase A, Journal of Neurochemistry 65, 882-888. 
53.  Winge, I., McKinney, J. A., Ying, M., D’Santos, C. S., Kleppe, R., Knappskog, P. M., and Haavik, J. 
(2008) Activation and stabilization of human tryptophan hydroxylase 2 by phosphorylation and 14-3-
3 binding, The Biochemical Journal 410, 195-204. 
54.  Kuhn, D. M., Sakowski, S. A., Geddes, T. J., Wilkerson, C., and Haycock, J. W. (2007) Phosphorylation 
and activation of tryptophan hydroxylase 2: identification of serine-19 as the substrate site for 
calcium, calmodulin-dependent protein kinase II, Journal of Neurochemistry 103, 1567-1573. 
55.  Banik, U., Wang, G. A., Wagner, P. D., and Kaufman, S. (1997) Interaction of phosphorylated 
tryptophan hydroxylase with 14-3-3 proteins, The Journal of Biological Chemistry 272, 26219-26225. 
56.  Furukawa, Y., Ikuta, N., Omata, S., Yamauchi, T., Isobe, T., and Ichimura, T. (1993) Demonstration of 
the phosphorylation-dependent interaction of tryptophan hydroxylase with the 14-3-3 protein, 
Biochemical and Biophysical Research Communications 194, 144-149. 
57.  Chen, G.-L., and Miller, G. M. (2012) Advances in tryptophan hydroxylase-2 gene expression 
regulation: new insights into serotonin-stress interaction and clinical implications, American Journal 
of Medical Genetics, Part B, Neuropsychiatric Genetics 159B, 152-171. 
58.  Koehntop, K. D., Emerson, J. P., and Que, L. (2005) The 2-His-1-carboxylate facial triad: a versatile 
platform for dioxygen activation by mononuclear non-heme iron(II) enzymes, Journal of Biological 
Inorganic Chemistry 10, 87-93. 
59.  McKinney, J., Teigen, K., Frøystein, N. A., Salaün, C., Knappskog, P. M., Haavik, J., and Martínez, A. 
(2001) Conformation of the substrate and pterin cofactor bound to human tryptophan hydroxylase. 
Important role of Phe313 in substrate specificity, Biochemistry 40, 15591-15601. 
60.  Daubner, S. C., Moran, G. R., and Fitzpatrick, P. F. (2002) Role of tryptophan hydroxylase phe313 in 
determining substrate specificity, Biochemical and Biophysical Research Communications 292, 639-
641. 
61.  Kino, K., Hara, R., and Nozawa, A. (2009) Enhancement of l-tryptophan 5-hydroxylation activity by 
structure-based modification of l-phenylalanine 4-hydroxylase from Chromobacterium violaceum, 
Journal of Bioscience and Bioengineering 108, 184-189. 
62.  Jiang, G. C., Yohrling, G. J., Schmitt, J. D., Vrana, K. E., and Schmitt, I. V. (2000) Identification of 
substrate orienting and phosphorylation sites within tryptophan hydroxylase using homology-based 
molecular modeling, Journal of Molecular Biology 302, 1005-1017. 
  
 
vi 
 
63.  Goodwill, K. E., Sabatier, C., Marks, C., Raag, R., Fitzpatrick, P. F., and Stevens, R. C. (1997) Crystal 
structure of tyrosine hydroxylase at 2.3 A and its implications for inherited neurodegenerative 
diseases, Nature Structural Biology 4, 578-585. 
64.  Fusetti, F., Erlandsen, H., Flatmark, T., and Stevens, R. C. (1998) Structure of tetrameric human 
phenylalanine hydroxylase and its implications for phenylketonuria, Journal of Biological Chemistry 
273, 16962-16967. 
65.  Andersen, O. A., Flatmark, T., and Hough, E. (2001) High resolution crystal structures of the catalytic 
domain of human phenylalanine hydroxylase in its catalytically active Fe(II) form and binary complex 
with tetrahydrobiopterin, Journal of Molecular Biology 314, 279-291. 
66.  Andersen, O. A., Stokka, A. J., Flatmark, T., and Hough, E. (2003) 2.0 angstrom resolution crystal 
structures of the ternary complexes of human phenylalanine hydroxylase catalytic domain with 
tetrahydrobiopterin and 3-(2-thienyl)-L-alanine or L-norleucine: Substrate specificity and molecular 
motions related to substrate, Journal of Molecular Biology 333, 747-757. 
67.  Kemsley, J. N., Zaleski, K. L., Caradonna, J. P., and Solomon, E. I. (1999) Circular dichroism and 
magnetic circular dichroism spectrocscopy of the catalytically competent ferrous active site of 
phenylalanine hydroxylase and its interaction with pterin cofactor, Journal of the American Chemical 
Society 121, 1528-1536. 
68.  Wasinger, E. C., Mitic, N., Hedman, B., Caradonna, J., Solomon, E. I., and Hodgson, K. O. (2002) X-ray 
absorption spectroscopic investigation of the resting ferrous and cosubstrate-bound active sites of 
phenylalanine hydroxylase, Biochemistry 41, 6211-6217. 
69.  Loeb, K. E., Westre, T. E., Kappock, T. J., Glasfeld, E., Caradonna, J. P., Hedman, B., Hodgson, K. O., 
and Solomon, E. I. (1997) Spectroscopic characterization of the catalytically competent ferrous site 
of the resting , activated , and substrate-bound forms of phenylalanine hydroxylase, Journal of the 
American Chemical Society 119, 1901-1915. 
70.  Chow, M. S., Eser, B. E., Wilson, S. a, Hodgson, K. O., Hedman, B., Fitzpatrick, P. F., and Solomon, E. I. 
(2009) Spectroscopy and kinetics of wild-type and mutant tyrosine hydroxylase: mechanistic insight 
into O2 activation., Journal of the American Chemical Society 131, 7685-7698. 
71.  Fitzpatrick, P. F. (1991) Steady-state kinetic mechanism of rat tyrosine hydroxylase, Biochemistry 30, 
3658-3662. 
72.  Pember, S. O., Johnson, K. A., Villafranca, J. J., and Benkovic, S. J. (1989) Mechanistic studies on 
phenylalanine hydroxylase from chromobacterium-violaceum. Evidence for the formation of an 
enzyme-oxygen complex, Biochemistry 28, 2124-2130. 
73.  Volner, A., Zoidakis, J., and Abu-Omar, M. M. (2003) Order of substrate binding in bacterial 
phenylalanine hydroxylase and its mechanistic implication for pterin-dependent oxygenases, Journal 
of Biological Inorganic Chemistry 8, 121-128. 
74.  Bassan, A., Blomberg, M. R. a, and Siegbahn, P. E. M. (2003) Mechanism of dioxygen cleavage in 
tetrahydrobiopterin-dependent amino acid hydroxylases, Chemistry 9, 106-115. 
 vii 
 
75.  Bassan, A., Borowski, T., and Siegbahn, P. E. M. (2004) Quantum chemical studies of dioxygen 
activation by mononuclear non-heme iron enzymes with the 2-His-1-carboxylate facial triad, Dalton 
Transactions 3153-3162. 
76.  Haahr, L. T., Jensen, K. P., Boesen, J., and Christensen, H. E. M. (2010) Experimentally calibrated 
computational chemistry of tryptophan hydroxylase: trans influence, hydrogen-bonding, and 18-
electron rule govern O2-activation, Journal of Inorganic Biochemistry 104, 136-145. 
77.  Olsson, E., Martinez, A., Teigen, K., and Jensen, V. R. (2011) Substrate hydroxylation by the oxido-
iron intermediate in aromatic amino acid hydroxylases: A DFT mechanistic study, European Journal 
of Inorganic Chemistry 2011, 2720-2732. 
78.  Olsson, E., Martinez, A., Teigen, K., and Jensen, V. R. (2011) Formation of the iron-oxo hydroxylating 
species in the catalytic cycle of aromatic amino acid hydroxylases, Chemistry 17, 3746-3758. 
79.  Eser, B. E., Barr, E. W., Frantom, P. a, Saleh, L., Bollinger, J. M., Krebs, C., and Fitzpatrick, P. F. (2007) 
Direct spectroscopic evidence for a high-spin Fe(IV) intermediate in tyrosine hydroxylase, Journal of 
the American Chemical Society 129, 11334-11335. 
80.  Panay, A. J., Lee, M., Krebs, C., Bollinger, J. M., and Fitzpatrick, P. F. (2011) Evidence for a high-spin 
Fe(IV) species in the catalytic cycle of a bacterial phenylalanine hydroxylase, Biochemistry 50, 1928-
1933. 
81.  Lange, S. J., Miyake, H., and Que, L. (1999) Evidence for a nonheme Fe(IV)=O species in the 
intramolecular hydroxylation of a phenyl moiety, Journal of the American Chemical Society 121, 
6330-6331. 
82.  Krebs, C., Galonić Fujimori, D., Walsh, C. T., and Bollinger, J. M. (2007) Non-heme Fe(IV)-oxo 
intermediates, Accounts of Chemical Research 40, 484-492. 
83.  Francisco, W. A., Tian, G. C., Fitzpatrick, P. F., and Klinman, J. P. (1998) Oxygen-18 kinetic isotope 
effect studies of the tyrosine hydroxylase reaction: Evidence of rate limiting oxygen activation, 
Journal of the American Chemical Society 120, 4057-4062. 
84.  Kemsley, J. N., Wasinger, E. C., Datta, S., Mitić, N., Acharya, T., Hedman, B., Caradonna, J. P., 
Hodgson, K. O., and Solomon, E. I. (2003) Spectroscopic and kinetic studies of PKU-inducing mutants 
of phenylalanine hydroxylase: Arg158Gln and Glu280Lys, Journal of the American Chemical Society 
125, 5677-5686. 
85.  Hillas, P. J., and Fitzpatrick, P. F. (1996) A mechanism for hydroxylation by tyrosine hydroxylase 
based on partitioning of substituted phenylalanines, Biochemistry 35, 6969-6975. 
86.  Moran, G. R., Derecskei-Kovacs, A., Hillas, P. J., and Fitzpatrick, P. F. (2000) On the catalytic 
mechanism of tryptophan hydroxylase, Journal of the American Chemical Society 122, 4535-4541. 
87.  Moran, G. R., Phillips, R. S., and Fitzpatrick, P. F. (1999) Influence of steric bulk and electrostatics on 
the hydroxylation regiospecificity of tryptophan hydroxylase: characterization of methyltryptophans 
and azatryptophans as substrates, Biochemistry 38, 16283-16289. 
  
 
viii 
 
88.  Renson, J., Daly, J., Weissbach, H., Witkop, B., and Udenfriend, S. (1966) Enzymatic conversion of 5-
tritiotryptophan to 4-tritio-5-hydroxytryptophan, Biochemical and Biophysical Research 
Communications 25, 504-513. 
89.  Guroff, G., and Daly, J. (1967) Quantitative studies on the hydroxylation-induced migration of 
deuterium and tritium during phenylalanine hydroxylation, Archives of Biochemistry and Biophysics 
122, 212-217. 
90.  Daly, J., Levitt, M., Guroff, G., and Udenfriend, S. (1968) Isotope studies on the mechanism of action 
of adrenal tyrosine hydroxylase, Archives of Biochemistry and Biophysics 126, 593-598. 
91.  Bassan, A., Blomberg, M. R. a, and Siegbahn, P. E. M. (2003) Mechanism of aromatic hydroxylation 
by an activated FeIV=O core in tetrahydrobiopterin-dependent hydroxylases, Chemistry 9, 4055-
4067. 
92.  Shiota, Y., and Yoshizawa, K. (2004) QM/MM study of the mononuclear non-heme iron active site of 
phenylalanine hydroxylase, Journal of Physical Chemistry B 108, 17226-17237. 
93.  Abitas, J.-pierre, Parniaks, M., Kaufmann, S., Abita, J. P., Parniak, M., and Kaufman, S. (1984) The 
activation of rat liver phenylalanine hydroxylase by limited proteolysis, lysolecithin, and tocopherol 
phosphate. Changes in conformation and catalytic properties, The Journal of Biological Chemistry 
259, 14560-14566. 
94.  Boesen, J. (2007) Cloning, production and chromatographic purification of human tryptophan 
hydroxylase isoform 1 variants and initial kinetic studies (in Danish), Master thesis. Department of 
Chemistry, Technical University of Denmark. 
95.  McPherson, A. (2004) Introduction to protein crystallization, Methods 34, 254-265. 
96.  Nielsen, M. S., Petersen, C. R., Munch, A., Vendelboe, T. V., Boesen, J., Harris, P., and Christensen, H. 
E. (2008) A simple two step procedure for purification of the catalytic domain of chicken tryptophan 
hydroxylase 1 in a form suitable for crystallization, Protein Expression and Purification 57, 116-126. 
97.  Yang, X. J., and Kaufman, S. (1994) High-level expression and deletion mutagenesis of human 
tryptophan hydroxylase, Proceedings of the National Academy of Sciences of the United States of 
America 91, 6659-6663. 
98.  McKinney, J., Knappskog, P. M., Pereira, J., Ekern, T., Toska, K., Kuitert, B. B., Levine, D., Gronenborn, 
A. M., Martinez, A., and Haavik, J. (2004) Expression and purification of human tryptophan 
hydroxylase from Escherichia coli and Pichia pastoris, Protein Expression and Purification 33, 185-
194. 
99.  Mockus, S. M., Kumer, S. C., and Vrana, K. E. (1997) A chimeric tyrosine/tryptophan hydroxylase. The 
tyrosine hydroxylase regulatory domain serves to stabilize enzyme activity, Journal of Molecular 
Neuroscience 9, 35-48. 
100.  Mockus, S. M., Kumer, S. C., and Vrana, K. E. (1997) Carboxyl terminal deletion analysis of 
tryptophan hydroxylase, Biochimica et Biophysica Acta 1342, 132-140. 
 ix 
 
101.  D’Sa, C. M., Arthur, R. E., and Kuhn, D. M. (1996) Expression and deletion mutagenesis of tryptophan 
hydroxylase fusion proteins: delineation of the enzyme catalytic core, Journal of Neurochemistry 67, 
917-926. 
102.  Winge, I., McKinney, J. a, Knappskog, P. M., and Haavik, J. (2007) Characterization of wild-type and 
mutant forms of human tryptophan hydroxylase 2, Journal of Neurochemistry 100, 1648-1657. 
103.  Kowlessur, D., and Kaufman, S. (1999) Cloning and expression of recombinant human pineal 
tryptophan hydroxylase in Escherichia coli: Purification and characterization of the cloned enzyme, 
Biochimica et Biophysica Acta 1434, 317-330. 
104.  Munch, A. (2004) Affinity ligands for purification of tryptophan hydroxylase. Department of 
Chemistry, Technical University of Denmark. 
105.  Waugh, D. S. (2005) Making the most of affinity tags, Trends in Biotechnology 23, 316-320. 
106.  GE Healthcare. (2009) Recombinant Protein Purification Handbook - Principles and methods. GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden. 
107.  Waugh, D. S. (2011) An overview of enzymatic reagents for the removal of affinity tags, Protein 
Expression and Purification 80, 283-293. 
108.  Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) How to measure and predict the 
molar absorption coefficient of a protein, Protein Science 4, 2411-2423. 
109.  Wilkins, M. R., Gasteiger, E., Bairoch, A., Sanchez, J. C., Williams, K. L., Appel, R. D., and Hochstrasser, 
D. F. (1999) Protein identification and analysis tools in the ExPASy server, Methods in Molecular 
Biology 112, 531-552. 
110.  BioRad webpage. www.bio-rad.com, 03.04.2012. 
111.  Waters. (2006) LCT Premier XE Quick Start Guide 71500127003 / Revision A, in Waters LCT Premier 
XE Bookshelf. Waters coperation. 
112.  Cordingley, M. G., Callahan, P. L., Sardana, V. V., Garsky, V. M., and Colonno, R. J. (1990) Substrate 
requirements of human rhinovirus 3C protease for peptide cleavage in-vitro, Journal of Biological 
Chemistry 265, 9062-9065. 
113.  Walker, P. A., Leong, L. E. C., Ng, P. W. P., Tan, S. H., Waller, S., Murphy, D., and Porter, A. G. (1994) 
Efficient and rapid affinity purification of proteins using recombinant fusion proteases, Bio-
Technology 12, 601-605. 
114.  Kaplan, W., Hüsler, P., Klump, H., Erhardt, J., Sluis-Cremer, N., and Dirr, H. (1997) Conformational 
stability of pGEX-expressed Schistosoma japonicum glutathione S-transferase: a detoxification 
enzyme and fusion-protein affinity tag, Protein Science 6, 399-406. 
115.  Kapust, R. B., and Waugh, D. S. (1999) Escherichia coli maltose-binding protein is uncommonly 
effective at promoting the solubility of polypeptides to which it is fused, Protein Science 8, 1668-
1674. 
  
 
x 
 
116.  Sachdev, D., and Chirgwin, J. M. (1998) Order of fusions between bacterial and mammalian proteins 
can determine solubility in Escherichia coli, Biochemical and Biophysical Research Communications 
244, 933-937. 
117.  Schein, C. H., and Noteborn, M. H. M. (1988) Formation of soluble recombinant proteins in 
Escherichia coli is favored by lower growth temperatures, Biotechnology 6, 291-294. 
118.  Hernández, H., and Robinson, C. V. (2007) Determining the stoichiometry and interactions of 
macromolecular assemblies from mass spectrometry, Nature Protocols 2, 715-726. 
119.  Niesen, F. H., Berglund, H., and Vedadi, M. (2007) The use of differential scanning fluorimetry to 
detect ligand interactions that promote protein stability, Nature Protocols 2, 2212-2221. 
120.  Bright, G. R., Fisher, G. W., Rogowska, J., and Taylor, D. L. (1987) Fluorescence ratio imaging 
microscopy: temporal and spatial measurements of cytoplasmic pH, The Journal of Cell Biology 104, 
1019-1033. 
121.  Joh, T. H., Shikimi, T., Pickel, V. M., and Reis, D. J. (1975) Brain tryptophan hydroxylase: purification 
of, production of antibodies to, and cellular and ultrastructural localization in serotonergic neurons 
of rat midbrain, Proceedings of the National Academy of Sciences of the United States of America 72, 
3575-3579. 
122.  Bergfors, T. (Ed.). (1999) Protein Crystallization: Techniques, Strategies, and Tips - A Laboratory 
Manual. IUL Biotechnology Series, La Jolla, California. 
123.  Jancarik, J., and Kim, S.-H. (1991) Sparse matrix sampling. A screening method for crystallization of 
proteins, Journal of Applied Crystallography 24, 409-411. 
124.  Rupp, B., and Wang, J. (2004) Predictive models for protein crystallization, Methods 34, 390-407. 
125.  Chayen, N. E., and Saridakis, E. (2008) Protein crystallization: from purified protein to diffraction-
quality crystal, Nature Methods 5, 147-153. 
126.  Jin, H., Cianchetta, G., Devasagayaraj, A., Gu, K., Marinelli, B., Samala, L., Scott, S., Stouch, T., 
Tunoori, A., Wang, Y., Zang, Y., Zhang, C., David Kimball, S., Main, A. J., Ding, Z.-M. M., Sun, W., Yang, 
Q., Yu, X.-Q. Q., Powell, D. R., Wilson, A., Liu, Q., and Shi, Z.-C. C. (2009) Substituted 3-(4-(1,3,5-
triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors, Bioorganic 
& Medicinal Chemistry Letters 19, 5229-5232. 
127.  Goodwill, K. E., Sabatier, C., and Stevens, R. C. (1998) Crystal structure of tyrosine hydroxylase with 
bound cofactor analogue and iron at 2.3 A resolution: self-hydroxylation of Phe300 and the pterin-
binding site, Biochemistry 37, 13437-13445. 
128.  Erlandsen, H., Fusetti, F., Martinez, A., Hough, E., Flatmark, T., and Stevens, R. C. (1997) Crystal 
structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis 
for phenylketonuria, Nature Structural Biology 4, 995-1000. 
 xi 
 
129.  Erlandsen, H., Flatmark, T., Stevens, R. C., and Hough, E. (1998) Crystallographic analysis of the 
human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 angstrom 
resolution, Biochemistry 37, 15638-15646. 
130.  Erlandsen, H., Bjorgo, E., Flatmark, T., and Stevens, R. C. (2000) Crystal structure and site-specific 
mutagenesis of pterin-bound human phenylalanine hydroxylase, Biochemistry 39, 2208-2217. 
131.  Erlandsen, H., Kim, J. Y., Patch, M. G., Han, A., Volner, A., Abu-Omar, M. M., and Stevens, R. C. (2002) 
Structural comparison of bacterial and human iron-dependent phenylalanine hydroxylases: Similar 
fold, different stability and reaction rates, Journal of Molecular Biology 320, 645-661. 
132.  Andersen, O. A., Flatmark, T., and Hough, E. (2002) Crystal structure of the ternary complex of the 
catalytic domain of human phenylalanine hydroxylase with tetrahydrobiopterin and 3-(2-thienyl)-L-
alanine, and its implications for the mechanism of catalysis and substrate activation, Journal of 
Molecular Biology 320, 1095-1108. 
133.  Erlandsen, H., Pey, A. L., Gamez, A., Perez, B., Desviat, L. R., Aguado, C., Koch, R., Surendran, S., 
Tyring, S., Matalon, R., Scriver, C. R., Ugarte, M., Martinez, A., and Stevens, R. C. (2004) Correction of 
kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain 
phenylalanine hydroxylase mutations, Proceedings of the National Academy of Sciences of the 
United States of America 101, 16903-16908. 
134.  Leiros, H. K. S., Pey, A. L., Innselset, M., Moe, E., Leiros, I., Steen, I. H., and Martinez, A. (2007) 
Structure of phenylalanine hydroxylase from Colwellia psychrerythraea 34H, a monomeric cold 
active enzyme with local flexibility around the active site and high overall stability, Journal of 
Biological Chemistry 282, 21973-21986. 
135.  Ursby, T., Mammen, C. B., Cerenius, Y., Svensson, C., Sommarin, B., Fodje, M. N., Kvick, A., Logan, D. 
T., Als-Nielsen, J., and Thunnissen, M. M. G. M. (2004) The new macromolecular crystallography 
stations at MAX-lab: The MAD station, AIP Conference Proceedings 705, 1241-1246. 
136.  Robinson, H., Soares, A. S., Becker, M., Sweet, R., and Heroux, A. (2006) Mail-in crystallography 
program at brookhaven national laboratory’s national synchrotron light source, Acta 
Crystallographica Section D Biological Crystallography 62, 1336-1339. 
137.  Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., and Leslie, A. G. W. (2011) iMOSFLM: a 
new graphical interface for diffraction image processing with MOSFLM, Acta Crystallographica, 
Section D (Biological Crystallography) D67, 271-281. 
138.  Kabsch, W. (2010) XDS, Acta Crystallographica, Section D (Biological Crystallography) D66, 125-132. 
139.  Potterton, E., Briggs, P., Turkenburg, M., and Dodson, E. (2003) A graphical user interface to the 
CCP4 program suite, Acta Crystallographica Section D Biological Crystallography 59, 1131-1137. 
140.  Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot, 
Acta Crystallographica, Section D (Biological Crystallography) D66, 486-501. 
141.  Schmit, J. D., and Dill, K. (2012) Growth rates of protein crystals, Journal of the American Chemical 
Society 134, 3934-3937. 
  
 
xii 
 
142.  Vergara, A., Lorber, B., Zagari, A., and Giegé, R. (2002) Physical aspects of protein crystal growth 
investigated with the Advanced Protein Crystallization Facility in reduced-gravity environments, Acta 
Crystallographica Section D Biological Crystallography 59, 2-15. 
143.  Brünger, A. T. (1997) Free R value: cross-validation in crystallography, Methods in Enzymology 277, 
366-396. 
144.  P-CUBE (Infrastructure for Protein Production Platforms). http://www.p-cube.eu/, 21.05.2012. 
145.  Gräslund, S., Sagemark, J., Berglund, H., Dahlgren, L.-G., Flores, A., Hammarström, M., Johansson, I., 
Kotenyova, T., Nilsson, M., Nordlund, P., and Weigelt, J. (2008) The use of systematic N- and C-
terminal deletions to promote production and structural studies of recombinant proteins, Protein 
Expression and Purification 58, 210-221. 
146.  McKinney, J. A., Turel, B., Winge, I., Knappskog, P. M., and Haavik, J. (2009) Functional properties of 
missense variants of human tryptophan hydroxylase 2, Human Mutation 30, 787-794. 
147.  Daubner, S. C., and Fitzpatrick, P. F. (1999) Site-directed mutants of charged residues in the active 
site of tyrosine hydroxylase, Biochemistry 38, 4448-4454. 
148.  Daubner, S. C., and Fitzpatrick, P. F. (1998) Mutation to phenylalanine of tyrosine 371 in tyrosine 
hydroxylase increases the affinity for phenylalanine, Biochemistry 37, 16440-16444. 
149.  Kinzie, S. D., Thevis, M., Ngo, K., Whitelegge, J., Loo, J. a, and Abu-Omar, M. M. (2003) 
Posttranslational hydroxylation of human phenylalanine hydroxylase is a novel example of enzyme 
self-repair within the second coordination sphere of catalytic iron, Journal of the American Chemical 
Society 125, 4710-4711. 
150.  Miranda, F. F., Kolberg, M., Andersson, K. K., Geraldes, C. F. G. C., and Martínez, A. (2005) The active 
site residue tyrosine 325 influences iron binding and coupling efficiency in human phenylalanine 
hydroxylase, Journal of Inorganic Biochemistry 99, 1320-1328. 
151.  Li, J., and Fitzpatrick, P. F. (2008) Characterization of metal ligand mutants of phenylalanine 
hydroxylase: Insights into the plasticity of a 2-histidine-1-carboxylate triad, Archives of Biochemistry 
and Biophysics 475, 164-168. 
152.  Fitzpatrick, P. F., Ralph, E. C., Ellis, H. R., Willmon, O. J., and Daubner, S. C. (2003) Characterization of 
metal ligand mutants of tyrosine hydroxylase: Insights into the plasticity of a 2-histidine-1-
carboxylate triad, Biochemistry 42, 2081-2088. 
153.  Gibbss, B. S., Wojchowski, D., and Benkovic, S. J. (1993) Expression of rat liver phenylalanine 
hydroxylase in insect cells and site-directed mutagenesis of putative non-heme, Journal of Biological 
Chemistry 268, 8046-8052. 
154.  Ramsey, A. J., Daubner, S. C., Ehrlich, J. I., and Fitzpatrick, P. F. (1995) Identification of iron ligands in 
tyrosine hydroxylase by mutagenesis of conserved histidinyl residues, Protein Science 4, 2082-2086. 
155.  Diebold, A. R., Neidig, M. L., Moran, G. R., Straganz, G. D., and Solomon, E. I. (2010) The three-his 
triad in Dke1: comparisons to the classical facial triad, Biochemistry 49, 6945-6952. 
 xiii 
 
156.  McCoy, J. G., Bailey, L. J., Bitto, E., Bingman, C. A., Aceti, D. J., Fox, B. G., and Phillips Jr, G. N. (2006) 
Structure and mechanism of mouse cysteine dioxygenase, Proceedings of the National Academy of 
Sciences of the United States of America 103, 3084-3089. 
157.  Gill, S. C., and von Hippel, P. H. (1989) Calculation of protein extinction coefficients from amino acid 
sequence data, Analytical Biochemistry 182, 319-326. 
158.  Solomon, E. I., Pavel, E. G., Loeb, K. E., and Campochiaro, C. (1995) Magnetic circular dichroism 
spectroscopy as a probe of the geometric and electronic structure of non-heine ferrous enzymes, 
Coordination Chemistry Reviews 44, 369-460. 
159.  Solomon, E. I., and Hanson, M. A. (1999) Bioinorganic spectroscopy, in Inorganic electronic structure 
and spectroscopy, Volume II: Applications and Case Studies (Solomon, E. I., and Lever, A. B. P., Eds.), 
pp 1-129. John Wiley & Sons, Inc., New York. 
160.  Neidig, M. L., and Solomon, E. I. (2005) Structure-function correlations in oxygen activating non-
heme iron enzymes, Chemical Communications 5843-5863. 
161.  Solomon, E. I., Brunold, T. C., Davis, M. I., Kemsley, J. N., Lee, S. K., Lehnert, N., Neese, F., Skulan, A. 
J., Yang, Y. S., and Zhou, J. (2000) Geometric and electronic structure/function correlations in non-
heme iron enzymes, Chemical Reviews 100, 235-350. 
162.  Pavel, E., Kitajima, N., and Solomon, E. I. (1998) Magnetic circular dichroism spectroscopic studies of 
mononuclear non-heme ferrous model complexes. Correlation of excited- and ground- state 
electronic structure with geometry, Journal of the American Chemical Society 120, 3949-3962. 
163.  Bucci, E. The circular dichroism site. http://www.imb-jena.de/ImgLibDoc/cd/tut1b.html, 15.05.2012, 
Jena Library of Biological Macromolecules. 
164.  Johnson, M. K. (2000) CD and MCD Spectroscopy, in Physical methods in bioinorganic chemistry - 
spectroscopy and magnetism (Que, L., Ed.), pp 233-286. University Science Books, Sausalito, 
California. 
165.  Piepho, S. B., and Schatz, P. N. (1983) Group theory in spectroscopy: With applications to magnetic 
circular dichroism. John Wiley, New York. 
166.  Vagenende, V., Yap, M. G. S., and Trout, B. L. (2009) Mechanisms of protein stabilization and 
prevention of protein aggregation by glycerol, Biochemistry 48, 11084-11096. 
167.  Bendtsen, N. T. (2011) Computational studies of tryptophan hydroxylase, Master thesis. DTU 
Chemistry, Technical University of Denmark. 
168.  Andersson, K. K., Cox, D. D., Que, L. J. R., Flatmark, T., and Haavik, J. (1988) Resonance raman studies 
on the blue-green-colored bovine adrenal tyrosine 3-monooxygenase tyrosine hydroxylase. 
Evidence that the feedback inhibitors adrenaline and noradrenaline coordinate to iron, Journal of 
Biological Chemistry 263, 18621-18626. 
  
 
xiv 
 
169.  Nakamura, K., Sugawara, Y., Sawabe, K., Ohashi, A., Tsurui, H., Xiu, Y., Ohtsuji, M., Lin, Q. S., 
Nishimura, H., Hasegawa, H., and Hirose, S. (2006) Late developmental stage-specific role of 
tryptophan hydroxylase 1 in brain serotonin levels, The Journal of Neuroscience 26, 530-534. 
170.  Tenner, K., Walther, D. J., and Bader, M. (2007) Structural and functional determinants of human 
tryptophan hydroxylase 2 activity, FASEB Journal 21, A1178. 
171.  Freyer, M. W., and Lewis, E. A. (2008) Isothermal titration calorimetry: experimental design, data 
analysis, and probing macromolecule/ligand binding and kinetic interactions, Methods in Cell Biology 
84, 79-113. 
172.  MicroCal. The Use of Reducing Agents. User manual. 
173.  GE Healthcare. (2012) MicroCal webpage on ITC. http://www.microcal.com/technology/itc.asp, 
15.05.2012, What is ITC? 
174.  Moran, G. R., and Fitzpatrick, P. F. (1999) A continuous fluorescence assay for tryptophan 
hydroxylase, Analytical Biochemistry 266, 148-152. 
175.  Deng, H., Callender, R., and Dale, G. E. (2000) A vibrational structure of 7,8-dihydrobiopterin bound 
to dihydroneopterin aldolase, Journal of Biological Chemistry 275, 30139-30143. 
176.  Davis, M. D., Kaufman, S., and Milstien, S. (1988) The auto-oxidation of tetrahydrobiopterin, 
European Journal of Biochemistry 173, 345-351. 
177.  Pfleiderer, W. (1987) Chemistry of pterins, in Unconjugated pterins in neurobiology (Lovenberg, W., 
and Levine, R. A., Eds.). Taylor and Francis Ltd, London.  
 
 xv 
 
9 Appendix 
9.1 Appendix: Protein amino acid sequences .................................................................................... xvi 
9.2 Appendix: Description of the 1st optimization screen for cgTPH1 ................................................. iv 
9.3 Appendix: Overview of the additive screen used in the 2nd optimization screen for cgTPH1 ........ v 
9.4 Appendix: Description of the 3rd optimization screen for cgTPH1 ................................................ vi 
9.5 Appendix: Description of the 4th optimization screen, part 1 for cgTPH1 .................................... vii 
9.6 Appendix: Describtion of the 4th optimization screen, part 2 for cgTPH1 ................................... viii 
9.7 Appendix: Describtion of the 4th optimization screen, part 3 for cgTPH1 ..................................... ix 
9.8 Appendix: Composition of structure screen 1 ................................................................................ x 
  
 
xvi 
 
9.1 Appendix: Protein amino acid sequences 
 
Color code: 
XXXX = GST  
XXXX = MBP 
XXXX = 3CP 
XXXX = Linker 
XXXX = 3CP recognition sequence and cleavage site (marked with ↔) 
XXXX = Regulatory domain of TPH 
XXXX = Catalytic domain of TPH 
XXXX = Tetramerization domain of TPH 
 
GST-3CP: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYID 
GDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKV 
DFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFK 
KRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLIEGRGIPGPEHEFLNALIR 
RNCHIITTDKGEFNLLGIYSNCAVVPTHAEPGDVVDIDGRLVRVLKQQVLTDMNDVDTEV 
TVLWLDQNEKFRDIRRFIPEHQQDWHNIHLATNVTKFPMLNVEVGHTVPYGEINLSGNAT 
CRLYKYDYPTQPGQCGAVLANTGNIIGIHVGGNGRVGYAAALLRKYFAEEQ 
 
MBP-3CP: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDI 
IFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNK 
DLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIK 
DVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK 
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL 
GAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDE 
ALKDAQTNSSSNNNNNNNNNNLGGIPGPEHEFLNALIRRNCHIITTDKGEFNLLGIYSNC 
AVVPTHAEPGDVVDIDGRLVRVLKQQVLTDMNDVDTEVTVLWLDQNEKFRDIRRFIPEHQ 
QDWHNIHLATNVTKFPMLNVEVGHTVPYGEINLSGNATCRLYKYDYPTQPGQCGAVLANT 
GNIIGIHVGGNGRVGYAAALLRKYFAEEQ 
 
GST-chTPH1: 
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYID 
GDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETL 
KVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVC 
FKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQ↔GPLGSDGMETV 
PWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVE 
FTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERT 
GFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPS 
FAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHAL 
SGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYT 
RSIQILKD 
  
 
ii 
 
 
MBP-hTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGD 
GPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSL 
IYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGK 
YDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNI 
DTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNK 
DKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQ 
TVDEALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↔GPGSIEDNKENKDHSLERGRASLIFSL 
KNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHT 
NVLSVNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKR 
RKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYC 
GYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFY 
TPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQD 
GQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKE 
KMREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI 
 
MBP-rchTPH1: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDI 
IFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNK 
DLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIK 
DVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK 
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL 
GAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDE 
ALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↔GPGSIEDNKENKDHSLERGRASLIFSLKNEV 
GGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHTNVLS 
VNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYF 
ADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYRE 
DNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEP 
DTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLR 
VFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMRE 
FTKTIKRPFGVKYNPYTRSIQILKD 
 
chTPH2: 
EELEDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQ 
PIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKYCGYREDNVPQLEDVSM 
FLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHV 
PLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSI 
GELKHALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFS 
VYFNPYTQSIEILKD 
 
cthTPH2: 
EELEDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQ 
PIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKYCGYREDNVPQLEDVSM 
FLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHVP 
LLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIG 
ELKHALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSV 
YFNPYTQSIEILKDTRSIENVVQDLRSDLNTVCDALNKMNQYLGI 
 iii 
 
 
MBP-rchTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDI 
IFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNK 
DLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIK 
DVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK 
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL 
GAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDE 
ALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↔GPGSQPAMMMFSSKYWARRGFSLDSAVPEEH 
QLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTAVVFSLKNEVGGLVKALRLFQEKR 
VNMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTLNPPENIWTEEEEL 
EDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIP 
RVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLK 
ERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLA 
DPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELK 
HALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFN 
PYTQSIEILKD 
 
MBP-hTPH2: 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDI 
IFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNK 
DLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIK 
DVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK 
VNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL 
GAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDE 
ALKDAQTNSSSNNNNNNNNNNLGLEVLFQ↔GPGSQPAMMMFSSKYWARRGFSLDSAVPEEH 
QLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTAVVFSLKNEVGGLVKALRLFQEKR 
VNMVHIESRKSRRRSSEVEIFVDCECGKTEFNELIQLLKFQTTIVTLNPPENIWTEEEEL 
EDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNVYRQRRKYFVDVAMGYKYGQPIP 
RVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLLTKYCGYREDNVPQLEDVSMFLK 
ERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGSDPLYTPEPDTCHELLGHVPLLA 
DPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGLCKQEGQLRAYGAGLLSSIGELK 
HALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFEEAKEKMRDFAKSITRPFSVYFN 
PYTQSIEILKDTRSIENVVQDLRSDLNTVCDALNKMNQYLGI 
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9.2 Appendix: Description of the 1st optimization screen for cgTPH1 
 
Description of the 1st optimization screen, which was set up at room temperature and 5 °C. The screen was set up in combiclover 
trays (4 drop chambers for each well). Conditions in green writing produced crystals at room temperature. 
Conditions varying protein concentration: Each dropchamber was added the following: a: nothing, b: 310 µM tryptophan, c: 1600 
µM BH2, d: 155 µM tryptophan+800 µM BH2. The protein concentration was different in drop chamber a compared to b-d.  
Conditions varying PEG type and concentration: The protein concentration was kept constant at 2.8 mg/ml in drop chambers a-
d, and each drop chamber was added the following: a: nothing, b: 160 µM tryptophan, c: 160 µM BH2, d: 160 µM 
tryptophan+160 µM BH2. 
Protein concentration Protein concentration PEG type and 
concentration 
PEG type and 
concentration 
22.5 (w/v)% PEG 10000 
0.2 M imidazole malate pH 8.5 
a: 2.8 mg/ml cgTPH1 
b-d: 2.8 mg/ml cgTPH1 
22.5 (w/v)% PEG 10000 
0.2 M imidazole malate pH 8.5 
a: 2.9 mg/ml cgTPH1 
b-d: 2.3 mg/ml cgTPH1 
18 (w/v)% PEG 10000 
10 (v/v) % PEG 400 
0.2 M imidazole malate pH 8.5 
a-d: 2.8 mg/ml cgTPH1 
45 (v/v) % PEG 400 
0.1 M Tris acetate pH 8.5 
a-d: 2.8 mg/ml cgTPH1 
22.5 (w/v)% PEG 10000 
0.2 M imidazole malate pH 8.5 
a: 2.5 mg/ml cgTPH1 
b-d: 2.0 mg/ml cgTPH1 
22.5 (w/v)% PEG 10000 
0.2 M imidazole malate pH 8.5 
a: 3.0 mg/ml cgTPH1 
b-d: 2.4 mg/ml cgTPH1 
25 (v/v) % PEG 400 
0.1 M Tris acetate pH 8.5 
a-d: 2.8 mg/ml cgTPH1 
40 (v/v) % PEG 400 
0.1 M Tris acetate pH 8.5 
a-d: 2.8 mg/ml cgTPH1 
22.5 (w/v)% PEG 10000 
0.2 M imidazole malate pH 8.5 
a: 2.6 mg/ml cgTPH1 
b-d: 2.1 mg/ml cgTPH1 
22.5 (w/v)% PEG 10000 
0.2 M imidazole malate pH 8.5 
a: 3.1 mg/ml cgTPH1 
b-d: 2.5 mg/ml cgTPH1 
23 (v/v) % PEG 400 
0.1 M Tris acetate pH 8.5 
a-d: 2.8 mg/ml cgTPH1 
35 (v/v) % PEG 400 
0.1 M Tris acetate pH 8.5 
a-d: 2.8 mg/ml cgTPH1 
22.5 (w/v)% PEG 10000 
0.2 M imidazole malate pH 8.5 
a: 2.7 mg/ml cgTPH1 
b-d: 2.2 mg/ml cgTPH1 
 20 (w/v)% PEG 10000 
6 (v/v) % PEG 400 
0.2 M imidazole malate pH 8.5 
a-d: 2.8 mg/ml cgTPH1 
30 (v/v) % PEG 400 
0.1 M Tris acetate pH 8.5 
a-d: 2.8 mg/ml cgTPH1 
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9.3 Appendix: Overview of the additive screen used in the 2nd 
optimization screen for cgTPH1 
 
Overview of the additive screen MD1-11 from Molecular Dimensions used in the 2nd optimization screen. The screen was set up 
at room temperature with the original crystallization conditions (22.5 (w/v)% PEG 10000, 0.2 M imidazole malate pH 8.5) and a 
protein concentration of 2.8 mg/mL. The screen was set up in combiclover trays (4 drop chambers for each well). None of the 
conditions produced crystals.  
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9.4 Appendix: Description of the 3rd optimization screen for cgTPH1 
 
Description of the 3rd optimization screen, which was set up at room temperature. The screen was set up in combiclover trays (4 
drop chambers for each well). Conditions in green writing produced crystals. 
Conditions varying protein concentration: Each drop chamber was added the following: a: nothing, b: 310 µM tryptophan, c: 
1600 µM BH2, d: 155 µM tryptophan+800 µM BH2. The concentration was different in drop chamber a compared to b-d.  
Conditions varying PEG 10000 concentration: The protein concentration was kept constant at 2.8 mg/ml in drop chambers a-d, 
and each drop chamber was added the following: a: nothing, b: 160 µM tryptophan, c: 160 µM BH2, d: 160 µM tryptophan+160 
µM BH2. 
Protein 
concentration 
(imidazole) 
Protein 
concentration 
(imidazole) 
Protein 
concentration 
(Tris acetate) 
Protein 
concentration 
(Tris acetate) 
PEG 10000 
concentration 
(Tris acetate) 
PEG 10000 
concentration 
(Tris acetate) 
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
a-d: 2.8 mg/ml 
cgTPH1 
 
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
a: 2.9 mg/ml cgTPH1 
b-d: 2.3 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a: 2.8 mg/ml cgTPH1 
b-d: 2.8 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a: 2.9 mg/ml cgTPH1 
b-d: 2.3 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a-d: 2.8 mg/ml 
cgTPH1 
 
25 (w/v)% PEG 10000 
0.1 M Tris acetate pH 
8.5 
a-d: 2.8 mg/ml 
cgTPH1 
 
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
a: 2.5 mg/ml cgTPH1 
b-d: 2.0 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
a: 3.0 mg/ml cgTPH1 
b-d: 2.4 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a: 2.5 mg/ml cgTPH1 
b-d: 2.0 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a: 3.0 mg/ml cgTPH1 
b-d: 2.4 mg/ml 
cgTPH1 
15 (w/v)% PEG 10000 
0.1 M Tris acetate pH 
8.5 
a-d: 2.8 mg/ml 
cgTPH1 
 
27 (w/v)% PEG 10000 
0.1 M Tris acetate pH 
8.5 
a-d: 2.8 mg/ml 
cgTPH1 
 
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
a: 2.6 mg/ml cgTPH1 
b-d: 2.1 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
a: 3.1 mg/ml cgTPH1 
b-d: 2.5 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a: 2.6 mg/ml cgTPH1 
b-d: 2.1 mg/ml 
cgTPH1 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a: 3.1 mg/ml cgTPH1 
b-d: 2.5 mg/ml 
cgTPH1 
17  (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a-d: 2.8 mg/ml 
cgTPH1 
 
29 (w/v)% PEG 10000 
0.1 M Tris acetate pH 
8.5 
a-d: 2.8 mg/ml 
cgTPH1 
 
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
a: 2.7 mg/ml cgTPH1 
b-d: 2.2 mg/ml 
cgTPH1 
 22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate pH 
8.5 
a: 2.7 mg/ml cgTPH1 
b-d: 2.2 mg/ml 
cgTPH1 
 20 (w/v)% PEG 10000 
0.1 M Tris acetate pH 
8.5 
a-d: 2.8 mg/ml 
cgTPH1 
 
35 (w/v)% PEG 10000 
0.1 M Tris acetate pH 
8.5 
a-d: 2.8 mg/ml 
cgTPH1 
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9.5 Appendix: Description of the 4th optimization screen, part 1 for 
cgTPH1 
 
Description of the 4th optimization screen, part 1, which was set up at room temperature. The screen was set up in combiclover 
trays (4 drop chambers for each well). Conditions in green writing produced crystals. Only one drop was set up per reservoir.  
PEG 10000 
concentration  
PEG 10000 
concentration  
Protein 
concentration  
PEG 10000 
concentration 
  
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
27 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp  
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
312 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
312 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
312 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp  
25 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp  
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp+700 µM 
BH2 
24 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
24 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
312 µM trp 
24 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.1 mg/ml cgTPH1 
312 µM trp 
35 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp  
20 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp  
22.5 (w/v)% PEG 
10000 
0.2 M imidazole 
malate pH 8.5 
2.1 mg/ml cgTPH1 
156 µM trp+700 µM 
BH2 
26 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
26 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
312 µM trp 
26 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.3 mg/ml cgTPH1 
312 µM trp 
29 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp  
 22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp+700 µM 
BH2 
29 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
29 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
312 µM trp 
29 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.3 mg/ml cgTPH1 
312 µM trp 
 
 
 
 
  
  
 
viii 
 
9.6 Appendix: Describtion of the 4th optimization screen, part 2 for 
cgTPH1 
 
Description of the 4th optimization screen, part 2, which was set up at room temperature. The screen was set up in pre-greased 
hanging-drop trays. Conditions in green writing produced crystals. Only one drop was set up per reservoir and at conditions 
assigned 4 µL+4 µL, the drop size was double the usual. 
- - - - - - 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
24.3 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
25.2 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
26.1 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
27.0 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
27.9 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
25.2 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
4 µL+4 µL 
27.0 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
4 µL+4 µL 
25.2 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
2 (v/v)% glycerol 
27.0 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.8 mg/ml cgTPH1 
156 µM trp 
2 (v/v)% glycerol 
27.0 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
2 (v/v)% glycerol 
21.6 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
24.3 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
25.2 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
19.8 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
20.7 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
21.6 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
4 µL+4 µL 
19.8 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
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9.7 Appendix: Describtion of the 4th optimization screen, part 3 for 
cgTPH1 
 
Description of the 4th optimization screen, part 3, which was set up at room temperature. The screen was set up in sitting drop 
trays with only one chamber per reservoir. Conditions in green writing produced crystals. At conditions assigned 4 µL+4 µL, the 
drop size was double the usual. 
Trp Trp Trp Trp+BH2 Trp+BH2 Trp+BH2 
20.7 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
21.6 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
4 µL+4 µL 
20.7 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
21.6 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
4 µL+4 µL 
21.6 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.25 mg/ml cgTPH1 
156 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.25 mg/ml cgTPH1 
156 µM trp 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.25 mg/ml cgTPH1 
156 µM trp 
4 µL+4 µL 
21.6 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.25 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.25 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.25 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
4 µL+4 µL 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
4 µL+4 µL 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
24.3 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
4 µL+4 µL 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
24.3 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
21.6 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
2 (v/v)% glycerol 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp 
2 (v/v)% glycerol 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp 
2 (v/v)% glycerol 
21.6 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
2 (v/v)% glycerol 
22.5 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.5 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
2 (v/v)% glycerol 
23.4 (w/v)% PEG 
10000 
0.1 M Tris acetate 
pH 8.5 
2.0 mg/ml cgTPH1 
156 µM trp+156 µM 
BH2 
2 (v/v)% glycerol 
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9.8 Appendix: Composition of structure screen 1 
 
 
